

PCT

WORLD INT

Exp Mail EV335610938US
USAN 09/895,814

TION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/574, 33/577, C07K 16/30, A61K 39/395, 47/48, C12Q 1/68, G01N 33/543		A2	(11) International Publication Number: WO 98/37418
			(43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/03690		(81) Designated States: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 25 February 1998 (25.02.98)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 08/806,596 25 February 1997 (25.02.97) US 08/904,809 1 August 1997 (01.08.97) US Not furnished 9 February 1998 (09.02.98) US			
(71) Applicant: CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).			
(72) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US).			
(74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).			
(54) Title: COMPOUNDS FOR IMMUNODIAGNOSIS OF PROSTATE CANCER AND METHODS FOR THEIR USE			
(57) Abstract Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMPOUNDS FOR IMMUNODIAGNOSIS OF PROSTATE CANCER AND METHODS FOR THEIR USE

TECHNICAL FIELD

The present invention relates generally to the treatment and monitoring of prostate cancer. The invention is more particularly related to polypeptides comprising at least a portion of a prostate protein. Such polypeptides may be used for the production of compounds, such as antibodies, useful for diagnosing and monitoring the progression of prostate cancer, and possibly other tumor types, in a patient.

BACKGROUND OF THE INVENTION

Prostate cancer is the most common form of cancer among males, with an estimated incidence of 30% in men over the age of 50. Overwhelming clinical evidence shows that human prostate cancer has the propensity to metastasize to bone, and the disease appears to progress inevitably from androgen dependent to androgen refractory status, leading to increased patient mortality. This prevalent disease is currently the second leading cause of cancer death among men in the U.S.

In spite of considerable research into diagnosis and therapy of the disease, prostate cancer remains difficult to detect and to treat. Commonly, treatment is based on surgery and/or radiation therapy, but these methods are ineffective in a significant percentage of cases. Two previously identified prostate specific proteins - prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) - have limited diagnostic and therapeutic potential. For example, PSA levels do not always correlate well with the presence of prostate cancer, being positive in a percentage of non-prostate cancer cases, including benign prostatic hyperplasia (BPH). Furthermore, PSA measurements correlate with prostate volume, and do not indicate the level of metastasis.

Accordingly, there remains a need in the art for improved and diagnostic methods for prostate cancer.

SUMMARY OF THE INVENTION

The present invention provides methods for immunodiagnosis of prostate cancer, together with kits for use in such methods. Polypeptides are disclosed which comprise at least an immunogenic portion of a prostate tumor protein or a variant of said protein that differs only in conservative substitutions and/or modifications, wherein the prostate tumor protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-11, 115-171, 173-175, 177, 179-224 and variants thereof. Such polypeptides may be usefully employed in the diagnosis and monitoring of prostate cancer.

In one specific aspect of the present invention, methods are provided for detecting prostate cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binding agent that is capable of binding to one of the above polypeptides; and (b) detecting in the sample a protein or polypeptide that binds to the binding agent. In preferred embodiments, the binding agent is an antibody, most preferably a monoclonal antibody.

In related aspects, methods are provided for monitoring the progression of prostate cancer in a patient, comprising: (a) contacting a biological sample obtained from a patient with a binding agent that is capable of binding to one of the above polypeptides; (b) determining in the sample an amount of a protein or polypeptide that binds to the binding agent; (c) repeating steps (a) and (b); and comparing the amounts of polypeptide detected in steps (b) and (c).

Within related aspects, the present invention provides antibodies, preferably monoclonal antibodies, that bind to the inventive polypeptides, as well as diagnostic kits comprising such antibodies, and methods of using such antibodies to inhibit the development of prostate cancer.

The present invention further provides methods for detecting prostate cancer comprising: (a) obtaining a biological sample from a patient; (b) contacting the sample with a first and a second oligonucleotide primer in a polymerase chain reaction, at least one of the oligonucleotide primers being specific for a DNA molecule that encodes one of the above polypeptides; and (c) detecting in the sample a DNA sequence that amplifies in the presence of the first and second oligonucleotide primers. In a preferred embodiment, at least one of the

generate antibodies that detect the presence or absence of prostate cancer. Such modified sequences may be prepared and tested using, for example, the representative procedures described herein.

As used herein, a "conservative substitution" is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. In general, the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.

Variants may also, or alternatively, contain other modifications, including the deletion or addition of amino acids that have minimal influence on the antigenic properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (*e.g.*, poly-His), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.

A nucleotide "variant" is a sequence that differs from the recited nucleotide sequence in having one or more nucleotide deletions, substitutions or additions. Such modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (*DNA*, 2:183, 1983). Nucleotide variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant nucleotide sequences preferably exhibit at least about 70%, more preferably at least about 80% and most preferably at least about 90% identity to the recited sequence. Such variant nucleotide sequences will generally hybridize to the recite nucleotide sequence under stringent conditions. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65 °C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65 °C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65 °C.

"Polypeptides" as used herein also include combination, or fusion, polypeptides. A "combination polypeptide" is a polypeptide comprising at least one of the above immunogenic portions and one or more additional immunogenic prostate tumor-specific sequences, which are joined via a peptide linkage into a single amino acid chain. The sequences may be joined directly (*i.e.*, with no intervening amino acids) or may be joined by way of a linked sequence (*e.g.*, Gly-Cys-Gly) that does not significantly diminish the immunogenic properties of the component polypeptides.

The prostate tumor proteins of the present invention, and DNA molecules encoding such proteins, may be isolated from prostate tumor tissue using any of a variety of methods well known in the art. DNA sequences corresponding to a gene (of a portion thereof) encoding one of the inventive prostate tumor proteins may be isolated from a prostate tumor cDNA library using a subtraction technique as described in detail below. Examples of such DNA sequences are provided in SEQ ID Nos: 1-107, 109-111, 115-171, 173-175, 177 and 179-224. Partial DNA sequences thus obtained may be used to design oligonucleotide primers for the amplification of full-length DNA sequences in a polymerase chain reaction (PCR), using techniques well known in the art (see, for example, Mullis et al., *Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich ed., *PCR Technology*, Stockton Press, NY, 1989). Once a DNA sequence encoding a polypeptide is obtained, any of the above modifications may be readily introduced using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis as taught, for example, by Adelman et al. (*DNA*, 2:183, 1983).

The prostate tumor polypeptides disclosed herein may also be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (see, for example, Merrifield, *J. Am. Chem. Soc.* 85:2149-2146, 1963). Equipment for automated synthesis of polypeptides is commercially available from

oligonucleotide primers comprises at least about 10 contiguous nucleotides of a DNA molecule having a partial sequence selected from the group consisting of SEQ ID Nos: 2-3, 5-107, 109-11, 115-171, 173-175, 177 and 179-224.

In a further aspect, the present invention provides a method for detecting prostate cancer in a patient comprising: (a) obtaining a biological sample from the patient; (b) contacting the sample with an oligonucleotide probe specific for a DNA molecule that encodes one of the above polypeptides; and (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe. Preferably, the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule having a partial sequence selected from the group consisting of SEQ ID Nos: : 2-3, 5-107, 109-11, 115-171, 173-175, 177 and 179-224.

In related aspects, diagnostic kits comprising the above oligonucleotide probes or primers are provided.

These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.

DETAILED DESCRIPTION OF THE INVENTION

As noted above, the present invention is generally directed to compositions and methods for the immunodiagnosis and monitoring of prostate cancer. The inventive compositions are generally polypeptides that comprise at least a portion of a prostate tumor protein. Also included within the present invention are molecules (such as an antibody or fragment thereof) that bind to the inventive polypeptides. Such molecules are referred to herein as "binding agents."

In particular, the subject invention discloses polypeptides comprising at least a portion of a human prostate tumor protein, or a variant thereof such a protein, wherein the prostate tumor protein includes an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-11, 115-171, 173-175, 177, 179-224, the complements of said nucleotide sequences and variants thereof. As used herein, the term "polypeptide"

encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds. Thus, a polypeptide comprising a portion of one of the above prostate proteins may consist entirely of the portion, or the portion may be present within a larger polypeptide that contains additional sequences. The additional sequences may be derived from the native protein or may be heterologous, and such sequences may be immunoreactive and/or antigenic.

As used herein, an "immunogenic portion" of a human prostate tumor protein is a portion that is capable of eliciting an immune response in a patient inflicted with prostate cancer and as such binds to antibodies present within sera from a prostate cancer patient. Immunogenic portions of the proteins described herein may thus be identified in antibody binding assays. Such assays may generally be performed using any of a variety of means known to those of ordinary skill in the art, as described, for example, in Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. For example, a polypeptide may be immobilized on a solid support (as described below) and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A. Alternatively, a polypeptide may be used to generate monoclonal and polyclonal antibodies for use in detection of the polypeptide in blood or other fluids of prostate cancer patients.

The compositions and methods of the present invention also encompass variants of the above polypeptides and DNA molecules. A polypeptide "variant," as used herein, is a polypeptide that differs from the recited polypeptide only in conservative substitutions and/or modifications, such that the therapeutic, antigenic and/or immunogenic properties of the polypeptide are retained. Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% identity to the identified polypeptides. For prostate tumor polypeptides with immunoreactive properties, variants may, alternatively, be identified by modifying the amino acid sequence of one of the above polypeptides, and evaluating the immunoreactivity of the modified polypeptide. For prostate tumor polypeptides useful for the generation of diagnostic binding agents, a variant may be identified by evaluating a modified polypeptide for the ability to

suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, CA), and may be operated according to the manufacturer's instructions.

Alternatively, any of the above polypeptides may be produced recombinantly by inserting a DNA sequence that encodes the polypeptide into an expression vector and expressing the protein in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this invention. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, yeast or a mammalian cell line, such as CHO cells. The DNA sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof.

In general, regardless of the method of preparation, the polypeptides disclosed herein are prepared in substantially pure form (*i.e.*, the polypeptides are homogenous as determined by amino acid composition and primary sequence analysis). Preferably, the polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. In certain embodiments, described in more detail below, the substantially pure polypeptides are incorporated into pharmaceutical compositions or vaccines for use in one or more of the methods disclosed herein.

In a related aspect, the present invention provides fusion proteins comprising a first and a second inventive polypeptide or, alternatively, a polypeptide of the present invention and a known prostate antigen, together with variants of such fusion proteins. The fusion proteins of the present invention may also include a linker peptide between the first and second polypeptides.

A DNA sequence encoding a fusion protein of the present invention is constructed using known recombinant DNA techniques to assemble separate DNA sequences encoding the first and second polypeptides into an appropriate expression vector. The 3' end of a DNA sequence encoding the first polypeptide is ligated, with or without a peptide linker, to the 5' end of a DNA sequence encoding the second polypeptide so that the reading frames

of the sequences are in phase to permit mRNA translation of the two DNA sequences into a single fusion protein that retains the biological activity of both the first and the second polypeptides.

A peptide linker sequence may be employed to separate the first and the second polypeptides by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., *Gene* 40:39-46, 1985; Murphy et al., *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5' to the DNA sequence encoding the first polypeptides. Similarly, stop codons require to end translation and transcription termination signals are only present 3' to the DNA sequence encoding the second polypeptide.

Polypeptides and/or fusion proteins of the present invention may be used to generate binding agents, such as antibodies or fragments thereof, that are capable of detecting metastatic human prostate tumors. Binding agents of the present invention may generally be prepared using methods known to those of ordinary skill in the art, including the representative procedures described herein. Binding agents are capable of differentiating between patients with and without prostate cancer, using the representative assays described

herein. In other words, antibodies or other binding agents raised against a prostate tumor protein, or a suitable portion thereof, will generate a signal indicating the presence of primary or metastatic prostate cancer in at least about 20% of patients afflicted with the disease, and will generate a negative signal indicating the absence of the disease in at least about 90% of individuals without primary or metastatic prostate cancer. Suitable portions of such prostate tumor proteins are portions that are able to generate a binding agent that indicates the presence of primary or metastatic prostate cancer in substantially all (*i.e.*, at least about 80%, and preferably at least about 90%) of the patients for which prostate cancer would be indicated using the full length protein, and that indicate the absence of prostate cancer in substantially all of those samples that would be negative when tested with full length protein. The representative assays described below, such as the two-antibody sandwich assay, may generally be employed for evaluating the ability of a binding agent to detect metastatic human prostate tumors.

The ability of a polypeptide and/or fusion protein prepared as described herein to generate antibodies capable of detecting primary or metastatic human prostate tumors may generally be evaluated by raising one or more antibodies against the polypeptide (using, for example, a representative method described herein) and determining the ability of such antibodies to detect such tumors in patients. This determination may be made by assaying biological samples from patients with and without primary or metastatic prostate cancer for the presence of a polypeptide that binds to the generated antibodies. Such test assays may be performed, for example, using a representative procedure described below. Polypeptides that generate antibodies capable of detecting at least 20% of primary or metastatic prostate tumors by such procedures are considered to be useful in assays for detecting primary or metastatic human prostate tumors. Polypeptide specific antibodies may be used alone or in combination to improve sensitivity.

Polypeptides and/or fusion proteins capable of detecting primary or metastatic human prostate tumors may be used as markers for diagnosing prostate cancer or for monitoring disease progression in patients. In one embodiment, prostate cancer in a patient may be diagnosed by evaluating a biological sample obtained from the patient for the level of

one or more of the above polypeptides, relative to a predetermined cut-off value. As used herein, suitable "biological samples" include blood, sera, urine and/or prostate secretions.

The level of one or more of the above polypeptides may be evaluated using any binding agent specific for the polypeptide(s). A "binding agent," in the context of this invention, is any agent (such as a compound or a cell) that binds to a polypeptide as described above. As used herein, "binding" refers to a noncovalent association between two separate molecules (each of which may be free (*i.e.*, in solution) or present on the surface of a cell or a solid support), such that a "complex" is formed. Such a complex may be free or immobilized (either covalently or noncovalently) on a support material. The ability to bind may generally be evaluated by determining a binding constant for the formation of the complex. The binding constant is the value obtained when the concentration of the complex is divided by the product of the component concentrations. In general, two compounds are said to "bind" in the context of the present invention when the binding constant for complex formation exceeds about 10^3 L/mol. The binding constant may be determined using methods well known to those of ordinary skill in the art.

Any agent that satisfies the above requirements may be a binding agent. For example, a binding agent may be a ribosome with or without a peptide component, an RNA molecule or a peptide. In a preferred embodiment, the binding partner is an antibody, or a fragment thereof. Such antibodies may be polyclonal, or monoclonal. In addition, the antibodies may be single chain, chimeric, CDR-grafted or humanized. Antibodies may be prepared by the methods described herein and by other methods well known to those of skill in the art.

There are a variety of assay formats known to those of ordinary skill in the art for using a binding partner to detect polypeptide markers in a sample. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In a preferred embodiment, the assay involves the use of binding partner immobilized on a solid support to bind to and remove the polypeptide from the remainder of the sample. The bound polypeptide may then be detected using a second binding partner that contains a reporter group. Suitable second binding partners include antibodies that bind to the binding partner/polypeptide complex. Alternatively, a competitive assay may be utilized, in which a

polypeptide is labeled with a reporter group and allowed to bind to the immobilized binding partner after incubation of the binding partner with the sample. The extent to which components of the sample inhibit the binding of the labeled polypeptide to the binding partner is indicative of the reactivity of the sample with the immobilized binding partner.

The solid support may be any material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681. The binding agent may be immobilized on the solid support using a variety of techniques known to those of skill in the art, which are amply described in the patent and scientific literature. In the context of the present invention, the term "immobilization" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Immobilization by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the binding agent, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and about 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of binding agent ranging from about 10 ng to about 10 μ g, and preferably about 100 ng to about 1 μ g, is sufficient to immobilize an adequate amount of binding agent.

Covalent attachment of binding agent to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the binding agent. For example, the binding agent may be covalently attached to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the binding partner (*see, e.g.,* Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is a two-antibody sandwich assay. This assay may be performed by first contacting an antibody that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that polypeptides within the sample are allowed to bind to the immobilized antibody. Unbound sample is then removed from the immobilized polypeptide-antibody complexes and a second antibody (containing a reporter group) capable of binding to a different site on the polypeptide is added. The amount of second antibody that remains bound to the solid support is then determined using a method appropriate for the specific reporter group.

More specifically, once the antibody is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO). The immobilized antibody is then incubated with the sample, and polypeptide is allowed to bind to the antibody. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (*i.e.*, incubation time) is that period of time that is sufficient to detect the presence of polypeptide within a sample obtained from an individual with prostate cancer. Preferably, the contact time is sufficient to achieve a level of binding that is at least about 95% of that achieved at equilibrium between bound and unbound polypeptide. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. The second antibody, which contains a reporter group, may then be added to the solid support. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups and biotin. The conjugation of antibody to reporter group may be achieved using standard methods known to those of ordinary skill in the art.

The second antibody is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound polypeptide. An appropriate amount of time may generally be determined by assaying the level of binding that occurs over a period of time. Unbound second antibody is then removed and bound second antibody is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of prostate cancer, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antibody is incubated with samples from patients without prostate cancer. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for prostate cancer. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., 1985, p. 106-7. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for prostate cancer.

In a related embodiment, the assay is performed in a flow-through or strip test format, wherein the antibody is immobilized on a membrane, such as nitrocellulose. In the flow-through test, polypeptides within the sample bind to the immobilized antibody as the sample passes through the membrane. A second, labeled antibody then binds to the antibody-polypeptide complex as a solution containing the second antibody flows through the membrane. The detection of bound second antibody may then be performed as described above. In the strip test format, one end of the membrane to which antibody is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing second antibody and to the area of immobilized antibody. Concentration of second antibody at the area of immobilized antibody indicates the presence of prostate cancer. Typically, the concentration of second antibody at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of antibody immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of polypeptide that would be sufficient to generate a positive signal in the two-antibody sandwich assay, in the format discussed above. Preferably, the amount of antibody immobilized on the membrane ranges from about 25 ng to about 1 μ g, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount of biological sample.

Of course, numerous other assay protocols exist that are suitable for use with the antigens or antibodies of the present invention. The above descriptions are intended to be exemplary only.

In another embodiment, the above polypeptides may be used as markers for the progression of prostate cancer. In this embodiment, assays as described above for the diagnosis of prostate cancer may be performed over time, and the change in the level of reactive polypeptide(s) evaluated. For example, the assays may be performed every 24-72 hours for a period of 6 months to 1 year, and thereafter performed as needed. In general, prostate cancer is progressing in those patients in whom the level of polypeptide detected by the binding agent increases over time. In contrast, prostate cancer is not progressing when the level of reactive polypeptide either remains constant or decreases with time.

Antibodies for use in the above methods may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988. In one such technique, an immunogen comprising the antigenic polypeptide is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptides of this invention may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.

Monoclonal antibodies specific for the antigenic polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, *Eur. J. Immunol.* 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.

Monoclonal antibodies may be isolated from the supernatants of growing hybridoma colonies. In addition, various techniques may be employed to enhance the yield,

such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. The polypeptides of this invention may be used in the purification process in, for example, an affinity chromatography step.

Monoclonal antibodies of the present invention may also be used as therapeutic reagents, to diminish or eliminate prostate tumors. The antibodies may be used on their own (for instance, to inhibit metastases) or coupled to one or more therapeutic agents. Suitable agents in this regard include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof. Preferred radionuclides include ^{90}Y , ^{123}I , ^{125}I , ^{131}I , ^{186}Re , ^{188}Re , ^{211}At , and ^{212}Bi . Preferred drugs include methotrexate, and pyrimidine and purine analogs. Preferred differentiation inducers include phorbol esters and butyric acid. Preferred toxins include ricin, abrin, diphtheria toxin, cholera toxin, gelonin, *Pseudomonas* exotoxin, *Shigella* toxin, and pokeweed antiviral protein.

A therapeutic agent may be coupled (*e.g.*, covalently bonded) to a suitable monoclonal antibody either directly or indirectly (*e.g.*, via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (*e.g.*, a halide) on the other.

Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional (such as those described in the

catalog of the Pierce Chemical Co., Rockford, IL), may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, *e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.

Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (*e.g.*, U.S. Patent No. 4,489,710, to Spitler), by irradiation of a photolabile bond (*e.g.*, U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (*e.g.*, U.S. Patent No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (*e.g.*, U.S. Patent No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (*e.g.*, U.S. Patent No. 4,569,789, to Blattler et al.).

It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used. Alternatively, a carrier can be used.

A carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (*e.g.*, U.S. Patent No. 4,507,234, to Kato et al.), peptides and polysaccharides such as aminodextran (*e.g.*, U.S. Patent No. 4,699,784, to Shih et al.). A carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (*e.g.*, U.S. Patent Nos. 4,429,008 and 4,873,088). Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792 discloses representative radiohalogenated small molecules and their synthesis. A radionuclide chelate may be formed from chelating compounds that include those containing

nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide. For example, U.S. Patent No. 4,673,562, to Davison et al. discloses representative chelating compounds and their synthesis.

A variety of routes of administration for the antibodies and immunoconjugates may be used. Typically, administration will be intravenous, intramuscular, subcutaneous or in the bed of a resected tumor. It will be evident that the precise dose of the antibody/immunoconjugate will vary depending upon the antibody used, the antigen density on the tumor, and the rate of clearance of the antibody.

Diagnostic reagents of the present invention may also comprise DNA sequences encoding one or more of the above polypeptides, or one or more portions thereof. For example, at least two oligonucleotide primers may be employed in a polymerase chain reaction (PCR) based assay to amplify prostate tumor-specific cDNA derived from a biological sample, wherein at least one of the oligonucleotide primers is specific for a DNA molecule encoding a prostate tumor protein of the present invention. The presence of the amplified cDNA is then detected using techniques well known in the art, such as gel electrophoresis. Similarly, oligonucleotide probes specific for a DNA molecule encoding a prostate tumor protein of the present invention may be used in a hybridization assay to detect the presence of an inventive polypeptide in a biological sample.

As used herein, the term "oligonucleotide primer/probe specific for a DNA molecule" means an oligonucleotide sequence that has at least about 80%, preferably at least about 90% and more preferably at least about 95%, identity to the DNA molecule in question. Oligonucleotide primers and/or probes which may be usefully employed in the inventive diagnostic methods preferably have at least about 10-40 nucleotides. In a preferred embodiment, the oligonucleotide primers comprise at least about 10 contiguous nucleotides of a DNA molecule having a sequence selected from SEQ ID Nos: 1-107, 109-111, 115-171, 173-175, 177 and 179-224. Preferably, oligonucleotide probes for use in the inventive diagnostic methods comprise at least about 15 contiguous oligonucleotides of a DNA molecule having a sequence provided in SEQ ID Nos: 1-107, 109-111, 115-171, 173-175, 177 and 179-224. Techniques for both PCR based assays and hybridization assays are well known in the art (see, for example, Mullis et al. *Ibid*; Ehrlich, *Ibid*). Primers or probes may

thus be used to detect prostate tumor-specific sequences in biological samples, including blood, semen, prostate tissue and/or prostate tumor tissue.

Polypeptides of the present invention that comprise an immunogenic portion of a prostate tumor protein may also be used for immunotherapy of prostate cancer, wherein the polypeptide stimulates the patient's own immune response to prostate tumor cells. In further aspects, the present invention provides methods for using one or more of the immunoreactive polypeptides encoded by a DNA molecule having a sequence provided in SEQ ID NO: 1-107, 109-111, 115-171, 173-175, 177 and 179-224 (or DNA encoding such polypeptides) for immunotherapy of prostate cancer in a patient. As used herein, a "patient" refers to any warm-blooded animal, preferably a human. A patient may be afflicted with a disease, or may be free of detectable disease. Accordingly, the above immunoreactive polypeptides may be used to treat prostate cancer or to inhibit the development of prostate cancer. The polypeptides may be administered either prior to or following surgical removal of primary tumors and/or treatment by administration of radiotherapy and conventional chemotherapeutic drugs.

In these aspects, the polypeptide is generally present within a pharmaceutical composition and/or a vaccine. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable carrier. The vaccines may comprise one or more of such polypeptides and a non-specific immune response enhancer, such as an adjuvant, biodegradable microsphere (e.g., polylactic galactide) or a liposome (into which the polypeptide is incorporated). Pharmaceutical compositions and vaccines may also contain other epitopes of prostate tumor antigens, either incorporated into a combination polypeptide (i.e., a single polypeptide that contains multiple epitopes) or present within a separate polypeptide.

Alternatively, a pharmaceutical composition or vaccine may contain DNA encoding one or more of the above polypeptides, such that the polypeptide is generated *in situ*. In such pharmaceutical compositions and vaccines, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid

expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an epitope of a prostate cell antigen on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., *PNAS* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *PNAS* 91:215-219, 1994; Kass-Eisler et al., *PNAS* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be "naked," as described, for example, in published PCT application WO 90/11092, and Ulmer et al., *Science* 259:1745-1749, 1993, reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

Routes and frequency of administration, as well as dosage, will vary from individual to individual and may parallel those currently being used in immunotherapy of other diseases. In general, the pharmaceutical compositions and vaccines may be administered by injection (e.g., intracutaneous, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Between 1 and 10 doses may be administered over a 3-24 week period. Preferably, 4 doses are administered, at an interval of 3 months, and booster administrations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that is effective to raise an immune response (cellular and/or humoral) against prostate tumor cells in a treated patient. A suitable immune response is at least 10-50% above the basal (i.e., untreated) level. In general, the amount of polypeptide present in a dose (or produced *in situ* by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from

about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 μ g. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.01 mL to about 5 mL.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax and/or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and/or magnesium carbonate, may be employed. Biodegradable microspheres (*e.g.*, polylactic glycolide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

Any of a variety of non-specific immune response enhancers may be employed in the vaccines of this invention. For example, an adjuvant may be included. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune response, such as lipid A, *Bordella pertussis* or *Mycobacterium tuberculosis*. Such adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ).

Polypeptides disclosed herein may also be employed in *ex vivo* treatment of prostate cancer. For example, cells of the immune system, such as T cells, may be isolated from the peripheral blood of a patient, using a commercially available cell separation system, such as CellPro Incorporated's (Bothell, WA) CEPRATE™ system (see U.S. Patent No. 5,240,856; U.S. Patent No. 5,215,926; WO 89/06280; WO 91/16116 and WO 92/07243). The separated cells are stimulated with one or more of the immunoreactive polypeptides contained within a delivery vehicle, such as a microsphere, to provide antigen-specific T cells. The population of tumor antigen-specific T cells is then expanded using standard techniques and the cells are administered back to the patient.

The following Examples are offered by way of illustration and not by way of limitation.

EXAMPLES

EXAMPLE 1

ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES

This Example describes the isolation of prostate tumor polypeptides from a prostate tumor cDNA library.

A human prostate tumor cDNA expression library was constructed from prostate tumor poly A⁺ RNA using a Superscript Plasmid System for cDNA Synthesis and Plasmid Cloning kit (BRL Life Technologies, Gaithersburg, MD 20897) following the manufacturer's protocol. Specifically, prostate tumor tissues were homogenized with polytron (Kinematica, Switzerland) and total RNA was extracted using Trizol reagent (BRL Life Technologies) as directed by the manufacturer. The poly A⁺ RNA was then purified using a Qiagen oligotex spin column mRNA purification kit (Qiagen, Santa Clarita, CA 91355) according to the manufacturer's protocol. First-strand cDNA was synthesized using the NotI/Oligo-dT18 primer. Double-stranded cDNA was synthesized, ligated with EcoRI/BAXI adaptors (Invitrogen, San Diego, CA) and digested with NotI. Following size fractionation with Chroma Spin-1000 columns (Clontech, Palo Alto, CA 94303), the cDNA was ligated into the EcoRI/NotI site of pCDNA3.1 (Invitrogen) and transformed into ElectroMax *E. coli* DH10B cells (BRL Life Technologies) by electroporation.

Using the same procedure, a normal human pancreas cDNA expression library was prepared from a pool of six tissue specimens (Clontech). The cDNA libraries were characterized by determining the number of independent colonies, the percentage of clones that carried insert, the average insert size and by sequence analysis. The prostate tumor library contained 1.64×10^7 independent colonies, with 70% of clones having an insert and the average insert size being 1745 base pairs. The normal pancreas cDNA library contained 3.3×10^6 independent colonies, with 69% of clones having inserts and the average insert size

being 1120 base pairs. For both libraries, sequence analysis showed that the majority of clones had a full length cDNA sequence and were synthesized from mRNA, with minimal rRNA and mitochondrial DNA contamination.

cDNA library subtraction was performed using the above prostate tumor and normal pancreas cDNA libraries, as described by Hara et al. (*Blood*, 84:189-199, 1994) with some modifications. Specifically, a prostate tumor-specific subtracted cDNA library was generated as follows. Normal pancreas cDNA library (70 µg) was digested with EcoRI, NotI, and SfuI, followed by a filling-in reaction with DNA polymerase Klenow fragment. After phenol-chloroform extraction and ethanol precipitation, the DNA was dissolved in 100 µl of H₂O, heat-denatured and mixed with 100 µl (100 µg) of Photoprobe biotin (Vector Laboratories, Burlingame, CA). As recommended by the manufacturer, the resulting mixture was irradiated with a 270 W sunlamp on ice for 20 minutes. Additional Photoprobe biotin (50 µl) was added and the biotinylation reaction was repeated. After extraction with butanol five times, the DNA was ethanol-precipitated and dissolved in 23 µl H₂O to form the driver DNA.

To form the tracer DNA, 10 µg prostate tumor cDNA library was digested with BamHI and XhoI, phenol chloroform extracted and passed through Chroma spin-400 columns (Clontech). Following ethanol precipitation, the tracer DNA was dissolved in 5 µl H₂O. Tracer DNA was mixed with 15 µl driver DNA and 20 µl of 2 x hybridization buffer (1.5 M NaCl/10 mM EDTA/50 mM HEPES pH 7.5/0.2% sodium dodecyl sulfate), overlaid with mineral oil, and heat-denatured completely. The sample was immediately transferred into a 68 °C water bath and incubated for 20 hours (long hybridization [LH]). The reaction mixture was then subjected to a streptavidin treatment followed by phenol/chloroform extraction. This process was repeated three more times. Subtracted DNA was precipitated, dissolved in 12 µl H₂O, mixed with 8 µl driver DNA and 20 µl of 2 x hybridization buffer, and subjected to a hybridization at 68 °C for 2 hours (short hybridization [SH]). After removal of biotinylated double-stranded DNA, subtracted cDNA was ligated into BamHI/XhoI site of chloramphenicol resistant pBCSK⁺ (Stratagene, La Jolla, CA 92037) and transformed into ElectroMax *E. coli* DH10B cells by electroporation to generate a prostate tumor specific subtracted cDNA library (prostate subtraction 1).

To analyze the subtracted cDNA library, plasmid DNA was prepared from 100 independent clones, randomly picked from the subtracted prostate tumor specific library and grouped based on insert size. Representative cDNA clones were further characterized by DNA sequencing with a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A (Foster City, CA). Six cDNA clones, hereinafter referred to as F1-13, F1-12, F1-16, H1-1, H1-9 and H1-4, were shown to be abundant in the subtracted prostate-specific cDNA library. The determined 3' and 5' cDNA sequences for F1-12 are provided in SEQ ID NO: 2 and 3, respectively, with determined 3' cDNA sequences for F1-13, F1-16, H1-1, H1-9 and H1-4 being provided in SEQ ID No: 1 and 4-7, respectively.

The cDNA sequences for the isolated clones were compared to known sequences in the gene bank using the EMBL and GenBank databases (release 96). Four of the prostate tumor cDNA clones, F1-13, F1-16, H1-1, and H1-4, were determined to encode the following previously identified proteins: prostate specific antigen (PSA), human glandular kallikrein, human tumor expression enhanced gene, and mitochondria cytochrome C oxidase subunit II. H1-9 was found to be identical to a previously identified human autonomously replicating sequence. No significant homologies to the cDNA sequence for F1-12 were found.

Subsequent studies led to the isolation of a full-length cDNA sequence for F1-12. This sequence is provided in SEQ ID NO: 107, with the corresponding predicted amino acid sequence being provided in SEQ ID NO: 108.

To clone less abundant prostate tumor specific genes, cDNA library subtraction was performed by subtracting the prostate tumor cDNA library described above with the normal pancreas cDNA library and with the three most abundant genes in the previously subtracted prostate tumor specific cDNA library: human glandular kallikrein, prostate specific antigen (PSA), and mitochondria cytochrome C oxidase subunit II. Specifically, 1 µg each of human glandular kallikrein, PSA and mitochondria cytochrome C oxidase subunit II cDNAs in pCDNA3.1 were added to the driver DNA and subtraction was performed as described above to provide a second subtracted cDNA library hereinafter referred to as the "subtracted prostate tumor specific cDNA library with spike".

Twenty-two cDNA clones were isolated from the subtracted prostate tumor specific cDNA library with spike. The determined 3' and 5' cDNA sequences for the clones referred to as J1-17, L1-12, N1-1862, J1-13, J1-19, J1-25, J1-24, K1-58, K1-63, L1-4 and L1-14 are provided in SEQ ID Nos: 8-9, 10-11, 12-13, 14-15, 16-17, 18-19, 20-21, 22-23, 24-25, 26-27 and 28-29, respectively. The determined 3' cDNA sequences for the clones referred to as J1-12, J1-16, J1-21, K1-48, K1-55, L1-2, L1-6, N1-1858, N1-1860, N1-1861, N1-1864 are provided in SEQ ID Nos: 30-40, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to three of the five most abundant DNA species, (J1-17, L1-12 and N1-1862; SEQ ID Nos: 8-9, 10-11 and 12-13, respectively). Of the remaining two most abundant species, one (J1-12; SEQ ID NO:30) was found to be identical to the previously identified human pulmonary surfactant-associated protein, and the other (K1-48; SEQ ID NO:33) was determined to have some homology to *R. norvegicus* mRNA for 2-arylpropionyl-CoA epimerase. Of the 17 less abundant cDNA clones isolated from the subtracted prostate tumor specific cDNA library with spike, four (J1-16, K1-55, L1-6 and N1-1864; SEQ ID Nos:31, 34, 36 and 40, respectively) were found to be identical to previously identified sequences, two (J1-21 and N1-1860; SEQ ID Nos: 32 and 38, respectively) were found to show some homology to non-human sequences, and two (L1-2 and N1-1861; SEQ ID Nos: 35 and 39, respectively) were found to show some homology to known human sequences. No significant homologies were found to the polypeptides J1-13, J1-19, J1-24, J1-25, K1-58, K1-63, L1-4, L1-14 (SEQ ID Nos: 14-15, 16-17, 20-21, 18-19, 22-23, 24-25, 26-27, 28-29; respectively).

Subsequent studies led to the isolation of full length cDNA sequences for J1-17, L1-12 and N1-1862 (SEQ ID NOS: 109-111, respectively). The corresponding predicted amino acid sequences are provided in SEQ ID NOS: 112-114.

In a further experiment, four additional clones were identified by subtracting a prostate tumor cDNA library with normal prostate cDNA prepared from a pool of three normal prostate poly A+ RNA (prostate subtraction 2). The determined cDNA sequences for these clones, hereinafter referred to as U1-3064, U1-3065, V1-3692 and 1A-3905, are provided in SEQ ID NO: 69-72, respectively. Comparison of the determined sequences with those in the gene bank revealed no significant homologies to U1-3065.

A second subtraction with spike (prostate subtraction spike 2) was performed by subtracting a prostate tumor specific cDNA library with spike with normal pancreas cDNA library and further spiked with PSA, J1-17, pulmonary surfactant-associated protein, mitochondrial DNA, cytochrome c oxidase subunit II, N1-1862, autonomously replicating sequence, L1-12 and tumor expression enhanced gene. Four additional clones, hereinafter referred to as V1-3686, R1-2330, 1B-3976 and V1-3679, were isolated. The determined cDNA sequences for these clones are provided in SEQ ID NO:73-76, respectively. Comparison of these sequences with those in the gene bank revealed no significant homologies to V1-3686 and R1-2330.

Further analysis of the three prostate subtractions described above (prostate subtraction 2, subtracted prostate tumor specific cDNA library with spike, and prostate subtraction spike 2) resulted in the identification of sixteen additional clones, referred to as 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1G-4734, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4810, 1I-4811, 1J-4876, 1K-4884 and 1K-4896. The determined cDNA sequences for these clones are provided in SEQ ID NOS: 77-92, respectively. Comparison of these sequences with those in the gene bank as described above, revealed no significant homologies to 1G-4741, 1G-4734, 1I-4807, 1J-4876 and 1K-4896 (SEQ ID NOS: 79, 81, 87, 90 and 92, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1G-4736, 1G-4738, 1G-4741, 1G-4744, 1H-4774, 1H-4781, 1H-4785, 1H-4787, 1H-4796, 1I-4807, 1J-4876, 1K-4884 and 1K-4896, provided in SEQ ID NOS: 179-188 and 191-193, respectively, and to the determination of additional partial cDNA sequences for 1I-4810 and 1I-4811, provided in SEQ ID NOS: 189 and 190, respectively.

An additional subtraction was performed by subtracting a normal prostate cDNA library with normal pancreas cDNA (prostate subtraction 3). This led to the identification of six additional clones referred to as 1G-4761, 1G-4762, 1H-4766, 1H-4770, 1H-4771 and 1H-4772 (SEQ ID NOS: 93-98). Comparison of these sequences with those in the gene bank revealed no significant homologies to 1G-4761 and 1H-4771 (SEQ ID NOS: 93 and 97, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1G-4761, 1G-4762, 1H-4766 and 1H-4772 provided in SEQ

ID NOS: 194-196 and 199, respectively, and to the determination of additional partial cDNA sequences for 1H-4770 and 1H-4771, provided in SEQ ID NOS: 197 and 198, respectively.

Subtraction of a prostate tumor cDNA library, prepared from a pool of polyA+ RNA from three prostate cancer patients, with a normal pancreas cDNA library (prostate subtraction 4) led to the identification of eight clones, referred to as 1D-4297, 1D-4309, 1D.1-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280 (SEQ ID NOS: 99-107). These sequences were compared to those in the gene bank as described above. No significant homologies were found to 1D-4283 and 1D-4304 (SEQ ID NOS: 103 and 104, respectively). Further analysis of the isolated clones led to the determination of extended cDNA sequences for 1D-4309, 1D.1-4278, 1D-4288, 1D-4283, 1D-4304, 1D-4296 and 1D-4280, provided in SEQ ID NOS: 200-206, respectively.

cDNA clones isolated in prostate subtraction 1 and prostate subtraction 2, described above, were colony PCR amplified and their mRNA expression levels in prostate tumor, normal prostate and in various other normal tissues were determined using microarray technology (Synteni, Palo Alto, CA). Briefly, the PCR amplification products were dotted onto slides in an array format, with each product occupying a unique location in the array. mRNA was extracted from the tissue sample to be tested, reverse transcribed, and fluorescent-labeled cDNA probes were generated. The microarrays were probed with the labeled cDNA probes, the slides scanned and fluorescence intensity was measured. This intensity correlates with the hybridization intensity. Two novel clones (referred to as P509S and P510S) were found to be over-expressed in prostate tumor and normal prostate and expressed at low levels in all other normal tissues tested (liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon). The determined cDNA sequences for P509S and P510S are provided in SEQ ID NO: 223 and 224, respectively. Comparison of these sequences with those in the gene bank as described above, revealed some homology to previously identified ESTs.

EXAMPLE 2

DETERMINATION OF TISSUE SPECIFICITY OF PROSTATE TUMOR POLYPEPTIDES

Using gene specific primers, mRNA expression levels for the representative prostate tumor polypeptides F1-16, H1-1, J1-17, L1-12, F1-12 and N1-1862 were examined in a variety of normal and tumor tissues using RT-PCR.

Briefly, total RNA was extracted from a variety of normal and tumor tissues using Trizol reagent as described above. First strand synthesis was carried out using 1-2 μ g of total RNA with SuperScript II reverse transcriptase (BRL Life Technologies) at 42 °C for one hour. The cDNA was then amplified by PCR with gene-specific primers. To ensure the semi-quantitative nature of the RT-PCR, β -actin was used as an internal control for each of the tissues examined. First, serial dilutions of the first strand cDNAs were prepared and RT-PCR assays were performed using β -actin specific primers. A dilution was then chosen that enabled the linear range amplification of the β -actin template and which was sensitive enough to reflect the differences in the initial copy numbers. Using these conditions, the β -actin levels were determined for each reverse transcription reaction from each tissue. DNA contamination was minimized by DNase treatment and by assuring a negative PCR result when using first strand cDNA that was prepared without adding reverse transcriptase.

mRNA Expression levels were examined in four different types of tumor tissue (prostate tumor from 2 patients, breast tumor from 3 patients, colon tumor, lung tumor), and sixteen different normal tissues, including prostate, colon, kidney, liver, lung, ovary, pancreas, skeletal muscle, skin, stomach, testes, bone marrow and brain. F1-16 was found to be expressed at high levels in prostate tumor tissue, colon tumor and normal prostate, and at lower levels in normal liver, skin and testes, with expression being undetectable in the other tissues examined. H1-1 was found to be expressed at high levels in prostate tumor, lung tumor, breast tumor, normal prostate, normal colon and normal brain, at much lower levels in normal lung, pancreas, skeletal muscle, skin, small intestine, bone marrow, and was not detected in the other tissues tested. J1-17 and L1-12 appear to be specifically over-expressed in prostate, with both genes being expressed at high levels in prostate tumor and normal prostate but at low to undetectable levels in all the other tissues

examined. N1-1862 was found to be over-expressed in 60% of prostate tumors and detectable in normal colon and kidney. The RT-PCR results thus indicate that F1-16, H1-1, J1-17, N1-1862 and L1-12 are either prostate specific or are expressed at significantly elevated levels in prostate.

Further RT-PCR studies showed that F1-12 is over-expressed in 60% of prostate tumors, detectable in normal kidney but not detectable in all other tissues tested. Similarly, R1-2330 was shown to be over-expressed in 40% of prostate tumors, detectable in normal kidney and liver, but not detectable in all other tissues tested. U1-3064 was found to be over-expressed in 60% of prostate tumors, and also expressed in breast and colon tumors, but was not detectable in normal tissues.

RT-PCR characterization of R1-2330, U1-3064 and 1D-4279 showed that these three antigens are over-expressed in prostate and/or prostate tumors.

Northern analysis with four prostate tumors, two normal prostate samples, two BPH prostates, and normal colon, kidney, liver, lung, pancreas, skeletal muscle, brain, stomach, testes, small intestine and bone marrow, showed that L1-12 is over-expressed in prostate tumors and normal prostate, while being undetectable in other normal tissues tested. J1-17 was detected in two prostate tumors and not in the other tissues tested. N1-1862 was found to be over-expressed in three prostate tumors and to be expressed in normal prostate, colon and kidney, but not in other tissues tested. F1-12 was found to be highly expressed in two prostate tumors and to be undetectable in all other tissues tested.

The micro-array technology described above was used to determine the expression levels of representative antigens described herein in prostate tumor, breast tumor and the following normal tissues: prostate, liver, pancreas, skin, bone marrow, brain, breast, adrenal gland, bladder, testes, salivary gland, large intestine, kidney, ovary, lung, spinal cord, skeletal muscle and colon. L1-12 was found to be over-expressed in normal prostate and prostate tumor, with some expression being detected in normal skeletal muscle. Both J1-12 and F1-12 were found to be over-expressed in prostate tumor, with expression being lower or undetectable in all other tissues tested. N1-1862 was found to be expressed at high levels in prostate tumor and normal prostate, and at low levels in normal large intestine and normal colon, with expression being undetectable in all other tissues tested. R1-2330 was found to

be over-expressed in prostate tumor and normal prostate, and to be expressed at lower levels in all other tissues tested. 1D-4279 was found to be over-expressed in prostate tumor and normal prostate, expressed at lower levels in normal spinal cord, and to be undetectable in all other tissues tested.

Example 3

ISOLATION AND CHARACTERIZATION OF PROSTATE TUMOR POLYPEPTIDES BY PCR-BASED SUBTRACTON

A cDNA subtraction library, containing cDNA from normal prostate subtracted with ten other normal tissue cDNAs (brain, heart, kidney, liver, lung, ovary, placenta, skeletal muscle, spleen and thymus) and then submitted to a first round of PCR amplification, was purchased from Clontech. This library was subjected to a second round of PCR amplification, following the manufacturer's protocol. The resulting cDNA fragments were subcloned into the vector pT7 Blue T-vector (Novagen, Madison, WI) and transformed into XL-1 Blue MRF' *E. coli* (Stratagene). DNA was isolated from independent clones and sequenced using a Perkin Elmer/Applied Biosystems Division Automated Sequencer Model 373A.

Fifty-nine positive clones were sequenced. Comparison of the DNA sequences of these clones with those in the gene bank, as described above, revealed no significant homologies to 25 of these clones, hereinafter referred to as P5, P8, P9, P18, P20, P30, P34, P36, P38, P39, P42, P49, P50, P53, P55, P60, P64, P65, P73, P75, P76, P79, and P84. The determined cDNA sequences for these clones are provided in SEQ ID NO:41-45, 47-52 and 54-65, respectively. P29, P47, P68, P80 and P82 (SEQ ID NO:46, 53 and 66-68, respectively) were found to show some degree of homology to previously identified DNA sequences. To the best of the inventors' knowledge, none of these sequences have been previously shown to be present in prostate. Further studies using the PCR-based methodology described above resulted in the isolation of more than 180 additional clones, of which 23 clones were found to show no significant

homologies to known sequences. The determined cDNA sequences for these clones are provided in SEQ ID NO: 115-123, 127, 131, 137, 145, 147-151, 153, 156-158 and 160. Twenty-three clones (SEQ ID NO: 124-126, 128-130, 132-136, 138-144, 146, 152, 154, 155 and 159) were found to show some homology to previously identified ESTs. An additional ten clones (SEQ ID NO: 161-170) were found to have some degree of homology to known genes. An additional clone, referred to as P703, was found to have five splice variants. The determined DNA sequence for the variants referred to as DE1, DE13 and DE14 are provided in SEQ ID NOS: 171, 175 and 177, respectively, with the corresponding predicted amino acid sequences being provided in SEQ ID NO: 172, 176 and 178, respectively. The DNA sequences for the splice variants referred to as DE2 and DE6 are provided in SEQ ID NOS: 173 and 174, respectively.

mRNA Expression levels for representative clones in tumor tissues (prostate (n=5), breast (n=2), colon and lung) normal tissues (prostate (n=5), colon, kidney, liver, lung (n=2), ovary (n=2), skeletal muscle, skin, stomach, small intestine and brain), and activated and non-activated PBMC was determined by RT-PCT as described above. Expression was examined in one sample of each tissue type unless otherwise indicated.

P9 was found to be highly expressed in normal prostate and prostate tumor compared to all normal tissues tested except for normal colon which showed comparable expression. P20 was found to be highly expressed in normal prostate and prostate tumor, compared to all twelve normal tissues tested. A modest increase in expression of P20 in breast tumor (n=2), colon tumor and lung tumor was seen compared to all normal tissues except lung (1 of 2). Increased expression of P18 was found in normal prostate, prostate tumor and breast tumor compared to other normal tissues except lung and stomach. A modest increase in expression of P5 was observed in normal prostate compared to most other normal tissues. However, some elevated expression was seen in normal lung and PBMC. Elevated expression of P5 was also observed in prostate tumors (2 of 5), breast tumor and one lung tumor sample. For P30, similar expression levels were seen in normal prostate and prostate tumor, compared to six of twelve other normal tissues tested. Increased expression was seen in breast tumors, one lung tumor sample and one colon tumor sample, and also in normal PBMC. P29 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5

of 5) compared to the majority of normal tissues. However, substantial expression of P29 was observed in normal colon and normal lung (2 of 2). P80 was found to be over-expressed in prostate tumor (5 of 5) and normal prostate (5 of 5) compared to all other normal tissues tested, with increased expression also being seen in colon tumor.

Further studies using the above methodology resulted in the isolation of twelve additional clones, hereinafter referred to as 10-d8, 10-h10, 11-c8, 7-g6, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3, 8-h11, g-f12 and g-f3. The determined DNA sequences for 10-d8, 10-h10, 11-c8, 8-d4, 8-d9, 8-h11, g-f12 and g-f3 are provided in SEQ ID NO: 207, 208, 209, 216, 217, 220, 221 and 222, respectively. The determined forward and reverse DNA sequences for 7-g6, 8-b5, 8-b6 and 8-g3 are provided in SEQ ID NO: 210 and 211; 212 and 213; 214 and 215; and 218 and 219, respectively. Comparison of these sequences with those in the gene bank revealed no significant homologies to the sequences of 7-g6 and g-f3. The clones 10-d8, 11-c8 and 8-h11 were found to show some homology to previously isolated ESTs, while 10-h10, 8-b5, 8-b6, 8-d4, 8-d9, 8-g3 and g-f12 were found to show some homology to previously identified genes.

EXAMPLE 4

SYNTHESIS OF POLYPEPTIDES

Polypeptides may be synthesized on an Applied Biosystems 430A peptide synthesizer using FMOC chemistry with HPTU (O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate) activation. A Gly-Cys-Gly sequence may be attached to the amino terminus of the peptide to provide a method of conjugation, binding to an immobilized surface, or labeling of the peptide. Cleavage of the peptides from the solid support may be carried out using the following cleavage mixture: trifluoroacetic acid:ethanedithiol:thioanisole:water:phenol (40:1:2:2:3). After cleaving for 2 hours, the peptides may be precipitated in cold methyl-t-butyl-ether. The peptide pellets may then be dissolved in water containing 0.1% trifluoroacetic acid (TFA) and lyophilized prior to purification by C18 reverse phase HPLC. A gradient of 0%-60% acetonitrile (containing 0.1% TFA) in water (containing 0.1% TFA) may be used to elute the peptides. Following

lyophilization of the pure fractions, the peptides may be characterized using electrospray or other types of mass spectrometry and by amino acid analysis.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: Xu, Jiangchun
Dillon, Davin C.

(ii) TITLE OF INVENTION: COMPOUNDS FOR IMMUNODIAGNOSIS OF PROSTATE CANCER
AND METHODS FOR THEIR USE

(iii) NUMBER OF SEQUENCES: 224

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SEED and BERRY LLP
(B) STREET: 6300 Columbia Center, 701 Fifth Avenue
(C) CITY: Seattle
(D) STATE: WA
(E) COUNTRY: USA
(F) ZIP: 98104

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 23-FEB-1998
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Maki, David J.
(B) REGISTRATION NUMBER: 31,392
(C) REFERENCE/DOCKET NUMBER: 210121.428C3

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (206) 622-4900
(B) TELEFAX: (206) 682-6031

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 814 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TTTTTTTTTT TTTTTCACAG TATAACAGCT CTTTATTCT GTGAGTTCTA CTAGGAAATC

ATCAAATCTG	AGGGTTGTCT	GGAGGACTTC	AATACACCTC	CCCCCATAGT	GAATCAGCTT	120
CCAGGGGGTC	CAGTCCCTCT	CCTTACTTCA	TCCCCATCCC	ATGCCAAAGG	AAGACCCTCC	180
CTCCTTGGCT	CACAGCCTTC	TCTAGGCTTC	CCAGTGCCTC	CAGGACAGAG	TGGGTTATGT	240
TTTCAGCTCC	ATCCTTGCTG	TGAGTGTCTG	GTGCGTTGTG	CCTCCAGCTT	CTGCTCAGTG	300
CTTCATGGAC	AGTGTCCAGC	ACATGTCACT	CTCCACTCTC	TCAGTGTGGA	TCCACTAGTT	360
CTAGAGCGGC	CGCCACCGCG	GTGGAGCTCC	AGCTTTTGTT	CCCTTTAGTG	AGGGTTAATT	420
GCGCGCTTGG	CGTAATCATG	GTCATAACTG	TTTCCTGTGT	GAAATTGTTA	TCCGCTCACA	480
ATTCCACACA	ACATACGAGC	CGGAAGCATA	AAGTGTAAG	CCTGGGGTGC	CTAATGAGTG	540
ANCTAACTCA	CATTAATTGC	GTGCGCTCA	CTGNCCGCTT	TCCAGTCNGG	AAAACGTGTCG	600
TGCCAGCTGC	ATTAATGAAT	CGCCAACGC	NCGGGGAAAA	GCGGTTTGCG	TTTTGGGGGC	660
TCTTCCGCTT	CTCGCTCACT	NANTCCTGCG	CTCGGTCNTT	CGGCTGCGGG	GAACGGTATC	720
ACTCCTCAAA	GGNGGTATTA	CGGTTATCCN	NAAATCNGGG	GATACCCNGG	AAAAAANTTT	780
AACAAAAGGG	CANCAAAGGG	CNGAAACGTA	AAAA			814

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 816 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ACAGAAATGT	TGGATGGTGG	AGCACCTTTC	TATACGACTT	ACAGGACAGC	AGATGGGGAA	60
TCATGGCTG	TTGGAGCAAT	AGAACCCCAG	TTCTACGAGC	TGCTGATCAA	AGGACTTGGA	120
CTAAAGTCTG	ATGAACTTCC	CAATCAGATG	AGCATGGATG	ATTGGCCAGA	AATGAAGAAG	180
AAGTTTGCAG	ATGTATTGTC	AAAGAAGACG	AAGGCAGAGT	GGTGTCAAAT	CTTTGACGGC	240
ACAGATGCCT	GTGTGACTCC	GGTTCTGACT	TTTGAGGAGG	TTGTTTCATCA	TGATCACAAC	300
AAGGAACGGG	GCTCGTTTAT	CACCAGTGAG	GAGCAGGACG	TGAGCCCCCG	CCCTGCACCT	360
CTGCTGTTAA	ACACCCCAGC	CATCCCTTCT	TTCAAAAAGG	ATCCACTAGT	TCTAGAAGCG	420
GCCGCCACCG	CGGTGGAGCT	CCAGCTTTTG	TTCCCTTTAG	TGAGGGTTAA	TTGCGCGCTT	480
GGCGTAATCA	TGGTCATAGC	TGTTTCCTGT	GTGAAATTGT	TATCCGCTCA	CAATTCCCCC	540
AACATACGAG	CCGGAACATA	AAGTGTTAAG	CCTGGGGTGC	CTAATGANTG	AGCTAACTCN	600
CATTAATTGC	GTTGCGCTCA	CTGCCCCTT	TCCAGTCGGG	AAAACGTGTCG	TGCCACTGCN	660
TTANTGAATC	NGCCACCCCC	CGGGAAAAGG	CGGTTGCNTT	TTGGGCCTCT	TCCGCTTTCC	720
TCGCTCATTG	ATCCTNGCNC	CCGGTCTTCG	GCTGCGGNGA	ACGGTTCACT	CCTCAAAGGC	780
GGTNTNCCGG	TTATCCCCAA	ACNGGGGATA	CCNGA			816

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 773 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTTTTGAAAG	AAGGGATGGC	TGGGGTGTTT	AACAGCAGAG	GTGCAGGGCG	GGGGCTCACC	60
TCCTGCTCCT	CACTGGTGAT	AAACGAGCCC	CGTTCCTTGT	TGTGATCATG	ATGAACAACC	120

TCCTCAAAAG	TCAGAACCGG	AGTCACACAG	GCATCTGTGC	CGTCAAAGAT	TTGACACCAC	180
TCTGCCTTCG	TCTTCTTTGC	AAATACATCT	GCAAACCTCT	TCTTCATTTT	TGGCCAATCA	240
TCCATGCTCA	TCTGATTGGG	AAGTTCATCA	GACTTTAGTC	CANNTCCTTT	GATCAGCAGC	300
TCGTAGAACT	GGGGTTCTAT	TGCTCCAACA	GCCATGAATT	CCCCATCTGC	TGTCCTGTAA	360
GTCGTATAGA	AAGGTGCTCC	ACCATCCAAC	ATGTTCTGTC	CTCGAGGGGG	GGCCCGGTAC	420
CCAATTCGCC	CTATANTGAG	TCGTATTACG	CGCGCTCACT	GGCCGTCGTT	TTACAACGTC	480
GTGACTGGGA	AAACCCTGGG	CGTTACCAAC	TTAATCGCCT	TGCAGCACAT	CCCCCTTTTCG	540
CCAGCTGGGC	GTAATANCGA	AAAGGCCCGC	ACCGATCGCC	CTTCCAACAG	TTGCGCACCT	600
GAATGGGNAA	ATGGGACCCC	CCTGTTACCG	CGCATTNAAC	CCCCGCNGGG	TTTNGTTGTT	660
ACCCCCACNT	NNACCGCTTA	CACTTTGCCA	GCGCCTTANC	GCCCGCTCCC	TTTCNCCTTT	720
CTTCCCTTCC	TTTCNCNCCN	CTTCCCCCGG	GGGTTTCCCC	CNTCAAACCC	CNA	773

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 828 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCTCCTGAGT	CCTACTGACC	TGTGCTTTCT	GGTGTGGAGT	CCAGGGCTGC	TAGGAAAAGG	60
AATGGGCAGA	CACAGGTGTA	TGCCAATGTT	TCTGAAATGG	GTATAATTTT	GTCCTCTCCT	120
TCGGAACACT	GGCTGTCTCT	GAAGACTTCT	CGCTCAGTTT	CAGTGAGGAC	ACACACAAAG	180
ACGTGGGTGA	CCATGTTGTT	TGTGGGGTGC	AGAGATGGGA	GGGGTGGGGC	CCACCCTGGA	240
AGAGTGGACA	GTGACACAAG	GTGGACACTC	TCTACAGATC	ACTGAGGATA	AGCTGGAGCC	300
ACAATGCATG	AGGCACACAC	ACAGCAAGGA	TGACNCTGTA	AACATAGCCC	ACGCTGTCCT	360
GNGGGCACTG	GGAAGCCTAN	ATNAGGCCGT	GAGCANAAAG	AAGGGGAGGA	TCCACTAGTT	420
CTANAGCGGC	CGCCACCGCG	GTGGANCTCC	ANCTTTTGTT	CCCTTTAGTG	AGGGTTAATT	480
GCGCGCTTGG	CNTAATCATG	GTGCATANCTN	TTTCCTGTGT	GAAATTGTGA	TCCGCTCACA	540
ATTCCACACA	ACATACGANC	CGGAAACATA	AANTGTAAAC	CTGGGGTGCC	TAATGANTGA	600
CTAACTCACA	TTAATTGCGT	TGCGCTCACT	GCCCCTTTTC	CAATCNGGAA	ACCTGTCTTG	660
CCNCTTGCAT	TNATGAATCN	GCCAACCCCC	GGGAAAAGG	GTTTGCGTTT	TGGGCGCTCT	720
TCCGCTTCCT	CNCTCANTTA	NTCCCTNCNC	TCGGTCATTG	CGGCTGCNGC	AAACCGGTTT	780
ACCNCCTCCA	AAGGGGGTAT	TCCGGTTTCC	CCNAATCCGG	GGANANCC		828

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 834 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTTTTTTTT	TTTTTACTGA	TAGATGGAAT	TTATTAAGCT	TTTCACATGT	GATAGCACAT	60
AGTTTTTAATT	GCATCCAAAG	TACTAACAAA	AACTCTAGCA	ATCAAGAATG	GCAGCATGTT	120
ATTTTATAAC	AATCAACACC	TGTGGCTTTT	AAAATTTGGT	TTTCATAAGA	TAATTTATAC	180
TGAAGTAAAT	CTAGCCATGC	TTTTAAAAAA	TGCTTTAGGT	CACTCCAAGC	TTGGCAGTTA	240

ACATTTGGCA	TAAACAATAA	TAAAACAATC	ACAATTTAAT	AAATAACAAA	TACAACATTG	300
TAGGCCATAA	TCATATACAG	TATAAGGAAA	AGGTGGTAGT	GTTGAGTAAG	CAGTTATTAG	360
AATAGAATAC	CTTGGCCTCT	ATGCAAATAT	GTCTAGACAC	TTTGATTAC	TCAGCCCTGA	420
CATTCAAGTTT	TCAAAGTAGG	AGACAGGTTT	TACAGTATCA	TTTTACAGTT	TCCAACACAT	480
TGAAAACAAG	TAGAAAATGA	TGAGTTGATT	TTTATTAATG	CATTACATCC	TCAAGAGTTA	540
TCACCAACCC	CTCAGTTATA	AAAAATTTTC	AAGTTATATT	AGTCATATAA	CTTGGTGTGC	600
TTATTTTAAA	TTAGTGCTAA	ATGGATTAAG	TGAAGACAAC	AATGGTCCCC	TAATGTGATT	660
GATATTGGTC	ATTTTACCA	GCTTCTAAAT	CTNAACTTT	AGGCTTTTGA	ACTGGAACAT	720
TGNATNACAG	TGTTCCANAG	TTNCAACCTA	CTGGAACATT	ACAGTGTGCT	TGATTCAAAA	780
TGTTATTTTG	TTAAAAATTA	AATTTTAACC	TGGTGGAAAA	ATAATTTGAA	ATNA	834

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 818 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTTTTTTTTT	TTTTTTTTTT	AAGACCCTCA	TCAATAGATG	GAGACATACA	GAAATAGTCA	60
AACCACATCT	ACAAAATGCC	AGTATCAGGC	GGCGGCTTCG	AAGCCAAAGT	GATGTTTGGA	120
TGTAAAGTGA	AATATTAGTT	GGCGGATGAA	GCAGATAGTG	AGGAAAGTTG	AGCCAATAAT	180
GACGTGAAGT	CCGTGGAAGC	CTGTGGCTAC	AAAAAATGTT	GAGCCGTAGA	TGCCGTCGGA	240
AATGGTGAAG	GGAGACTCGA	AGTACTCTGA	GGCTTGTAGG	AGGGTAAAAT	AGAGACCCAG	300
TAAAATTGTA	ATAAGCAGTG	CTTGAATTAT	TTGGTTTCGG	TTGTTTTCTA	TTAGACTATG	360
GTGAGCTCAG	GTGATTGATA	CTCCTGATGC	GAGTAATACG	GATGTGTTTA	GGAGTGGGAC	420
TTCTAGGGGA	TTTAGCGGGG	TGATGCCTGT	TGGGGGCCAG	TGCCCTCCTA	GTTGGGGGGT	480
AGGGGCTAGG	CTGGAGTGGT	AAAAGGCTCA	GAAAAATCCT	GCGAAGAAAA	AAACTTCTGA	540
GGTAATAAAT	AGGATTATCC	CGTATCGAAG	GCCTTTTTGG	ACAGGTGGTG	TGTGGTGGCC	600
TTGGTATGTG	CTTTCTCGTG	TTACATCGCG	CCATCATTGG	TATATGGTTA	GTGTGTTGGG	660
TTANTANGGC	CTANTATGAA	GAACCTTTGG	ANTGGAATTA	AATCAATNGC	TTGGCCGGAA	720
GTCATTANGA	NGGCTNAAAA	GGCCCTGTGA	NGGGTCTGGG	CTNGGTTTGA	CCCNACCCAT	780
GGAATNCNCC	CCCCGGACNA	NTGNATCCCT	ATTCTTAA			818

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 817 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TTTTTTTTTT	TTTTTTTTTT	TGGCTCTAGA	GGGGGTAGAG	GGGGTGCTAT	AGGGTAAATA	60
CGGGCCCTAT	TTCAAAGATT	TTAGGGGAA	TTAATTTCTAG	GACGATGGGT	ATGAACTGT	120
GGTTTGCTCC	ACAGATTTC	GAGCATTGAC	CGTAGTATAC	CCCCGGTCGT	GTCAGCGTGA	180
AAGTGTTTTG	GTTTAGACGT	CCGGGAATTG	CATCTGTTTT	TAAGCCTAAT	GTGGGGACAG	240
CTCATGAGTG	CAAGACGTCT	TGTGATGTAA	TTATTATACN	AATGGGGGCT	TCAATCGGGA	300

GTACTACTCG	ATTGTCAACG	TCAAGGAGTC	GCAGGTCGCC	TGGTTCTAGG	AATAATGGGG	360
GAAGTATGTA	GGAATTGAAG	ATTAATCCGC	CGTAGTCGGT	GTTCTCCTAG	GTTCAATACC	420
ATTGGTGGCC	AATTGATTTG	ATGGTAAGGG	GAGGGATCGT	TGAACTCGTC	TGTTATGTAA	480
AGGATNCCTT	NGGGATGGGA	AGGCNATNAA	GGACTANGGA	TNAATGGCGG	GCANGATATT	540
TCAAACNGTC	TCTANTTCCT	GAAACGTCTG	AAATGTTAAT	AANAATTAAN	TTTNGTTATT	600
GAATNTTNNG	GAAAAGGGCT	TACAGGACTA	GAAACCAAAT	ANGAAAANTA	ATNNTAANGG	660
CNTTATCNTN	AAAGGTNATA	ACCNCTCCTA	TNATCCCACC	CAATNGNATT	CCCCACNCNN	720
ACNATTGGAT	NCCCCANTTC	CANAAAANGG	CNCCCCCGG	TGNANNCCNC	CTTTTGTTC	780
CTTNANTGAN	GGTTATTCNC	CCCTNGCNTT	ATCANCC			817

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 799 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CATTTCGGG	TTTACTTTCT	AAGGAAAGCC	GAGCGGAAGC	TGCTAACGTG	GGAATCGGTG	60
CATAAGGAGA	ACTTTCTGCT	GGCAGCGCCT	AGGGACAAGC	GGGAGAGCGA	CTCCGAGCGT	120
CTGAAGCGCA	CGTCCCAGAA	GGTGGACTTG	GCACTGAAAC	AGCTGGGACA	CATCCGCGAG	180
TACGAACAGC	GCCTGAAAGT	GCTGGAGCGG	GAGGTCCAGC	AGTGTAGCCG	CGTCCTGGGG	240
TGGGTGGCCG	ANGCCTGANC	CGCTCTGCCT	TGCTGCCCCC	ANGTGGGCCG	CCACCCCTTG	300
ACCTGCCTGG	GTCCAAACAC	TGAGCCCTGC	TGGCGGACTT	CAAGGANAAC	CCCCACANGG	360
GGATTTTGCT	CCTANANTAA	GGCTCATCTG	GGCCTCGGCC	CCCCACCTG	GTTGGCCTTG	420
TCTTTGANGT	GAGCCCCATG	TCCATCTGGG	CCACTGTCTG	GACCACCTTT	NGGGAGTGTT	480
CTCCTTACAA	CCACANNATG	CCCGGCTCCT	CCCGGAAACC	ANTCCCANCC	TGNGAAGGAT	540
CAAGNCCTGN	ATCCACTNNT	NCTANAACCG	GCCNCCNCCG	CNGTGGAACC	CNCCTTNTGT	600
TCCTTTTCNT	TNAGGGTTAA	TNNGCGCTTG	GCCTTNCCAN	NGTCTTNCNC	NTTTTCCNNT	660
GTTNAAATTG	TTANGCNCCC	NCCNNTCCCN	CNNCNCNAN	CCCGACCCNN	ANNTTNNANN	720
NCCTGGGGGT	NCCNNCNGAT	TGACCCNCC	NCCCTNTANT	TGCNTTNGGG	NNCNNTGCCC	780
CTTCCCTCT	NGGGANNC					799

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 801 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ACGCCTTGAT	CCTCCCAGGC	TGGGACTGGT	TCTGGGAGGA	GCCGGGCATG	CTGTGGTTTG	60
TAANGATGAC	ACTCCCAAAG	GTGGTCCTGA	CAGTGGCCCA	GATGGACATG	GGGCTCACCT	120
CAAGGACAAG	GCCACCAGGT	GCGGGGGCCG	AAGCCCACAT	GATCCTTACT	CTATGAGCAA	180
AATCCCTGT	GGGGGCTTCT	CCTTGAAGTC	CGCCANCAGG	GCTCAGTCTT	TGGACCCANG	240
CAGGTCATGG	GGTTGTNGNC	CAACTGGGGG	CCNCAACGCA	AAANGGCNCA	GGGCCTCNGN	300
CACCCATCCC	ANGACGCGGC	TACACTNCTG	GACCTCCNC	TCCACCACTT	TCATGCGCTG	360

TTCNTACCCG	CGNATNTGTC	CCANCTGTTT	CNGTGCCNAC	TCCANCTTCT	NGGACGTGCG	420
CTACATACGC	CCGGANTCNC	NCTCCCGCTT	TGTCCCTATC	CACGTNCCAN	CAACAAATTT	480
CNCCNTANTG	CACCNATTCC	CACNTTTNNC	AGNTTTCNC	NMCGNGCTTC	CTTNTAAAAG	540
GGTTGANCCC	CGGAAAATNC	CCCAAAGGGG	GGGGGCCNNG	TACCCAACTN	CCCCCTNATA	600
GCTGAANTCC	CCATNACCNN	GNCTCNATGG	ANCCNTCCNT	TTTAANNACN	TTCTNAACTT	660
GGGAANANCC	CTCGNCCNTN	CCCCCNTTAA	TCCCNCTTG	CNANGNNCNT	CCCCCNNTCC	720
NCCCNNTNG	GCNTNTNANN	CNAAAAGGC	CCNNNANCAA	TCTCCTNNCN	CCTCANTTCG	780
CCANCCCTCG	AAATCGGCCN	C				801

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 789 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CAGTCTATNT	GGCCAGTGTG	GCAGCTTTCC	CTGTGGCTGC	CGGTGCCACA	TGCCTGTCCC	60
ACAGTGTGGC	CGTGGTGACA	GCTTCAGCCG	CCCTCACCGG	GTTCACCTTC	TCAGCCCTGC	120
AGATCCTGCC	CTACACACTG	GCCTCCCTCT	ACCACCGGGA	GAAGCAGGTG	TTCTTGCCCA	180
AATACCGAGG	GGACACTGGA	GGTGCTAGCA	GTGAGGACAG	CCTGATGACC	AGCTTCCTGC	240
CAGGCCCTAA	GCCTGGAGCT	CCCTTCCCTA	ATGGACACGT	GGGTGCTGGA	GGCAGTGGCC	300
TGCTCCCACC	TCCACCCGCG	CTCTGCGGGG	CCTCTGCCTG	TGATGTCTCC	GTACGTGTGG	360
TGGTGGGTGA	GCCACCCGAN	GCCAGGTGG	TTCCGGGCCG	GGGCATCTGC	CTGGACCTCG	420
CCATCCTGGA	TAGTGCTTCC	TGCTGTCCCA	NGTGCCCCCA	TCCCTGTTTA	TGGGCTCCAT	480
TGTCCAGCTC	AGCCAGTCTG	TCAGTGCCTA	TATGGTGTCT	GCCGAGGCC	TGGGTCTGGT	540
CCCATTACT	TTGCTACACA	GGTANTATTT	GACAAGAACG	ANTTGGCCAA	ATACTCAGCG	600
TTAAAAAATT	CCAGCAACAT	TGGGGGTGGA	AGGCCTGCCT	CACTGGGTCC	AACTCCCCGC	660
TCCTGTAAAC	CCCATGGGGC	TGCCGGCTTG	GCCGCCAATT	TCTGTTGCTG	CCAAANTNAT	720
GTGGCTCTCT	GCTGCCACCT	GTGCTGGCT	GAAGTGCNTA	CNGCNCANCT	NGGGGGGTNG	780
GGNGTTCCC						789

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 772 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCCACCCTAC	CCAAATATTA	GACACCAACA	CAGAAAAGCT	AGCAATGGAT	TCCCTTCTAC	60
TTTGTAAAT	AAATAAGTTA	AATATTTAAA	TGCCTGTGTC	TCTGTGATGG	CAACAGAAGG	120
ACCAACAGGC	CACATCCTGA	TAAAAGGTAA	GAGGGGGGTG	GATCAGCAAA	AAGACAGTGC	180
TGTGGGCTGA	GGGGACCTGG	TTCTTGTGTG	TTGCCCCCTA	GGACTCTTCC	CCTACAAATA	240
ACTTTCATAT	GTTCAAATCC	CATGGAGGAG	GTGTTTCATCC	TAGAAACTCC	CATGCAAGAG	300
CTACATTTAA	CGAAGCTGCA	GGTTAAGGGG	CTTANAGATG	GGAAACCAGG	TGACTGAGTT	360
TATTCAGCTC	CCAAAAACCC	TTCTCTAGGT	GTGTCTCAAC	TAGGAGGCTA	GCTGTTAACC	420

CTGAGCCTGG	GTAATCCACC	TGCAGAGTCC	CCGCATTCCA	GTGCATGGAA	CCCTTCTGGC	480
CTCCCTGTAT	AAGTCCAGAC	TGAAACCCCC	TTGGAAGGNC	TCCAGTCAGG	CAGCCCTANA	540
AACTGGGGAA	AAAAGAAAAG	GACGCCCCAN	CCCCCAGCTG	TGCANCTACG	CACCTCAACA	600
GCACAGGGTG	GCAGCAAAAA	AACCACTTTA	CTTTGGCACA	AACAAAAACT	NGGGGGGGCA	660
ACCCCGGCAC	CCCNANGGGG	GTTAACAGGA	ANCNGGGNAA	CNTGGAACCC	AATTNAGGCA	720
GGCCCNCCAC	CCCNAAATNTT	GCTGGGAAAT	TTTTCTCTCC	CTAAATTNTT	TC	772

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 751 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCCCCAATTC	CAGCTGCCAC	ACCACCCACG	GTGACTGCAT	TAGTTCGGAT	GTCATACAAA	60
AGCTGATTGA	AGCAACCCTC	TACTTTTGG	TCGTGAGCCT	TTTGCTTGGT	GCAGGTTTCA	120
TTGGCTGTGT	TGGTGACGTT	GTCATTGCAA	CAGAAATGGGG	GAAAGGCACT	GTTCTCTTTG	180
AAGTANGGTG	AGTCCTCAA	ATCCGTATAG	TTGGTGAAGC	CACAGCACTT	GAGCCCTTTC	240
ATGGTGGTGT	TCCACACTTG	AGTGAAGTCT	TCCTGGGAAC	CATAATCTTT	CTTGATGGCA	300
GGCACTACCA	GCAACGTCAG	GGAAGTGCTC	AGCCATTGTG	GTGTACACCA	AGGCGACCAC	360
AGCAGCTGCN	ACCTCAGCAA	TGAAGATGAN	GAGGANGATG	AAGAAGAACG	TCNCGAGGGC	420
ACACTTGCTC	TCAGTCTTAN	CACCATANCA	GCCCNTGAAA	ACCAANANCA	AAGACCACNA	480
CNCCGGCTGC	GATGAAGAAA	TNACCCCNCG	TTGACAAACT	TGCATGGCAC	TGGGANCCAC	540
AGTGGCCCN	AAAATCTTCA	AAAAGGATGC	CCCATCNATT	GACCCCCCAA	ATGCCCACTG	600
CCAACAGGGG	CTGCCCCACN	CNCNNAACGA	TGANCCNATT	GNACAAGATC	TNCNTGGTCT	660
TNATNAACNT	GAACCCTGCN	TNGTGGCTCC	TGTTCAAGNC	CNNGGCCTGA	CTTCTNAANN	720
AANGAACTCN	GAAGNCCCCA	CNGGANANNC	G			751

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 729 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAGCCAGGCG	TCCCTCTGCC	TGCCCACTCA	GTGGCAACAC	CCGGGAGCTG	TTTTGTCTTT	60
TGTGGANCC	CAGCAGTNCC	CTCTTTCAGA	ACTCANTGCC	AAGANCCCTG	AACAGGAGCC	120
ACCATGCAGT	GCTTCAGCTT	CATTAAGACC	ATGATGATCC	TCTTCAATTT	GCTCATCTTT	180
CTGTGTGGTG	CAGCCCTGTT	GGCAGTGGGC	ATCTGGGTGT	CAATCGATGG	GGCATCTTTT	240
CTGAAGATCT	TCGGGCCACT	GTGCTCCAGT	GCCATGCAGT	TTGTCAACGT	GGGCTACTTC	300
CTCATCGCAG	CCGGCGTTGT	GGTCTTAGCT	CTAGGTTTCC	TGGGCTGCTA	TGGTGCTAAG	360
ACTGAGAGCA	AGTGTGCCCT	CGTGACGTTT	TTCTTCATCC	TCCTCCTCAT	CTTCATTGCT	420
GAGGTTGCAA	TGCTGTGGTC	GCCTTGGTGT	ACACCACAAT	GGCTGAGCAC	TTCTTGACGT	480
TGCTGGTAAT	GCCTGCCATC	AANAAAAGAT	TATGGGTTCC	CAGGAANACT	TCACTCAAGT	540
GTTGGAACAC	CACCATGAAA	GGGCTCAAGT	GCTGTGGCTT	CNNCCAATA	TACGGATTTT	600

GAAGANTCAC	CTACTTCAAA	GAAAAAGTG	CCTTTCCCCC	ATTTCTGTTG	CAATTGACAA	660
ACGTCCCCAA	CACAGCCAAT	TGAAAACCTG	CACCCAACCC	AAANGGGTCC	CCAACCANAA	720
ATTNAAGGG						729

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 816 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TGCTCTTCCT	CAAAGTTGTT	CTTGTTGCCA	TAACAACCAC	CATAGGTAAA	GCGGGCGCAG	60
TGTTTCGCTGA	AGGGGTTGTA	GTACCAGCGC	GGGATGCTCT	CCTTGCAGAG	TCCTGTGTCT	120
GGCAGGTCCA	CGCAGTGCCC	TTTGTCACTG	GGGAAATGGA	TGCGCTGGAG	CTCGTCAAAG	180
CCACTCGTGT	ATTTTTCACA	GGCAGCCTCG	TCCGACGCGT	CGGGGCAGTT	GGGGGTGTCT	240
TCACACTCCA	GGAAACTGTC	NATGCAGCAG	CCATTGCTGC	AGCGGAACTG	GGTGGGCTGA	300
CANGTGCCAG	AGCACACTGG	ATGGCGCCTT	TCCATGNNAN	GGGCCCTGNG	GGAAAGTCCC	360
TGANCCCCAN	ANCTGCCTCT	CAAANGCCCC	ACCTTGACAC	CCCCGACAGG	CTAGAATGGA	420
ATCTTCTTCC	CGAAAGGTAG	TTNTTCTTGT	TGCCCCANCC	ANCCCCNTAA	ACAAACTCTT	480
GCANATCTGC	TCCGNGGGGG	TCNTANTACC	ANCGTGGGAA	AAGAACCCCA	GGCNGCGAAC	540
CAANCTTGTT	TGGATNCGAA	GCNATAATCT	NCTNTTCTGC	TTGGTGGACA	GCACCANTNA	600
CTGTNNANCT	TTAGNCCNTG	GTCCTCNTGG	GTTGNNCTTG	AACCTAATCN	CCNNTCAACT	660
GGGACAAGGT	AANTNGCCNT	CCTTTNAAAT	CCCNANCNTN	CCCCCTGGTT	TGGGGTTTTN	720
CNCNCTCCTA	CCCCAGAAAN	NCCGTGTTCC	CCCCCAACTA	GGGGCCNAAA	CCNNTTNTTC	780
CACAACCCCTN	CCCCACCCAC	GGGTTTCNGNT	GGTGTTNG			816

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 783 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCAAGGCCCTG	GGCAGGCATA	NACTTGAAGG	TACAACCCCA	GGAACCCCTG	GTGCTGAAGG	60
ATGTGGAAAA	CACAGATTGG	CGCCTACTGC	GGGGTGACAC	GGATGTCAGG	GTAGAGAGGA	120
AAGACCCAAA	CCAGGTGGAA	CTGTGGGGAC	TCAAGGAANG	CACCTACCTG	TTCCAGCTGA	180
CAGTGACTAG	CTCAGACCAC	CCAGAGGACA	CGGCCAACGT	CACAGTCACT	GTGCTGTCCA	240
CCAAGCAGAC	AGAAGACTAC	TGCCTCGCAT	CCAACAANGT	GGGTCGCTGC	CGGGGCTCTT	300
TCCCACGCTG	GTACTATGAC	CCCACGGAGC	AGATCTGCAA	GAGTTTCGTT	TATGGAGGCT	360
GCTTGGGCAA	CAAGAACAAC	TACCTTCGGG	AAGAAGAGTG	CATTCTANCC	TGTCNGGGTG	420
TGCAAGGTGG	GCCTTTGANA	NGCANCTCTG	GGGCTCANGC	GACTTTCCCC	CAGGGCCCCCT	480
CCATGGAAAG	GCGCCATCCA	NTGTTCTCTG	GCACCTGTCA	GCCCACCCAG	TTCCGCTGCA	540
NCAATGGCTG	CTGCATCNAC	ANTTTCCTNG	AATTGTGACA	ACACCCCCCA	NTGCCCCCAA	600
CCCTCCCAAC	AAAGCTTCCC	TGTTNAAAAA	TACNCCANTT	GGCTTTTNAC	AAACNCCC GG	660
CNCCTCCNTT	TTCCCCNNTN	AACAAAGGGC	NCTNGCNTTT	GAACTGCCCN	AACCCNGGAA	720

TCTNCCNNGG AAAAANTNCC CCCCCTGGTT CCTNNAANCC CCTCCNCNAA ANCTNCCCCC 780
 CCC 783

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 801 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCCCCAATTC CAGCTGCCAC ACCACCCACG GTGACTGCAT TAGTTCGGAT GTCATACAAA 60
 AGCTGATTGA AGCAACCCTC TACTTTTTGG TCGTGAGCCT TTTGCTTGGT GCAGGTTTCA 120
 TTGGCTGTGT TGGTGACGTT GTCATTGCAA CAGAATGGGG GAAAGGCACT GTTCTCTTTG 180
 AAGTAGGGTG AGTCCTCAA ATCCGTATAG TTGGTGAAGC CACAGCACTT GAGCCCTTTC 240
 ATGGTGGTGT TCCACACTTG AGTGAAGTCT TCCTGGGAAC CATAATCTTT CTTGATGGCA 300
 GGCACCTACCA GCAACGTCAG GAAGTGCTCA GCCATTGTGG TGTACACCAA GGCGACCACA 360
 GCAGCTGCAA CCTCAGCAAT GAAGATGAGG AGGAGGATGA AGAAGAACGT CNCGAGGGCA 420
 CACTTGCTCT CCGTCTTAGC ACCATAGCAG CCCANGAAAC CAAGAGCAAA GACCACAACG 480
 CCNGCTGCGA ATGAAAGAAA NTACCCACGT TGACAAACTG CATGGCCACT GGACGACAGT 540
 TGGCCCGAAN ATCTTCAGAA AAGGGATGCC CCATCGATTG AACACCCANA TGCCCACTGC 600
 CNACAGGGCT GCNCCNCNCN GAAAGAATGA GCCATTGAAG AAGGATCNTC NTGGTCTTAA 660
 TGAAGTGAAG CCNTGCATGG TGGCCCTGTG TCAGGGCTCT TGGCAGTGAA TTCTGANAAA 720
 AAGGAACNGC NTNAGCCCCC CCAAANGANA AAACACCCCC GGGTGTGGC CTGAATTGGC 780
 GGCCAAGGAN CCCTGCCCCN G 801

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 740 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTGAGAGCCA GGCGTCCCTC TGCCTGCCCC CTCAGTGGCA ACACCCGGGA GCTGTTTTGT 60
 CCTTTGTGGA GCCTCAGCAG TTCCCTCTTT CAGAACTCAC TGCCAAGAGC CCTGAACAGG 120
 AGCCACCATG CAGTGCTTCA GCTTCATTAA GACCATGATG ATCCTCTTCA ATTTGCTCAT 180
 CTTTCTGTGT GGTGCAGCCC TGTGGCAGT GGGCATCTGG GTGTCAATCG ATGGGGCATC 240
 CTTTCTGAAG ATCTTCGGGC CACTGTCGTC CAGTGCCATG CAGTTTGTCA ACGTGGGCTA 300
 CTTCTCATC GCAGCCGGCG TTGTGGTCTT TGCTCTTGGT TTCCTGGGCT GCTATGGTGC 360
 TAAGACGGAG AGCAAGTGTG CCCTCGTGAC GTTCTTCTTC ATCCTCCTCC TCATCTTCAT 420
 TGCTGAAGTT GCAGCTGCTG TGGTCGCCTT GTGTACACC ACAATGGCTG AACCATTCTT 480
 GACGTGCTG GTANTGCCTG CCATCAANAA AGATTATGGG TTCCAGGAA AAATTCATC 540
 AANTNTGGAA CACCNCATG AAAAGGGCTC CAATTTCTGN TGGCTTCCCC AACTATACCG 600
 GAATTTTGAA AGANTCNCCC TACTTCCAAA AAAAAANANT TGCCTTNCC CCCNTTCTGT 660
 TGCAATGAAA ACNTCCCAAN ACNGCCAATN AAAACCTGCC CNNNCAAAAA GGNTCNCAAA 720
 CAAAAAANT NNAAGGTTN 740

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 802 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

CCGCTGGTTG CGCTGGTCCA GNGNAGCCAC GAAGCACGTC AGCATAACACA GCCTCAATCA      60
CAAGGTCTTC CAGCTGCCGC ACATTACGCA GGGCAAGAGC CTCCAGCAAC ACTGCATATG      120
GGATACACTT TACTTTAGCA GCCAGGGTGA CAACTGAGAG GTGTCGAAGC TTATTCTTCT      180
GAGCCTCTGT TAGTGGAGGA AGATTCCGGG CTTTCAGCTAA GTAGTCAGCG TATGTCCCAT      240
AAGCAAACAC TGTGAGCAGC CGGAAGGTAG AGGCAAAGTC ACTCTCAGCC AGCTCTCTAA      300
CATTGGGCAT GTCCAGCAGT TCTCCAAACA CGTAGACACC AGNGGCCTCC AGCACCTGAT      360
GGATGAGTGT GGCCAGCGCT GCCCCCTTGG CCGACTTGGC TAGGAGCAGA AATTGCTCCT      420
GGTTCTGCCC TGTCACCTTC ACTTCCGCAC TCATCACTGC ACTGAGTGTG GGGGACTTGG      480
GCTCAGGATG TCCAGAGACG TGGTCCGCC CCCTCNCTTA ATGACACCGN CCANNAACCC      540
GTCGGCTCCC GCCGANTGNG TTCGTCGTNC CTGGGTCAGG GTCTGCTGGC CNCTACTTGC      600
AANCTTCGTC NGGCCCCATGG AATTCACCNC ACCGGAACCTN GTANGATCCA CTNNTTCTAT      660
AACCGGNCGC CACCGCNNNT GGAACCTCCAC TCTTNTTNC TTTACTTGAG GGTAAAGGTC      720
ACCTTNNCG TTACCTTGGT CCAAACCTN CCNTGTGTG ANATNGTNAA TCNGGNCCNA      780
TNCCANCCNC ATANGAAGCC NG                                     802

```

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 731 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

```

CNAAGCTTCC AGGTNACGGG CCGCNAANCC TGACCCNAGG TANCANAANG CAGNCNGCGG      60
GAGCCCACCG TCACGNGGNG GNGTCTTTAT NGGAGGGGGC GGAGCCACAT CNCTGGACNT      120
CNTGACCCCA ACTCCCNCC NCNCANTGCA GTGATGAGTG CAGAACTGAA GGTNACGTGG      180
CAGGAACCAA GANCAANNC TGCTCCNNTC CAAGTCGGCN NAGGGGGCGG GGCTGGCCAC      240
GCNCATCCNT CNA GTGCTGN AAAGCCCCNN CCTGTCTACT TGT TTGGAGA ACNGCNNGA      300
CATGCCCAGN GTTANATAAC NGGCNGAGAG TNANTTTGCC TCTCCCTTCC GGCTGCGCAN      360
CGNGTNGCT TAGNGGACAT AACCTGACTA CTTAAGTAA CCCNNGAATC TNCCNCCCCT      420
CCACTAAGCT CAGAACAAA AACTTCGACA CCACTCANTT GTCACCTGNC TGCTCAAGTA      480
AAGTGTAACC CATNCCCAAT GTNTGCTNGA NGCTCTGNCC TGCNTTANGT TCGGTCCTGG      540
GAAGACCTAT CAATTNAAGC TATGTTTTCTG ACTGCCTCTT GCTCCCTGNA ACAANCNACC      600
CNNCMTTCCA AGGGGGGGNC GGCCCCCAAT CCCCCCAACC NTNAATTNAN TTTANCCCN      660
CCCCNGGCC CGGCCTTTTA CNANCNTCNN NNACNGGGNA AAACCNNGC TTNCCCAAC      720
NNAATCCNCC T                                     731

```

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 754 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TTTTTTTTTT	TTTTTTTTTT	TAAAAACCCC	CTCCATTNAA	TGNAACTTC	CGAAATTGTC	60
CAACCCCTC	NTCCAAATNN	CCNTTTCGG	GNGGGGGTTC	CAAACCCAAN	TTANNTTTGG	120
ANNTTAAATT	AAATNTMNT	TGGNGGNNA	ANCCNAATGT	NANGAAAGTT	NAACCCANTA	180
TNANCTNAA	TNCCTGGAAA	CCNGTNGNTT	CCAAAAATNT	TTAACCCCTTA	ANTCCCTCCG	240
AAATNGTTNA	NGGAAAACCC	AANTTCTCNT	AAGGTTGTTT	GAAGGNTNAA	TNAAAANCCC	300
NNCCAATTGT	TTTTNGCCAC	GCCTGAATTA	ATTGGNTTCC	GNTGTTTTCC	NTTAAANAA	360
GGNNANCCCC	GGTTANTNAA	TCCCCCNCC	CCCAATTATA	CCGANTTTTT	TTNGAATTGG	420
GANCCCNCGG	GAATTAACGG	GGNNNTTCCC	TNTTGGGGGG	CNGGMNCCCC	CCCCNTCGGG	480
GGTTNGGGNC	AGGNCNNAAT	TGTTTAAGGG	TCCGAAAAAT	CCCTCCNAGA	AAAAANCTC	540
CCAGNTGAG	NNTNGGGTTT	NCCCCCCCCC	CANGGCCCT	CTCGNANAGT	TGGGGTTTGG	600
GGGGCTGGG	ATTTNTTTC	CCCTNTTNC	TCCCCCCCCC	CCNGGGANAG	AGGTTNGNGT	660
TTTGNTCNC	GGCCCCNCCN	AAGANCTTTN	CCGANTTNAN	TTAAATCCNT	GCCTNGGCCA	720
AGTCCNTTGN	AGGGNTAAAN	GGCCCCCTNN	CGGG			754

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 755 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ATCANCCCAT	GACCCCNAA	C	NNGGGACCNC	TCANCCGGNC	NNNCNACCNC	CGGCCNATCA	60
NNGTNAGNNC	ACTNCNNTTN	NATCACNCCC	CNCCNACTAC	GCCNCNANC	CNACGCNCTA		120
NNCANATNCC	ACTGANNGCG	CGANGTNGAN	NGAGAAANCT	NATACCANAG	NCACCANACN		180
CCAGCTGTCC	NANAANGCCT	NNNATACNGG	NNNATCCAAT	NTGNANCCCTC	CNAAGTATTN		240
NNCNNCANAT	GATTTTCCTN	ANCCGATTAC	CCNTNCCCCC	TANCCCTCC	CCCCCAACNA		300
CGAAGGCNCT	GGNCCNAAGG	NNGCGNCNCC	CCGCTAGNTC	CCCNCAAGT	CNCNCNCTA		360
AACTCANCCN	NATTACNCGC	TTCNTGAGTA	TCACTCCCCG	AATCTCACCC	TACTCAACTC		420
AAAAANATCN	GATACAAAAT	AATNCAAGCC	TGNTTATNAC	ACTNTGACTG	GGTCTCTATT		480
TTAGNGGTCC	NTNAANCNTC	CTAATACTTC	CAGTCTNCCT	TCNCCAATTT	CCNAANGGCT		540
CTTTCNGACA	GCAATNTTTG	GTTCCCNNTT	GGGTCTTAN	NGAATTGCCC	TTCNTNGAAC		600
GGGCTCNTCT	TTTCCTTCGG	TTANCCTGGN	TTCNNCCGGC	CAGTTATTAT	TTCCCNTTTT		660
AAATTCNTNC	CNTTTANTTT	TGGCNTTCNA	AACCCCCGGC	CTTGAAAACG	GCCCCCTGGT		720
AAAAGGTTGT	TTTGANAAAA	TTTTTGT	TTT	GTCC			755

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 849 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

TTTTTTTTTT	TTTTTANGTG	TNGTCGTGCA	GGTAGAGGCT	TACTACAANT	GTGAANACGT	60
ACGCTNGGAN	TAANGCGACC	CGANTTCTAG	GANNNCNCCT	AAAATCANAC	TGTGAAGATN	120
ATCCTGNNA	CGGAANGGTC	ACCGGNNGAT	MNTGCTAGGG	TGNCCNCTCC	CANNNCNTTN	180
CATAACTCNG	NGGCCCTGCC	CACCACCTTC	GGCGGCCCN	NGNCCGGGCC	CGGGTCATTN	240
GNNTTAACCN	CACTNNGCNA	NCGGTTTCCN	NCCCCNNCNG	ACCCNNGCGA	TCCGGGGTNC	300
TCTGTCTTCC	CCTGNAGNCN	ANAAANTGGG	CCNCGGNCCC	CTTTACCCCT	NNACAAGCCA	360
CNGCCNTCTA	NCCNCGCCC	CCCCTCCANT	NNGGGGGACT	GCCNANNGCT	CCGTTNCTNG	420
NNACCCNNN	GGGTNCCTCG	GTTGTCGANT	CNACCGNANG	CCANGGATTC	CNAAGGAAGG	480
TGCGTTNTTG	GCCCCTACCC	TTCGCTNCGG	NNCACCCTTC	CCGACNANGA	NCCGCTCCCG	540
CNCNCGNNG	CCTCNCCTCG	CAACACCCGC	NCTCNTCNGT	NCGNNNNCCC	CCCCACCCGC	600
NCCCTCNCNC	NGNCGNANCN	CTCCNCCNCC	GTCTCANNCA	CCACCCCGCC	CCGCCAGGCC	660
NTCANCCACN	GGMNGACNNG	NAGCNCNNTC	GCNCCGCGCN	GCGNCNCCCT	CGCCNCNGAA	720
CTNCNTCNGG	CCANTNNGCG	TCAANCCMNA	CNAAACGCCG	CTGCGCGGCC	CGNAGCGNCC	780
NCCTCCNCGA	GTCCTCCCGN	CTCCNACCC	ANGNNTTCCN	CGAGGACACN	NNACCCCGCC	840
NNCANGCGG						849

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 872 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCGCAAAC	TACTTCGCTC	GNACTCGTGC	GCCTCGCTNC	TCTTTTCCTC	CGCAACCATG	60
TCTGACNANC	CCGATTNGGC	NGATATCNAN	AAGNTCGANC	AGTCCAAACT	GANTAACACA	120
CACACNCNAN	AGANAAATCC	NCTGCCTTCC	ANAGTANACN	ATTGAACNNG	AGAACCANGC	180
NGGCGAATCG	TAATNAGGCG	TGCGCCGCCA	ATNTGTCNCC	GTTTATTNTN	CCAGCNTCNC	240
CTNCCNACCC	TACNTCTTCN	NAGCTGTCTN	ACCCCTNGTN	CGNACCCCCC	NAGGTCGGGA	300
TCGGGTTTNN	NNTGACCGNG	CNCCCCCTCC	CCCCNTCCAT	NACGANCCNC	CCGCACCACC	360
NANNGCNCGC	NCCCCGNCT	CTTCGCCNCC	CTGTCTTNTN	CCCCTGTNGC	CTGGCNCNGN	420
ACCGCATTGA	CCCTCGCCNN	CTNCNNGAAA	NCGNANACGT	CCGGGTTGNN	ANNANCGCTG	480
TGGGNMNGCG	TCTGCNCCGC	GTTCTTCCN	NCNNCTTCCA	CCATCTTCNT	TACNNGGTCT	540
CCNCGCCNTC	TCNNNCACNC	CCTGGGACGC	TNTCTNTGTC	CCCCCTTNAC	TCCCCCCTT	600
CGNCGTGNCC	CGNCCCCACC	NTCATTNCA	NACGNTCTTC	ACAANNNCCT	GGNTNNTCTC	660
CNANCNGNCG	GTCAACCCNAG	GGAAGGGNGG	GGNNCCNNTG	NTTGACGTTG	NGGNGANGTC	720
CGAANANTCC	TCNCCNTCAN	CNCTACCCCT	CGGGCGNNCT	CTCNGTTNCC	AACTTANCAA	780
NTCTCCCCCG	NGNGCNCNTC	TCAGCCTCNC	CCNCCCCNCT	CTCTGCANTG	TNCTCTGCTC	840
TNACCNNTAC	GANTNTTCGN	CNCCCTCTTT	CC			872

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 815 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GCATGCAAGC	TTGAGTATTC	TATAGNGTCA	CCTAAATANC	TTGGCNTAAT	CATGGTCNTA	60
NCTGNCTTCC	TGTGTCAAAT	GTATACNAAN	TANATATGAA	TCTNATNTGA	CAAGANNNGTA	120
TCNTNCATTA	GTAACAANTG	TNNTGTCCAT	CCTGTCNGAN	CANATTCCCA	TNNATTNCGN	180
CGCATTNCN	GCNCANTATN	TAATNGGGAA	NTCNNNTNNN	NCACCNNCAT	CTATCNTNCC	240
GCNCCCTGAC	TGGNAGAGAT	GGATNANTTC	TNNTNTGACC	NACATGTTCA	TCTTGGATTN	300
AANANCCCCC	CGCNGNCCAC	CGGTTNGNNG	CNAGCCNNTC	CCAAGACCTC	CTGTGGAGGT	360
AACCTGCGTC	AGANNCATCA	AACNTGGGAA	ACCCGCNNCC	ANGTNNAAGT	NGNNNCANAN	420
GATCCCGTCC	AGGNTTNACC	ATCCCTTCNC	AGCGCCCCCT	TTNGTGCCTT	ANAGNGNAGC	480
GTGTCCNANC	CNCTCAACAT	GANACGCGCC	AGNCCANCCG	CAATTNGGCA	CAATGTCGNC	540
GAACCCCTTA	GGGGGANTNA	TNCAAANCCC	CAGGATTGTC	CNCNCANGAA	ATCCCNCAAC	600
CCCNCCCTAC	CCNCTTTTGG	GACNGTGACC	AANTCCCGGA	GTNCCAGTCC	GGCCNGNCTC	660
CCCCACCGGT	NNCNTGTTGG	GGGTGAANCT	CNGNNTCANC	CNGNCGAGGN	NTCGNAAGGA	720
ACCGGNCCTN	GGNCGAANNG	ANCNNTCNGA	AGNGCCNCNT	CGTATAACCC	CCCCTCNCCA	780
NCCNACNGNT	AGNTCCCCCC	CNGGGTNCGG	AANGG			815

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 775 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CCGAGATGTC	TCGCTCCGTG	GCCTTAGCTG	TGCTCGCGCT	ACTCTCTCTT	TCTGGCCTGG	60
AGGCTATCCA	GCGTACTCCA	AAGATTACAG	TTTACTCACG	TCATCCAGCA	GAGAATGGAA	120
AGTCAAATTT	CCTGAATTGC	TATGTGTCTG	GGTTTCATCC	ATCCGACATT	GAANTTGACT	180
TACTGAAGAA	TGGANAGAGA	ATTGAAAAAG	TGGAGCATTC	AGACTTGTCT	TTCAGCAAGG	240
ACTGGTCTTT	CTATCTCNTG	TACTACACTG	AATTACACCC	CACTGAAAAA	GATGAGTATG	300
CCTGCCGTGT	GAACCATGTG	ACTTTGTGAC	AGCCCAAGAT	AGTTAAGTGG	GATCGAGACA	360
TGTAAGCAGN	CNNCATGGAA	GTTTGAAGAT	GCCGCATTTG	GATTGGATGA	ATTCCAAATT	420
CTGCTTGCTT	GCNTTTTAAT	ANTGATATGC	NTATACACCC	TACCCCTTTAT	GNCCCCAAAT	480
TGTAGGGGTT	ACATNANTGT	TCNCNTNGGA	CATGATCTTC	CTTTATAANT	CCNCCNTTCG	540
AATTGCCCCG	CNCCNGTTN	NGAATGTTTC	CNNAACCACG	GTTGGCTCCC	CCAGGTCNCC	600
TCTTACGGAA	GGGCCTGGGC	CNCTTTNCAA	GGTTGGGGGA	ACCNAAAATT	TCNCTTNTGC	660
CCNCCCNCNA	CNNTCTTGNG	NNCNCANTTT	GGAACCCTTC	CNATTCCTCT	TGGCTCNCNA	720
NCCTTNNCTA	ANAAAACTTN	AAANCGTNGC	NAAANNTTTN	ACTTCCCCCC	TTACC	775

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 820 base pairs
 - (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ANATTANTAC	AGTGTAATCT	TTCCTCAGAG	GTGTGTANAG	GGAACGGGGC	CTAGAGGCAT	60
CCCANAGATA	NCTTATANCA	ACAGTGCTTT	GACCAAGAGC	TGCTGGGCAC	ATTTCTGCA	120
GAAAAGGTGG	CGGTCCCAT	CACTCCTCCT	CTCCCATAGC	CATCCCAGAG	GGGTGAGTAG	180
CCATCANGCC	TTCGGTGGGA	GGGAGTCANG	GAAACAACAN	ACCACAGAGC	ANACAGACCA	240
NTGATGACCA	TGGGCGGGAG	CGAGCCTCTT	CCCTGNACCG	GGGTGGCANA	NGANAGCCTA	300
NCTGAGGGGT	CACACTATAA	ACGTTAACGA	CCNAGATNAN	CACCTGCTTC	AAGTGCACCC	360
TTCCTACCTG	ACNACCAGNG	ACCNNAACT	GCNGCCTGGG	GACAGCNCTG	GGANCAGCTA	420
ACNNAGCACT	CACCTGCCCC	CCCATGGCCG	TNCGCNTCCC	TGGTCCTGNC	AAGGGAAGCT	480
CCCTGTTGGA	ATTNCGGGGA	NACCAAGGGA	NCCCCCTCCT	CCANCTGTGA	AGGAAAAANN	540
GATGGAATTT	TNCCCTTCCG	GCCNNTCCCC	TCTTCTTTA	CACGCCCCCT	NNTACTCNTC	600
TCCCTCTNTT	NTCCTGNCNC	ACTTTTNACC	CCNNNATTTT	CCTTNATTGA	TCGGANNCTN	660
GANATTCCAC	TNNCGCCTNC	CNTCNATCNG	NAAACNAAA	NACTNTCTNA	CCNNGGGGAT	720
GGGNNCCTCG	NTCATCCTCT	CTTTTTCNCT	ACCNCCNNTT	CTTTGCCTCT	CCTTNGATCA	780
TCCAACNNTC	GNTGGCCNTN	CCCCCCCNNN	TCCTTTNCCC			820

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 818 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TCTGGGTGAT	GGCCTCTTCC	TCCTCAGGGA	CCTCTGACTG	CTCTGGGCCA	AAGAATCTCT	60
TGTTTTCTTCT	CCGAGCCCCA	GGCAGCGGTG	ATTGAGCCCT	GCCCAACCTG	ATTCTGATGA	120
CTGCGGATGC	TGTGACGGAC	CCAAGGGGCA	AATAGGGTCC	CAGGGTCCAG	GGAGGGGGCGC	180
CTGCTGAGCA	CTTCCGCCCC	TCACCCTGCC	CAGCCCCTGC	CATGAGCTCT	GGGCTGGGTC	240
TCCGCCTCCA	GGGTTCTGCT	CTTCCANGCA	NGCCANCAAG	TGGCGCTGGG	CCACACTGGC	300
TTCTTCCTGC	CCCNTCCCTG	GCTCTGANTC	TCTGTCTTCC	TGTCCTGTGC	ANGCNCCTTG	360
GATCTCAGTT	TCCCTCNCTC	ANNGAACTCT	GTTTCTGANN	TCTTCANTTA	ACTNTGANTT	420
TATNACCNAN	TGGNCTGTNC	TGTCNNACTT	TAATGGGCCN	GACCGGCTAA	TCCCTCCCTC	480
NCTCCCTTCC	ANTTCNNNNA	ACCNGCTTNC	CNTCNTCTCC	CCNTANCCCG	CCNGGGAANC	540
CTCCTTTGCC	CTNACCANGG	GCCNNNACCG	CCCNTNNCTN	GGGGGGCNGG	GTNNCTNCNC	600
CTGNTNNCCC	CNCTCNCNNT	TNCCTCGTCC	CNNCNCNCGN	NNGCANNTTC	NCNGTCCCN	660
TNNCTCTTCN	NGTNTCGNAA	NGNTCNCNTN	TNNNNNGNCN	NGNTNNTNCN	TCCCTCTCNC	720
CNNNTGNANG	TNNTTNNNNC	NCNGNNCCCC	NNNNCNCNNN	NGGNNNTNNN	TCTNCNCNGC	780
CCCNCCCCC	NGNATTAAGG	CCTCCNNTCT	CCGGCCNC			818

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 731 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

AGGAAGGGCG GAGGGATATT GTANGGGATT GAGGGATAGG AGNATAANGG GGGAGGTGTG      60
TCCCAACATG ANGGTGNNGT TCTCTTTTGA ANGAGGGTTG NGTTTTTANN CCNGGTGGGT      120
GATTNAACCC CATTGTATGG AGNNAAGGN TTTNAGGGAT TTTTCGGCTC TTATCAGTAT      180
NTANATTCCT GTNAATCGGA AAATNATNTT TCNNCNGGAA AATNTTGCTC CCATCCGNAA      240
ATTNCTCCCG GGTAGTGCAT NTTNGGGGGN CNGCCANGTT TCCCAGGCTG CTANAATCGT      300
ACTAAAGNTT NAAGTGGGAN TNCAAATGAA AACCTNNCAC AGAGNATCCN TACCCGACTG      360
TNNNTTNCCT TCGCCCTNTG ACTCTGCNNG AGCCCAATAC CCNNGNGNAT GTCNCCCNGN      420
NNNGCGNCNC TGAAANNNNC TCGNGGCTNN GANCATCANG GGGTTTCGCA TCAAAAAGCNC      480
CGTTTCNCAT NAAGGCACTT TNGCCTCATC CAACCNCTNG CCCTCNCCA TTNGCCGTC      540
NGGTTNCCT ACGCTNNTNG CNCCTNNNTN GANATTTTNC CCGCCTNGGG NAANCTCCT      600
GNAATGGGTA GGGNCTTNTC TTTNACCNN GNGGTNTACT AATCNNCTNC ACGCNTNCTT      660
TCTNACCCC CCCCTTTT CAATCCCANC GGCNAATGGG GTCTCCCCNN CGANGGGGGG      720
NNNCCCANNC C

```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 822 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGGNCNC TTCTATGANT ANTNTTAGAT      60
CGCTCANACC TCACANCTC CCNACNANGC CTATAANGAA NANNAATAGA NCTGTNCNNT      120
ATNTNTACNC TCATANNCCT CNNNACCCAC TCCCTCTTAA CCCNTACTGT GCCTATNGCN      180
TNNCTANTCT NTGCCGCTN CNANCCACCN GTGGGCCNAC CNCNNGNATT CTCNATCTCC      240
TCNCCATNTN GCCTANANTA NGTNCATACC CTATACCTAC NCCAATGCTA NNNCTAANCN      300
TCCATNANTT ANNTAACTA CCACTGACNT NGACTTTCNC ATNANCTCCT AATTTGAATC      360
TACTCTGACT CCCACNGCCT ANNNATTAGC ANCNTCCCCC NACNATNTCT CAACCAAATC      420
NTCAACAACC TATCTANCTG TTCNCCAACC NTNCTCCG ATCCCCNNAC AACCCCTC      480
CCAAATACCC NCCACCTGAC NCCTAACCCN CACCATCCCG GCAAGCCNAN GGNCATTTAN      540
CCACTGGAAT CACNATNGGA NAAAAAAAC CCNAACTCTC TANCNCNNAT CTCCCTAANA      600
AATNCTCCTN NAATTTACTN NCANTNCCAT CAANCCACN TGAAACNMAA CCCCTGTTTT      660
TANATCCCTT CTTTCGAAAA CCNACCCTTT ANNNCCCAAC CTTTNGGGCC CCCCNCNTNC      720
CCNAATGAAG GNCNCCAAT CNANGAAACG NCCNTGAAAA ANCNAGGCNA ANANNNTCCG      780
CANATCCTAT CCCTTANTTN GGGNCCCTT NCCNGGGCC CC

```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 787 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CGGCCGCCTG	CTCTGGCACA	TGCCTCCTGA	ATGGCATCAA	AAGTGATGGA	CTGCCCATTG	60
CTAGAGAAGA	CCTTCTCTCC	TACTGTCAAT	ATGGAGCCCT	GCAGACTGAG	GGCTCCCCTT	120
GTCTGCAGGA	TTTGATGTCT	GAAGTCGTGG	AGTGTGGCTT	GGAGCTCCTC	ATCTACATNA	180
GCTGGAAGCC	CTGGAGGGCC	TCTCTCGCCA	GCCTCCCCCT	TCTCTCCACG	CTCTCCANGG	240
ACACCAGGGG	CTCCAGGCAG	CCCATTATTC	CCAGNANGAC	ATGGTGTTTC	TCCACGCGGA	300
CCCATGGGGC	CTGNAAGGCC	AGGGTCTCCT	TTGACACCAT	CTCTCCCGTC	CTGCCTGGCA	360
GGCCGTGGGA	TCCACTANTT	CTANAACGGN	CGCCACCNCG	GTGGGAGCTC	CAGCTTTTGT	420
TCCCNNTAAT	GAAGGTTAAT	TGCNCGCTTG	GCGTAATCAT	NGGTCANAAC	TNTTTCCTGT	480
GTGAAATTGT	TNTCCCCCTC	NCNATTCNC	NCNACATACN	AACCCGGAAN	CATAAAGTGT	540
TAAAGCCTGG	GGGTNGCCTN	NNGAATNAAC	TNAACTCAAT	TAATTGCGTT	GGCTCATGGC	600
CCGCTTTCCN	TTCNGGAAAA	CTGTCNTCCC	CTGCNTTNNT	GAATCGGCCA	CCCCCNGGG	660
AAAAGCGGTT	TGCNTTTTNG	GGGGNTCCTT	CCNCTTCCCC	CCTCNCTAAN	CCCTNCGCCT	720
CGGTCGTTNC	NGGTNGCGGG	GAANGGNGAT	NNNCTCCNC	NAAGGGGGNG	AGNNNGNTAT	780
CCCCAAA						787

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 799 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TTTTTTTTTT	TTTTTTTGGC	GATGCTACTG	TTTAATTGCA	GGAGGTGGGG	GTGTGTGTAC	60
CATGTACCAG	GGCTATTAGA	AGCAAGAAGG	AAGGAGGGAG	GGCAGAGCGC	CCTGCTGAGC	120
AACAAAGGAC	TCCTGCAGCC	TTCTCTGTCT	GTCTCTTGGC	GCAGGCACAT	GGGGAGGCCT	180
CCCGCAGGGT	GGGGGCCACC	AGTCCAGGGG	TGGGAGCACT	ACANGGGGTG	GGAGTGGGTG	240
GTGGCTGGTN	CNAATGGCCT	GNCACANATC	CCTACGATTC	TTGACACCTG	GATTTACCA	300
GGGGACCTTC	TGTTCTCCCA	NGGNAACTTC	NTNNATCTCN	AAAGAACACA	ACTGTTTCTT	360
CNGCANTTCT	GGCTGTTTCT	GGAAAGCACA	GGTGTCCTAT	TTNGGCTGGG	ACTTGGTACA	420
TATGGTTCCG	GCCACCTCTA	CCCNTCNAAN	AAGTAATTCA	CCCCCCCCCN	CCNTCTNTTG	480
CCTGGGCCCT	TAANTACCCA	CACCGGAACT	CANTTANTTA	TTCATCTTNG	GNTGGGCTTG	540
NTNATNCN	CCTGAANGCG	CCAAGTTGAA	AGGCCACGCC	GTNCCCNCTC	CCCATAGNAN	600
NTTTTNNCNT	CANCTAATGC	CCCCCNGGC	AACNATCCAA	TCCCCCCCCN	TGGGGGCCCC	660
AGCCCANGGC	CCCCGNCTCG	GGNNNCCNGN	CNCGNANTCC	CCAGGNTCTC	CCANTCNGNC	720
CCNNNGCNCC	CCCGCACGCA	GAACANAAGG	NTNGAGCCNC	CGCANNNNNN	NGGTNNCNAC	780
CTCGCCCCCC	CCNNCGNNG					799

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 789 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	60
TTTTNCCNAG	GGCAGGTTTA	TTGACAACCT	CNCGGGACAC	AANCAGGCTG	GGGACAGGAC	120
GGCAACAGGC	TCCGGCGGCG	GCGGCGGCGG	CCCTACCTGC	GGTACCAAAT	NTGCAGCCTC	180
CGCTCCCGCT	TGATNTTCCT	CTGCAGCTGC	AGGATGCCNT	AAAACAGGGC	CTCGGCCNTN	240
GGTGGGCACC	CTGGGATTTN	AATTTCCACG	GGCACAATGC	GGTCGCANCC	CCTCACCACC	300
NATTAGGAAT	AGTGGTNTTA	CCCNCCNCCG	TTGGCNCAC	CCCCNTGGAA	ACCACTTNTC	360
GCGGCTCCGG	CATCTGGTCT	TAAACCTTGC	AAACNCTGGG	GCCCTCTTTT	TGGTTANTNT	420
NCCNGCCACA	ATCATNACTC	AGACTGGCNC	GGGCTGGCCC	CAAAAAANCN	CCCCAAAACC	480
GGNCCATGTC	TTNNCGGGGT	TGCTGCNATN	TNCATCACCT	CCCGGGCNCA	NCAGGNCAAC	540
CCAAAAGTTC	TTGNGGCCCN	CAAAAAANCT	CCGGGGGGNC	CCAGTTTCAA	CAAAGTCATC	600
CCCCTTGGCC	CCCAATCCT	CCCCCGNTT	NCTGGGTTTG	GGAACCCACG	CCTCTNNCTT	660
TGGNNGGCAA	GNTGGNTCCC	CCTTCGGGCC	CCCGGTGGGC	CCNCTCTAA	NGAAAACNCC	720
NTCCTNNNCA	CCATCCCCCC	NNGNNACGNC	TANCAANGNA	TCCCTTTTTT	TANAAACGGG	780
CCCCCCNCG						789

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 793 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GACAGAACAT	GTTGGATGGT	GGAGCACCTT	TCTATACGAC	TTACAGGACA	GCAGATGGGG	60
AATTCATGGC	TGTTGGAGCA	ATANAACCCC	AGTTCTACGA	GCTGCTGATC	AAAGGACTTG	120
GACTAAAGTC	TGATGAACCT	CCCAATCAGA	TGAGCATGGA	TGATTGGCCA	GAAATGAANA	180
AGAAGTTTGC	AGATGTATTT	GCAAAGAAGA	CGAAGGCAGA	GTGGTGTCAA	ATCTTTGACG	240
GCACAGATGC	CTGTGTGACT	CCGGTTCTGA	CTTTTGAGGA	GGTTGTTTCA	CATGATCACA	300
ACAANGAACG	GGGCTCGTTT	ATCACCANTG	AGGAGCAGGA	CGTGAGCCCC	CGCCCTGCAC	360
CTCTGCTGTT	AAACACCCCA	GCCATCCCTT	CTTTCAAAAG	GGATCCACTA	CTTCTAGAGC	420
GGNCGCCACC	GCGGTGGAGC	TCCAGCTTTT	GTTCCCTTTA	GTGAGGGTTA	ATTGCGCGCT	480
TGGCGTAATC	ATGGTCATAN	CTGTTTCCTG	TGTGAAATTG	TTATCCGCTC	ACAATTCCAC	540
ACAACATACG	ANCCGGAAGC	ATNAAATTTT	AAAGCCTGGN	GGTNGCCTAA	TGANTGAACT	600
NACTCACATT	AATTGGCTTT	GCGCTCACTG	CCCGCTTTCC	AGTCCGGAAA	ACCTGTCCTT	660
GCCAGCTGCC	NTTAATGAAT	CNGGCCACCC	CCCGGGGAAA	AGGCNGTTTG	CTTNTTGGGG	720
CGCNCTTCCC	GCTTTCTCGC	TTCCTGAANT	CCTTCCCCCC	GGTCTTTTCG	CTTGCGGCNA	780
ACGGTATCNA	CCT					793

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 756 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GCCGCGACCG	GCATGTACGA	GCAACTCAAG	GGCGAGTGGA	ACCGTAAAAG	CCCCAATCTT	60
ANCAAGTGCG	GGGAANAGCT	GGGTCGACTC	AAGCTAGTTC	TTCTGGAGCT	CAACTTCTTG	120
CCAACCACAG	GGACCAAGCT	GACCAAACAG	CAGCTAATTC	TGGCCCGTGA	CATACTGGAG	180
ATCGGGGCCC	AATGGAGCAT	CCTACGCAAN	GACATCCCCCT	CCTTCGAGCG	CTACATGGCC	240
CAGCTCAAAT	GCTACTACTT	TGATTACAAN	GAGCAGCTCC	CCGAGTCAGC	CTATATGCAC	300
CAGCTCTTGG	GCCTCAACCT	CCTCTTCCTG	CTGTCCCAGA	ACCGGGTGGC	TGANTNCCAC	360
ACGGANTTGG	ANCGGCTGCC	TGCCCAANGA	CATACANACC	AATGTCTACA	TCNACCACCA	420
GTGTCCTGGA	GCAATACTGA	TGGANGGCAG	CTACCNCAAA	GTNTTCCTGG	CCNAGGGTAA	480
CATCCCCCGC	CGAGAGCTAC	ACCTTCTTCA	TTGACATCCT	GCTCGACACT	ATCAGGGATG	540
AAAATCGCNG	GGTTGCTCCA	GAAAGGCTNC	AANAANATCC	TTTTCNCTGA	AGGCCCCCGG	600
ATNCNCTAGT	NCTAGAATCG	GCCCCCATC	GCGGTGGANC	CTCCAACCTT	TCGTTNCCCT	660
TTACTGAGGG	TTNATTGCCG	CCCTTGGCGT	TATCATGGTC	ACNCCNGTTN	CCTGTGTTGA	720
AATTNTTAAC	CCCCCACAAT	TCCACGCCNA	CATTNG			756

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 834 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GGGGATCTCT	ANATCNACCT	GNATGCATGG	TTGTGCGGTGT	GGTCGCTGTC	GATGAANATG	60
AACAGGATCT	TGCCCTTGAA	GCTCTCGGCT	GCTGTNTTTA	AGTTGCTCAG	TCTGCCGTCA	120
TAGTCAGACA	CNCTCTTGGG	CAAAAAACAN	CAGGATNTGA	GTCTTGATTT	CACCTCCAAT	180
AATCTTCNGG	GCTGTCTGCT	CGGTGAACTC	GATGACNANG	GGCAGCTGGT	TGTGTNTGAT	240
AAANTCCANC	ANGTTCTCCT	TGGTGACCTC	CCCTTCAAAG	TTGTTCCGGC	CTTCATCAAA	300
CTTCTNNAAN	ANGANNANCC	CANCTTTGTC	GAGCTGGNAT	TTGGANAACA	CGTCACTGTT	360
GGAAACTGAT	CCCAAATGGT	ATGTCATCCA	TCGCCTCTGC	TGCCTGCAAA	AAACTTGCTT	420
GGCNCAAATC	CGACTCCCCN	TCCTTGAAAG	AAGCCNATCA	CACCCCCCTC	CCTGGACTCC	480
NNCAANGACT	CTNCCGCTNC	CCCNTCCNNG	CAGGGTTGGT	GGCANNCCGG	GCCCNTGCGC	540
TTCTTCAGCC	AGTTACACNAT	NTTCATCAGC	CCCTCTGCCA	GCTGTTNTAT	TCCTTGGGGG	600
GGAANCCGTC	TCTCCCTTCC	TGAANNAACT	TTGACCGTNG	GAATAGCCGC	GCNTCNCCNT	660
ACNTNCTGGG	CCGGGTTCAA	ANTCCCTCCN	TTGNCNNTCN	CCTCGGGCCA	TTCTGGATT	720
NCCNAACTTT	TTCTTCCCC	CNCCCCNCGG	NGTTTGGNTT	TTTCATNGGG	CCCCAACTCT	780
GCTNTTGGCC	ANTCCCCTGG	GGGCNTNTAN	CNCCCCCTNT	GGTCCCNTNG	GGCC	834

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 814 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CGGNCGCTTT	CCNGCCGCGC	CCCGTTTCCA	TGACNAAGGC	TCCCTTCANG	TTAAATACNN	60
CCTAGNAAAC	ATTAATGGGT	TGCTCTACTA	ATACATCATA	CNAACCAGTA	AGCCTGCCCCA	120
NAACGCCAAC	TCAGGCCATT	CCTACCAAAG	GAAGAAAGGC	TGGTCTCTCC	ACCCCTGTGA	180
GGAAAGGCCT	GCCTTGTAAG	ACACCACAAT	NCGGCTGAAT	CTNAAGTCTT	GTGTTTTACT	240
AATGGAAAAA	AAAAATAAAC	AANAGGTTTT	GTTCTCATGG	CTGCCCACCG	CAGCCTGGCA	300
CTAAACANNC	CCAGCGCTCA	CTTCTGCTTG	GANAAATATT	CTTGCTCTTT	TTGGACATCA	360
GGCTTGATGG	TATCACTGCC	ACNTTTCAC	CCAGCTGGGC	NCCCTTCCCC	CATNTTGTGTC	420
ANTGANCTGG	AAGGCCTGAA	NCTTAGTCTC	CAAAAGTCTC	NGCCCACAAG	ACCGGCCACC	480
AGGGGANGTC	NTTNCAGTG	GATCTGCCAA	ANANTACCCN	TATCATCNNT	GAATAAAAAG	540
GCCCCTGAAC	GANATGCTTC	CANCANCTTT	TAAGACCCAT	AATCCTNGAA	CCATGGTGCC	600
CTTCCGGTCT	GATCCNAAAG	GAATGTTTCT	GGGTCCCANT	CCCTCCTTTG	TTNCTTACGT	660
TGTNTTGGAC	CCNTGCTNGN	ATNACCCAAN	TGANATCCCC	NGAAGCACCC	TNCCCCTGGC	720
ATTTGANTTT	CNTAAATTCT	CTGCCCTACN	NCTGAAAGCA	CNATTCCCTN	GGCNCNNAAN	780
GGNGAACTCA	AGAAGGTCTN	NGAAAAACCA	CNCN			814

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 760 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GCATGCTGCT	CTTCCTCAAA	GTTGTTCTTG	TTGCCATAAC	AACCACCATA	GGTAAAGCGG	60
GCGCAGTGTT	CGCTGAAGGG	GTTGTAGTAC	CAGCGCGGGA	TGCTCTCCTT	GCAGAGTCCT	120
GTGTCTGGCA	GGTCCACGCA	ATGCCCTTTG	TCCTGCGGGA	AATGGATGCG	CTGGAGCTCG	180
TCNAANCCAC	TCGTGTATTT	TTCACANGCA	GCCTCCTCCG	AAGCNTCCGG	GCAGTTGGGG	240
GTGTCGTCAC	ACTCCACTAA	ACTGTGCGATN	CANCAGCCCA	TTGCTGCAGC	GGAAGTGGGT	300
GGGCTGACAG	GTGCCAGAAC	ACACTGGATN	GGCCTTTCCA	TGGAAGGGCC	TGGGGGAAAT	360
CNCCTNANCC	CAAACAGCCT	CTCAAAGGCC	ACCTTGACAC	CCCCGACAGG	CTAGAAATGC	420
ACTCTTCTTC	CCAAAGGTAG	TTGTTCTTGT	TGCCCAAGCA	NCCTCCANCA	AACCAAAAAC	480
TTGCAAAATC	TGCTCCGTGG	GGGTCATNNN	TACCANGGTT	GGGGAAANAA	ACCCGGCNGN	540
GANCCNCCTT	GTTTGAATGC	NAAGGNAATA	ATCCTCCTGT	CTTGCTTGGG	TGGAANAGCA	600
CAATTGAAC	GTTAACNTTG	GGCCGNGTTC	CNCTNNGGTG	GTCTGAAACT	AATCACCGTC	660
ACTGGAAAAA	GGTANGTGCC	TTCTTTGAAT	TCCCAAANTT	CCCCTNGNTT	TGGGTNNNTT	720
CTCCTCTNCC	CTAAAAATCG	TNTTCCCCCC	CCNTANGGCG			760

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 724 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTAAAAA	CCCCCTCCAT	TGAATGAAAA	60
CTTCCNAAAT	TGTCCAACCC	CCTCNCCCAA	ATNNCCATTT	CCGGGGGGGG	GTTCCAAACC	120

CAAATTAATT TTGGANTTTA AATTAAATNT TNATTNGGGG AANAANCCAA ATGTNAAGAA	180
AATTTAACCC ATTATNAACT TAAATNCCTN GAAACCCNTG GNTTCCAAAA ATTTTAAACC	240
CTTAAATCCC TCCGAAATTG NTAANGGAAA ACCAAATTCN CCTAAGGCTN TTTGAAGGTT	300
NGATTTAAAC CCCCTTNANT TTTTTNACC CNNGNCTNAA NTATTNGNT TCCGGTGTTT	360
TCCTNTTAAN CNTNGGTAAC TCCCGNTAAT GAANNNCCCT AANCCAATTA AACCGAATTT	420
TTTTTGAATT GGAAATTCCN NGGGAATTNA CCGGGGTTTT TCCNTTTGG GGGCCATNCC	480
CCCNCCTTCG GGGTTTGGGN NTAGGTGAA TTTTTNNANG NCCCAAAAAA NCCCCAANA	540
AAAAAECTCC CAAGNNTTAA TTNGAATNTC CCCCTTCCCA GGCTTTTGG GAAAGGNGGG	600
TTTNTGGGG CCNGGGANTT CNTTCCCCCN TTNCCNCCCC CCCCCNGGT AAANGGTTAT	660
NGNNTTTGGT TTTTGGGCC CTTNANGGAC CTTCCGGATN GAAATTAAAT CCCCGGGNCG	720
GCCG	724

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 751 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

TTTTTTTTTT TTTTCTTTG CTCACATTTA ATTTTATTT TGATTTTTTT TAATGCTGCA	60
CAACACAATA TTTATTTTCA TTGTTTCTTT TATTTTCAAT TATTTGTTTG CTGCTGCTGT	120
TTTATTTATT TTTACTGAAA GTGAGAGGGA ACTTTTGTGG CTTTTTTTCC TTTTCTGTA	180
GGCCGCCTTA AGCTTTCTAA ATTTGGAACA TCTAAGCAAG CTGAANGGAA AAGGGGGTTT	240
CGCAAAATCA CTCGGGGGAA NGGAAAGGTT GCTTTGTAA TCATGCCCTA TGGTGGGTGA	300
TTAACTGCTT GTACAATTAC NTTTCACTTT TAATTAATTG TGCTNAANGC TTTAATTANA	360
CTTGGGGGTT CCCTCCCCAN ACCAACCCCN CTGACAAAAA GTGCCNGCCC TCAAATNATG	420
TCCCGGCNNT CNTTGAAACA CACNGCNGAA NGTTCTCATT NTCCCNCCNC CAGGTNAAAA	480
TGAAGGGTTA CCATNTTTAA CNCCACCTCC ACNTGGCNNN GCCTGAATCC TCNAAAANCN	540
CCCTCAANCN AATTNCTNNG CCCCAGTCNC GCNTNNGTCC CNCCGGGCT CCGGGAANTN	600
CACCCCNCA ANNCNNTNNC NAACNAAATT CCGAAAATAT TCCCNNTCNC TCAATTCCCC	660
CNNAGACTNT CCTCNNCNAN CNCAATTTTC TTTNNTCAC GAACNCGNNC CNNAAAATGN	720
NNNNCNCCTC CNCTNGTCCN NAATCNCCAN C	751

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 753 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GTGGTATTTT CTGTAAGATC AGGTGTTCTT CCCTCGTAGG TTTAGAGGAA ACACCCTCAT	60
AGATGAAAAC CCCCCGAGA CAGCAGCACT GCAACTGCCA AGCAGCCGGG GTAGGAGGGG	120
CGCCCTATGC ACAGCTGGGC CTTGAGACA GCAGGGCTTC GATGTCAGGC TCGATGTCAA	180
TGGTCTGGAA GCGGCGGCTG TACCTGCGTA GGGGCACACC GTCAGGGCCC ACCAGGAAT	240
TCTCAAAGTT CCAGGCAACN TCGTTGCGAC ACACCGGAGA CCAGGTGATN AGCTTGGGGT	300

CGGTCATAAN	CGCGGTGGCG	TCGTCGCTGG	GAGCTGGCAG	GGCCTCCCGC	AGGAAGGCNA	360
ATAAAAGGTG	CGCCCCGCA	CCGTTCANCT	CGCACTTCTC	NAANACCATG	ANGTTGGGCT	420
CNAACCCACC	ACCANNCCGG	ACTTCCTTGA	NGGAATTCCC	AAATCTCTTC	GNTCTTGGGC	480
TTCTNCTGAT	GCCCTANCTG	GTTGCCNNGN	ATGCCAANCA	NCCCCAANCC	CCGGGGTCCT	540
AAANCACCCN	CCTCCTCNTT	TCATCTGGGT	TNTTNTCCCC	GGACNTGGT	TCCTCTCAAG	600
GGANCCCAT	TCTCNACCAN	TACTCACCT	NCCCCCCCNT	GNNACCCANC	CTTCTANNGN	660
TTCCNCCCG	NCCTCTGGCC	CNTCAAANAN	GCTTNCACNA	CCTGGGTCTG	CCTTCCCCCC	720
TNCCCTATCT	GNACCCNCN	TTTGTCTCAN	TNT			753

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 341 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

ACTATATCCA	TCACAACAGA	CATGCTTCAT	CCCATAGACT	TCTTGACATA	GCTTCAAATG	60
AGTGAACCCA	TCCTTGATTT	ATATACATAT	ATGTTCTCAG	TATTTTGGGA	GCCTTTCCAC	120
TTCTTTAAAC	CTTGTTCAAT	ATGAACACTG	AAAATAGGAA	TTTGTGAAGA	GTAAAAAGT	180
TATAGCTTGT	TTACGTAGTA	AGTTTTTGA	GTCTACATTC	AATCCAGACA	CTTAGTTGAG	240
TGTTAAACTG	TGATTTTAA	AAAATATCAT	TTGAGAATAT	TCTTTCAGAG	GATTTTTCAT	300
TTTTACTTTT	TGATTAATTG	TGTTTTATAT	ATTAGGGTAG	T		341

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

ACTTACTGAA	TTTAGTTCTG	TGCTCTTCCT	TATTTAGTGT	TGTATCATAA	ATACTTTGAT	60
GTTTCAAACA	TTCTAAATAA	ATAATTTCA	GTGGCTTCAT	A		101

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 305 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

ACATCTTTGT TACAGTCTAA GATGTGTTCT TAAATCACCA TTCCTTCCTG GTCCTCACCC	60
TCCAGGGTGG TCTCACACTG TAATTAGAGC TATTGAGGAG TCTTTACAGC AAATTAAGAT	120
TCAGATGCCT TGCTAAGTCT AGAGTTCTAG AGTTATGTTT CAGAAAGTCT AAGAAACCCA	180
CCTCTTGAGA GGTCACTAAA GAGGACTTAA TATTTTCATAT CTACAAAATG ACCACAGGAT	240
TGGATACAGA ACGAGAGTTA TCCTGGATAA CTCAGAGCTG AGTACCTGCC CGGGGGCCGC	300
TCGAA	305

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 852 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

ACATAAATAT CAGAGAAAAG TAGTCTTTGA AATATTTACG TCCAGGAGTT CTTTGTCTTCT	60
GATTATTGG TGTGTGTTTT GGTGTGTGTC CAAAGTATTG GCAGCTTCAG TTTTCATTTT	120
CTCTCCATCC TCGGGCATTG TCCCAAATT TATATACCAG TCTTCGTCCA TCCACACGCT	180
CCAGAAATTC TCTTTTGTAG TAATATCTCA TAGCTCGGCT GAGCTTTTCA TAGGTCATGC	240
TGCTGTTGTT CTTCTTTTTA CCCCATAGCT GAGCCACTGC CTCTGATTTT AAGAACCTGA	300
AGACGCCCTC AGATCGGTCT TCCCATTTTA TTAATCCTGG GTTCTTGTCT GGGTTCAAGA	360
GGATGTCGCG GATGAATTCC CATAAGTGAG TCCCTCTCGG GTTGTGCTTT TTGGTGTGGC	420
ACTTGGCAGG GGGGTCTTGC TCCTTTTTCA TATCAGGTGA CTCTGCAACA GGAAGGTGAC	480
TGGTGGTTGT CATGGAGATC TGAGCCCGGC AGAAAGTTT GCTGTCCAAC AAATCTACTG	540
TGCTACCATA GTTGGTGTCA TATAAATAGT TCTNGTCTTT CCAGGTGTTT ATGATGGAAG	600
GCTCAGTTTG TTCAGTCTTG ACAATGACAT TGTGTGTGGA CTGGAACAGG TCACTACTGC	660
ACTGGCCGTT CCACTTCAGA TGCTGCAAGT TGCTGTAGAG GAGNTGCCCC GCCGTCCCTG	720
CCGCCCCGGT GAACTCCTGC AACTCATGC TGCAAAGGTG CTCGCCGTTG ATGTCGAACT	780
CNTGAAAGG GATACAATTG GCATCCAGCT GGTGGTGTG CAGGAGGTGA TGGAGCCACT	840
CCCACACCTG GT	852

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 234 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

ACAACAGACC CTTGCTCGCT AACGACCTCA TGCTCATCAA GTTGGACGAA TCCGTGTCCG	60
AGTCTGACAC CATCCGAGC ATCAGCATTG CTTGCGAGTG CCCTACCGCG GGGAACCTTT	120
GCCTCGTTTC TGGCTGGGGT CTGCTGGCGA ACGGCAGAAT GCCTACCGTG CTGCAGTGCG	180
TGAACGTGTC GGTGGTGTCT GAGGAGGTCT GCAGTAAGCT CTATGACCCG CTGT	234

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 590 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

ACTTTTTATT TAAATGTTTA TAAGGCAGAT CTATGAGAAT GATAGAAAAC ATGGTGTGTA	60
ATTTGATAGC AATATTTTGG AGATTACAGA GTTTTAGTAA TTACCAATTA CACAGTTAAA	120
AAGAAGATAA TATATTCCAA GCANATACAA AATATCTAAT GAAAGATCAA GGCAGGAAAA	180
TGANTATAAC TAATTGACAA TGGAAAATCA ATTTTAATGT GAATTGCACA TTATCCTTTA	240
AAAGCTTTCA AAANAAANAA TTATTGCAGT CTANTTAATT CAAACAGTGT TAAATGGTAT	300
CAGGATAAAN AACTGAAGGG CANAAAGAAT TAATTTTCAC TTCATGTAAC NCACCCANAT	360
TTACAATGGC TTAAATGCAN GGAAAAAGCA GTGGAAGTAG GGAAGTANTC AAGGTCTTTC	420
TGGTCTCTAA TCTGCCCTAC TCTTTGGGTG TGGCTTTGAT CCTCTGGAGA CAGCTGCCAG	480
GGCTCCTGTT ATATCCACA TCCCAGCAGC AAGATGAAGG GATGAAAAAG GACACATGCT	540
GCCTTCCTTT GAGGAGACTT CATCTCACTG GCCAACACTC AGTCACATGT	590

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 774 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ACAAGGGGGC ATAATGAAGG AGTGGGGANA GATTTTAAAG AAGGAAAAAA AACGAGGCC	60
TGAACAGAAT TTTCCTGNAC AACGGGGCTT CAAAATAATT TTCTTGGGGA GTTCAAGAC	120

GCTTCACTGC	TTGAACTTA	AATGGATGTG	GGACANAATT	TTCTGTAATG	ACCCTGAGGG	180
CATTACAGAC	GGGACTCTGG	GAGGAAGGAT	AAACAGAAAG	GGGACAAAGG	CTAATCCCAA	240
AACATCAAAG	AAAGGAAGGT	GGCGTCATAC	CTCCCAGCCT	ACACAGTTCT	CCAGGGCTCT	300
CCTCATCCCT	GGAGGACGAC	AGTGGAGGAA	CAACTGACCA	TGTCCCCAGG	CTCCTGTGTG	360
CTGGCTCCTG	GTCTTCAGCC	CCCAGCTCTG	GAAGCCCACC	CTCTGCTGAT	CCTGCGTGGC	420
CCACACTCCT	TGAACACACA	TCCCCAGGTT	ATATTCCTGG	ACATGGCTGA	ACCTCCTATT	480
CCTACTTCCG	AGATGCCTTG	CTCCCTGCAG	CCTGTCAAAA	TCCCCTCAC	CCTCCAAACC	540
ACGGCATGGG	AAGCCTTTCT	GACTTGCCTG	ATTACTCCAG	CATCTTGGAA	CAATCCCTGA	600
TTCCCCACTC	CTTAGAGGCA	AGATAGGGTG	GTAAAGAGTA	GGGCTGGACC	ACTTGGAGCC	660
AGGCTGCTGG	CTTCAAATTN	TGGCTCATTT	ACGAGCTATG	GGACCTTGGG	CAAGTNATCT	720
TCACTTCTAT	GGGCNTCATT	TTGTTCTACC	TGCAAAATGG	GGGATAATAA	TAGT	774

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 124 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

CANAAATTGA	AATTTTATAA	AAAGGCATTT	TTCTCTTATA	TCCATAAAAT	GATATAATTT	60
TTGCAANTAT	ANAAATGTGT	CATAAATTAT	AATGTTCCCT	AATTACAGCT	CAACGCAACT	120
TGGT						124

(2) INFORMATION FOR SEQ ID NO:49:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 147 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GCCGATGCTA	CTATTTTATT	GCAGGAGGTG	GGGGTGTTTT	TATTATTCTC	TCAACAGCTT	60
TGTGGCTACA	GGTGGTGTCT	GACTGCATNA	AAAANTTTTT	TACGGGTGAT	TGCAAAAATT	120
TTAGGGCACC	CATATCCCAA	GCANTGT				147

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 107 base pairs
 - (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

ACATTAAATT AATAAAAGGA CTGTTGGGGT TCTGCTAAAA CACATGGCTT GATATATTGC	60
ATGGTTTGAG GTTAGGAGGA GTTAGGCATA TGTTTTGGGA GAGGGGT	107

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 204 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GTCCTAGGAA GTCTAGGGGA CACACGACTC TGGGGTCACG GGGCCGACAC ACTTGCACGG	60
CGGGAAGGAA AGGCAGAGAA GTGACACCGT CAGGGGGAAA TGACAGAAAG GAAAATCAAG	120
GCCTTGCAAG GTCAGAAAGG GGAATCAGGG CTTCCACCAC AGCCCTGCCC CACTTGGCCA	180
CCTCCCTTTT GGGACCAGCA ATGT	204

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 491 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

ACAAAGATAA CATTTATCTT ATAACAAAAA TTTGATAGTT TTAAAGGTTA GTATTGTGTA	60
GGGTATTTTC CAAAAGACTA AAGAGATAAC TCAGGTAAAA AGTTAGAAAT GTATAAAACA	120
CCATCAGACA GGTTTTTTAAA AAACAACATA TTACAAAATT AGACAATCAT CCTTAAAAAA	180
AAAATTCTT GTATCAATT CTTTTGTTCA AAATGACTGA CTTAANTATT TTTAAATATT	240
TCANAAACAC TTCCTCAAAA ATTTTCAANA TGGTAGCTTT CANATGTNCC CTCAGTCCCA	300
ATGTTGCTCA GATAAATAAA TCTCGTGAGA ACTTACCACC CACCACAAGC TTTCTGGGGC	360
ATGCAACAGT GTCTTTTCTT TNCTTTTCT TTTTNTTTT TTACAGGCAC AGAAATCAT	420

CAATTTTATT TGGATAACAA AGGGTCTCCA AATTATATTG AAAAATAAAT CCAAGTTAAT 480
ATCACTCTTG T 491

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 484 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

ACATAATTTA GCAGGGCTAA TTACCATAAG ATGCTATTTA TTAANAGGTN TATGATCTGA	60
GTATTACAG TTGCTGAAGT TTGGTATTTT TATGCAGCAT TTTCTTTTGT CTTTGATAAC	120
ACTACAGAAC CCTTAAGGAC ACTGAAAATT AGTAAGTAAA GTTCAGAAAC ATTAGCTGCT	180
CAATCAAATC TCTACATAAC ACTATAGTAA TTAACCGTT AAAAAAAGT GTTGAAATCT	240
GCACTAGTAT ANACCGCTCC TGTCAGGATA ANACTGCTTT GGAACAGAAA GGGAAAAANC	300
AGCTTTGANT TTCTTTGTGC TGATANGAGG AAAGGCTGAA TTACCTTGTT GCCTCTCCCT	360
AATGATTGGC AGGTCNGGTA AATNCCAAAA CATATTCCAA CTCAACACTT CTTTTCNCG	420
TANCTTGANT CTGTGTATTC CAGGANCAGG CGGATGGAAT GGGCCAGCCC NCGGATGTTT	480
CANT	484

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

ACTAAACCTC GTGCTTGTGA ACTCCATACA GAAACGGTG CCATCCCTGA ACACGGCTGG	60
CCACTGGGTA TACTGCTGAC AACCGCAACA AAAAAACAC AAATCCTTGG CACTGGCTAG	120
TCTATGTCCT CTCAAGTGCC TTTTGTGTTG T	151

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

ACCTGGCTTG TCTCCGGGTG GTTCCCGGCG CCCCCACGG TCCCCAGAAC GGACACTTTC 60
GCCCTCCAGT GGATACTCGA GCCAAAGTGG T 91

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 133 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GGCGGATGTG CGTTGGTTAT ATACAAATAT GTCATTTTAT GTAAGGGACT TGAGTATACT 60
TGGATTTTGT GTATCTGTGG GTTGGGGGGA CGGTCCAGGA ACCAATACCC CATGGATACC 120
AAGGGACAAC TGT 133

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 147 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

ACTCTGGAGA ACCTGAGCCG CTGCTCCGCC TCTGGGATGA GGTGATGCAN GCNGTGGCGC 60
GACTGGGAGC TGAGCCCTTC CCTTTGCGCC TGCCTCAGAG GATTGTTGCC GACNTGCANA 120
TCTCANTGGG CTGGATNCAT GCAGGGT 147

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 198 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

ACAGGGATAT AGGTTTNAAG TTATTGTNAT TGAAAATAC ATTGAATTTT CTGTATACTC	60
TGATTACATA CATTTATCCT TTAAAAAGA TGAAATCTT AATTTTATG CCATCTATTA	120
ATTTACCAAT GAGTTACCTT GTAAATGAGA AGTCATGATA GCACTGAATT TTAAC TAGTT	180
TTGACTTCTA AGTTTGGT	198

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 330 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

ACAACAAATG GGTGTGAGG AAGTCTTATC AGCAAACTG GTGATGGCTA CTGAAAAGAT	60
CCATTGAAAA TTATCATTAA TGATTTTAAA TGACAAGTTA TCAAAACTC ACTCAATTTT	120
CACCTGTGCT AGCTTGCTAA AATGGGAGTT AACTCTAGAG CAAATATAGT ATCTTCTGAA	180
TACAGTCAAT AAATGACAAA GCCAGGGCCT ACAGGTGGTT TCCAGACTTT CCAGACCCAG	240
CAGAAGGAAT CTATTTTATC ACATGGATCT CCGTCTGTGC TCAAAATACC TAATGATATT	300
TTTCGTCTTT ATTGGACTTC TTTGAAGAGT	330

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 175 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

ACCGTGGGTG CTTTCTACAT TCCTGACGGC TCCTTCACCA ACATCTGGTT CTACTTCGGC	60
GTCTGTTGGT CTTTCTCTT CATCTCATC CAGCTGGTGC TGCTCATCGA CTTTGCAC	120
TCCTGGAACC AGCGGTGGCT GGGCAAGGCC GAGGAGTGCG ATTCCCGTGC CTGGT	175

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 154 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

```
ACCCCACTTT TCCTCCTGTG AGCAGTCTGG ACTTCTCACT GCTACATGAT GAGGGTGAGT      60
GGTTGTGCT CTTCAACAGT ATCCTCCCCT TTCCGGATCT GCTGAGCCGG ACAGCAGTGC      120
TGGACTGCAC AGCCCCGGGG CTCCACATTG CTGT                                  154
```

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

```
CGCTCGAGCC CTATAGTGAG TCGTATTAGA                                     30
```

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 89 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

```
ACAAGTCATT TCAGCACCTT TTGCTCTTCA AAAGTGACCA TCTTTTATAT TTAATGCTTC      60
CTGTATGAAT AAAAATGGTT ATGTCAAGT                                         89
```

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 97 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

ACCGGAGTAA CTGAGTCGGG ACGCTGAATC TGAATCCACC AATAAATAAA GGTTCTGCAG	60
AATCAGTGCA TCCAGGATTG GTCCTTGAT CTGGGGT	97

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 377 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

ACAACAANAA NTCCCTTCTT TAGGCCACTG ATGGAAACCT GGAACCCCT TTTGATGGCA	60
GCATGGCGTC CTAGGCCTTG ACACAGCGGC TGGGGTTTGG GCTNTCCCAA ACCGCACACC	120
CCAACCCTGG TCTACCCACA NTTCTGGCTA TGGGCTGTCT CTGCCACTGA ACATCAGGGT	180
TCGGTCATAA NATGAAATCC CAANGGGGAC AGAGGTCAGT AGAGGAAGCT CAATGAGAAA	240
GGTGCTGTTT GCTCAGCCAG AAAACAGCTG CCTGGCATTG GCCGCTGAAC TATGAACCCG	300
TGGGGGTGAA CTACCCCCAN GAGGAATCAT GCCTGGGCGA TGCAANGGTG CCAACAGGAG	360
GGGCGGGAGG AGCATGT	377

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 305 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

ACGCCTTTCC CTCAGAATTC AGGGAAGAGA CTGTCGCTG CCTTCCTCCG TTGTTGCGTG	60
--	----

AGAACCCGTG	TGCCCCCTTC	CACCATATCC	ACCCTCGCTC	CATCTTTGAA	CTCAAACACG	120
AGGAACCTAAC	TGCACCCTGG	TCCTCTCCCC	AGTCCCCAGT	TCACCCTCCA	TCCCTCACCT	180
TCCTCCACTC	TAAGGGATAT	CAACACTGCC	CAGCACAGGG	GCCCTGAATT	TATGTGGTTT	240
TTATATATTT	TTTAATAAGA	TGCACTTTAT	GTCATTTTTT	AATAAAGTCT	GAAGAATTAC	300
TGTTT						305

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 385 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

ACTACACACA	CTCCACTTGC	CCTTGTGAGA	CACTTTGTCC	CAGCACTTTA	GGAATGCTGA	60
GGTCGGACCA	GCCACATCTC	ATGTGCAAGA	TTGCCCAGCA	GACATCAGGT	CTGAGAGTTC	120
CCCTTTTAAA	AAAGGGGACT	TGCTTAAAAA	AGAAGTCTAG	CCACGATTGT	GTAGAGCAGC	180
TGTGCTGTGC	TGGAGATTCA	CTTTTGAGAG	AGTTCTCCTC	TGAGACCTGA	TCTTTAGAGG	240
CTGGGCAGTC	TTGCACATGA	GATGGGGCTG	GTCTGATCTC	AGCACTCCTT	AGTCTGCTTG	300
CCTCTCCCAG	GGCCCCAGCC	TGGCCACACC	TGCTTACAGG	GCACTCTCAG	ATGCCCATAC	360
CATAGTTTCT	GTGCTAGTGG	ACCGT				385

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

ACTTAACCAG	ATATATTTTT	ACCCAGATG	GGGATATTCT	TTGTAAAAAA	TGAAAATAAA	60
GTTTTTTTAA	TGG					73

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 536 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

ACTAGTCCAG	TGTGGTGGAA	TTCCATTGTG	TTGGGGGCTC	TCACCCTCCT	CTCCTGCAGC	60
TCCAGCTTTG	TGCTCTGCCT	CTGAGGAGAC	CATGGCCCAG	CATCTGAGTA	CCCTGCTGCT	120
CCTGCTGGCC	ACCCTAGCTG	TGGCCCTGGC	CTGGAGCCCC	AAGGAGGAGG	ATAGGATAAT	180
CCCGGGTGGC	ATCTATAACG	CAGACCTCAA	TGATGAGTGG	GTACAGCGTG	CCCTTCACTT	240
CGCCATCAGC	GAGTATAACA	AGGCCACCAA	AGATGACTAC	TACAGACGTC	CGCTGCGGGT	300
ACTAAGAGCC	AGGCAACAGA	CCGTTGGGGG	GGTGAATTAC	TTCTTCGACG	TAGAGGTGGG	360
CCGAACCATA	TGTACCAAGT	CCCAGCCCAA	CTTGGACACC	TGTGCCTTCC	ATGAACAGCC	420
AGAACTGCAG	AAGAAACAGT	TGTGCTCTTT	CGAGATCTAC	GAAGTTCCT	GGGGAGAACA	480
GAANGTCCCT	GGGTGAAATC	CAGGTGTCAA	GAAATCCTAN	GGATCTGTTG	CCAGGC	536

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 477 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

ATGACCCCTA	ACAGGGGCCC	TCTCAGCCCT	CCTAATGACC	TCCGGCCTAG	CCATGTGATT	60
TCACTTCCAC	TCCATAACGC	TCCTCATACT	AGGCCTACTA	ACCAACACAC	TAACCATATA	120
CCAATGATGG	CGCGATGTAA	CACGAGAAAG	CACATACCAA	GGCCACCACA	CACCACCTGT	180
CCAAAAAGGC	CTTCGATACG	GGATAATCCT	ATTTATTACC	TCAGAAGTTT	TTTTCTTCGC	240
AGGGATTTTT	CTGAGCCTTT	TACCACTCCA	GCCTAGCCCC	TACCCCCCAA	CTAGGAGGGC	300
ACTGGCCCCC	AACAGGCATC	ACCCCGCTAA	ATCCCCTAGA	AGTCCCCTC	CTAAACACAT	360
CCGTATTACT	CGCATCAGGA	GTATCAATCA	CCTGAGCTCA	CCATAGTCTA	ATAGAAAACA	420
ACCGAAACCA	AATTATTCAA	AGCACTGCTT	ATTACAATTT	TACTGGGTCT	CTATTTT	477

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 533 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

AGAGCTATAG	GTACAGTGTG	ATCTCAGCTT	TGCAAACACA	TTTTCTACAT	AGATAGTACT	60
AGGTATTAAT	AGATATGTAA	AGAAAGAAAT	CACACCATT	ATAATGGTAA	GATTGGTTTA	120
TGTGATTTTA	GTGGTATTTT	TGGCACCTT	ATATATGTTT	TCCAAACTTT	CAGCAGTGAT	180
ATTATTTCCA	TAACCTAAAA	AGTGAGTTTG	AAAAAGAAAA	TCTCCAGCAA	GCATCTCATT	240
TAAATAAAGG	TTTGTCTCT	TAAAAAATAC	AGCAATATGT	GACTTTTTAA	AAAAGCTGTC	300
AAATAGGTGT	GACCCTACTA	ATAATTATTA	GAAATACATT	TAAAAACATC	GAGTACCTCA	360
AGTCAGTTTG	CCTTGAAAAA	TATCAAATAT	AACCTTTAGA	GAAATGTACA	TAAAAGAATG	420
CTTCGTAATT	TTGGAGTANG	AGGTTCCCTC	CTCAATTTTG	TATTTTTTAA	AAGTACATGG	480
TAAAAAATAA	AATTCACAAC	AGTATATAAG	GCTGTAAAAT	GAAGAATTCT	GCC	533

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 511 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

TATTACGGAA	AAACACACCA	CATAATTCAA	CTANCAAAGA	ANACTGCTTC	AGGGCGTGTA	60
AAATGAAAGG	CTTCCAGGCA	GTTATCTGAT	TAAAGAACAC	TAAAAGAGGG	ACAAGGCTAA	120
AAGCCGCAGG	ATGTCTACAC	TATANCAGGC	GCTATTTGGG	TTGGCTGGAG	GAGCTGTGGA	180
AAACATGGAN	AGATTGGTGC	TGGANATCGC	CGTGGCTATT	CCTCATGTGT	ATTACANAGT	240
GAGGTTCTCT	GTGTGCCCAC	TGGTTTGAAA	ACCGTCTTNC	AATAATGATA	GAATAGTACA	300
CACATGAGAA	CTGAAATGGC	CCAAACCCAG	AAAGAAAGCC	CAACTAGATC	CTCAGAAANAC	360
GCTTCTAGGG	ACAATAACCG	ATGAAGAAAA	GATGGCCTCC	TTGTGCCCCC	GTCTGTTATG	420
ATTTCTCTCC	ATTGCAGCNA	NAAACCCGTT	CTTCTAAGCA	AACNCAGGTG	ATGATGGCNA	480
AAATACACCC	CCTCTGAAG	NACCNCGGAG	A			511

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 499 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

CAGTGCCAGC	ACTGGTGCCA	GTACCAGTAC	CAATAACAGT	GCCAGTGCCA	GTGCCAGCAC	60
CAGTGGTGGC	TTCACTGCTG	GTGCCAGCCT	GACCGCCACT	CTCACATTTG	GGCTCTTCGC	120
TGGCCTTGGT	GGAGCTGGTG	CCAGCACCAG	TGGCAGCTCT	GGTGCCTGTG	GTTTCTCCTA	180
CAAGTGAGAT	TTAGATATT	GTTAATCCTG	CCAGTCTTTC	TCTTCAAGCC	AGGGTGCATC	240

CTCAGAAACC TACTCAACAC AGCACTCTAG GCAGCCACTA TCAATCAATT GAAGTTGACA	300
CTCTGCATTA AATCTATTTG CCATTTCTGA AAAAAAAAAA AAAAAAAGGG CGGCCGCTCG	360
ANTCTAGAGG GCCCGTTTAA ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT ANTTGCCAGC	420
CATCTGTTGT TTGCCCCTCC CCCGNTGCCT TCCTTGACCC TGGAAAGTGC CACTCCCCT	480
GTCTTTTCTT AANTAAAAAT	499

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 537 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

TTTCATAGGA GAACACACTG AGGAGATACT TGAAGAATTT GGATTCAGCC GCGAAGAGAT	60
TTATCAGCTT AACTCAGATA AAATCATTGA AAGTAATAAG GTAAAAGCTA GTCTCTAACT	120
TCCAGGCCCA CGGCTCAAGT GAATTTGAAT ACTGCATTTA CAGTGTAGAG TAACACATAA	180
CATTGTATGC ATGGAAACAT GGAGGAACAG TATTACAGTG TCCTACCACT CTAATCAAGA	240
AAAGAATTAC AGACTCTGAT TCTACAGTGA TGATTGAATT CTAAAAATGG TAATCATTAG	300
GGCTTTTGAT TTATAANACT TTGGGTACTT ATACTAAATT ATGGTAGTTA TACTGCCTTC	360
CAGTTTGCTT GATATATTTG TTGATATTAA GATTCTTGAC TTATATTTTG AATGGGTTCT	420
ACTGAAAAAN GAATGATATA TTCTTGAAGA CATCGATATA CATTATTTTA CACTCTTGAT	480
TCTACAATGT AGAAAAATGAA GGAAATGCCC CAAATTGTAT GGTGATAAAA GTCCCGT	537

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 467 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CAANACAAT TGTTCAAAAG ATGCAAATGA TACACTACTG CTGCAGCTCA CAAACACCTC	60
TGCATATTAC ACGTACCTCC TCCTGCTCCT CAAGTAGTGT GGTCTATTTT GCCATCATCA	120
CCTGCTGTCT GCTTAGAAGA ACGGCTTTCT GCTGCAANGG AGAGAAATCA TAACAGACGG	180
TGGCACAAGG AGGCCATCTT TTCCTCATCG GTTATTGTCC CTAGAAGCGT CTTCTGAGGA	240
TCTAGTTGGG CTTTCTTTCT GGGTTTGGGC CATTTCANTT CTCATGTGTG TACTATTCTA	300
TCATTATTGT ATAACGGTTT TCAAACNGT GGGCACNCAG AGAACCTCAC TCTGTAATAA	360
CAATGAGGAA TAGCCACGGT GATCTCCAGC ACCAAATCTC TCCATGTTNT TCCAGAGCTC	420
CTCCAGCCAA CCCAAATAGC CGCTGCTATN GTGTAGAACA TCCCTGN	467

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 400 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

AAGCTGACAG CATTGCGGCC GAGATGTCTC GCTCCGTGGC CTTAGCTGTG CTCGCGCTAC	60
TCTCTCTTTC TGGCCTGGAG GCTATCCAGC GTACTCCAAA GATTCAGGTT TACTCACGTC	120
ATCCAGCAGA GAATGGAAAG TCAAATTTCC TGAATTGCTA TGTGTCTGGG TTTCATCCAT	180
CCGACATTGA AGTTGACTTA CTGAAGAATG GAGAGAGAAT TGAAAAAGTG GAGCATTGAG	240
ACTTGTCTTT CAGCAAGGAC TGGTCTTTCT ATCTCTTGTA CTACACTGAA TTCACCCCCA	300
CTGAAAAAGA TGAGTATGCC TGCCGTGTGA ACCATGTGAC TTTGTCACAG CCCAAGATNG	360
TTNAGTGGGA TCGANACATG TAAGCAGCAN CATGGGAGGT	400

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 248 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

CTGGAGTGCC TTGGTGTTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT	60
CCAGCTGCCC CGGCGGGGGA TGCGAGGCTC GGAGCACCTT TGCCCGGCTG TGATTGCTGC	120
CAGGCACTGT TCATCTCAGC TTTTCTGTCC CTTTGCTCCC GGCAAGCGCT TCTGCTGAAA	180
GTTTCATATCT GGAGCCTGAT GTCTTAACGA ATAAAGGTCC CATGCTCCAC CCGAAAAAAA	240
AAAAAAA	248

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 201 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA	60
TCACCCAGAC CCCGCCCTGC CCGTGCCCCA CGCTGCTGCT AACGACAGTA TGATGCTTAC	120
TCTGCTACTC GGAAACTATT TTTATGTAAT TAATGTATGC TTTCTTGTTT ATAAATGCCT	180
GATTTAAAAA AAAAAAAAAA A	201

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 552 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

TCCTTTTGTT AGGTTTTTGA GACAACCCTA GACCTAAACT GTGTCACAGA CTTCTGAATG	60
TTTAGGCAGT GCTAGTAATT TCCTCGTAAT GATTCTGTTA TTA CTTTCCT ATTCTTTATT	120
CCTCTTTCTT CTGAAGATTA ATGAAGTTGA AAATTGAGGT GGATAAATAC AAAAAGGTAG	180
TGTGATAGTA TAAGTATCTA AGTGCAGATG AAAGTGTGTT ATATATATCC ATTCAAAAATT	240
ATGCAAGTTA GTAATTACTC AGGGTTAACT AAATTACTTT AATATGCTGT TGAACCTACT	300
CTGTTTCCTTG GCTAGAAAAA ATTATAAACA GGA CTTTGTT AGTTTGGGAA GCCAAATTGA	360
TAATATTCTA TGTTCTAAAA GTTGGGCTAT ACATAAANTA TNAAGAAATA TGGAATTTTA	420
TTCCAGGAA TATGGGGTTC ATTTATGAAT ANTACCCGGG ANAGAAGTTT TGANTNAAAC	480
CNGTTTTGGT TAATACGTTA ATATGTCCTN AATNAACAAG GCNTGACTTA TTTCCAAAAA	540
AAAAAAAAAA AA	552

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 476 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

ACAGGGATTT GAGATGCTAA GGCCCCAGAG ATCGTTTGAT CCAACCCTCT TATTTTCAGA	60
GGGGAAAATG GGGCCTAGAA GTTACAGAGC ATCTAGCTGG TGCGCTGGCA CCCCTGGCCT	120
CACACAGACT CCCGAGTAGC TGGGACTACA GGCACACAGT CACTGAAGCA GGCCCTGTTT	180
GCAATTCACG TTGCCACCTC CAACTTAAAC ATTCTTCATA TGTGATGTCC TTAGTCACTA	240
AGGTTAAACT TTCCACCCA GAAAAGGCAA CTTAGATAAA ATCTTAGAGT ACTTTCATAC	300

TCTTCTAAGT CCTCTTCCAG CCTCACTTTG AGTCCTCCTT GGGGGTTGAT AGGAANTNTC	360
TCTTGGCTTT CTCAATAAAA TCTCTATCCA TCTCATGTTT AATTGGGTAC GCNTAAAAAT	420
GCTGAAAAAA TTAAATGTT CTGGTTTCNC TTAAAAAAA AAAAAAAAAA AAAAAA	476

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 232 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

TTTTTTTTTG TATGCCNTCN CTGTGGNGTT ATTGTTGCTG CCACCCTGGA GGAGCCCAGT	60
TTCTTCTGTA TCTTTCTTTT CTGGGGGATC TTCCTGGCTC TGCCCCTCCA TTCCCAGCCT	120
CTCATCCCCA TCTTGCACTT TTGCTAGGGT TGGAGGCGCT TTCCTGGTAG CCCCTCAGAG	180
ACTCAGTCAG CGGAATAAG TCCTAGGGGT GGGGGGTGTG GCAAGCCGGC CT	232

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 383 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC	60
AGTACCAGTA CCAATAACAT GCCAGTGCCA GTGCCAGCAC CAGTGGTGGC TTCAGTGCTG	120
GTGCCAGCCT GACCGCCACT CTCACATTTG GGCTCTTCGC TGGCCTTGGT GGAGCTGGTG	180
CCAGCACCAG TGGCAGCTCT GGTGCCTGTG GTTTCTCCTA CAAGTGAGAT TTTAGATATT	240
GTAAATCCTG CCAGTCTTTC TCTTCAAGCC AGGGTGCATC CTCAGAAACC TACTCAACAC	300
AGCACTCTNG GCAGCCACTA TCAATCAATT GAAGTTGACA CTCTGCATTA AATCTATTG	360
CCATTTCAAA AAAAAAAAAA AAA	383

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 494 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

```

ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTCCTC CAGTATTACC TCAACGAGCA      60
GGGAGATCGA GTCTATACGC TGAAGAAATT TGACCCGATG GGACAACAGA CCTGCTCAGC      120
CCATCCTGCT CGGTTCTCCC CAGATGACAA ATACTCTCGA CACCGAATCA CCATCAAGAA      180
ACGCTTCAAG GTGCTCATGA CCCAGCAACC GCGCCCTGTC CTCTGAGGGT CCTTAAACTG      240
ATGTCTTTTC TGCCACCTGT TACCCCTCGG AGACTCCGTA ACCAAACTCT TCGGACTGTG      300
AGCCCTGATG CTTTTTGCC AGCCATACTC TTTGGCNTCC AGTCTCTCGT GGCGATTGAT      360
TATGCTTGTG TGAGGCAATC ATGGTGGCAT CACCCATNAA GGGAACACAT TTGANTTTTT      420
TTTCNCATAT TTAAATTAC NACCAGAATA NTTCAGAATA AATGAATTGA AAAACTCTTA      480
AAAAAAAAAA AAAA
                                         494

```

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

```

GCTGGTAGCC TATGGCGTGG CCACGGANGG GCTCCTGAGG CACGGGACAG TGACTTCCCA      60
AGTATCCTGC GCCGCGTCTT CTACCGTCCC TACCTGCAGA TCTTCGGGCA GATTCCCCAG      120
GAGGACATGG ACGTGGCCCT CATGGAGCAC AGCAACTGCT CGTCGGAGCC CGGCTTCTGG      180
GCACACCCTC CTGGGGCCCA GCGGGGCACC TCGTCTCTCC AGTATGCCAA CTGGCTGGTG      240
GTGCTGCTCC TCGTCATCTT CCTGCTCGTG GCCAACATCC TGCTGGTCAC TTGCTCATTG      300
CCATGTTTCC TTACACATTC GGCAAAGTAC AGGGCAACAG CNATCTCTAC TGGGAAGGCC      360
AGCGTTNCCG CCTCATCCGG
                                         380

```

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 481 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

GAGTTAGCTC	CTCCACAACC	TTGATGAGGT	CGTCTGCAGT	GGCCTCTCGC	TTCATACCGC	60
TNCCATCGTC	ATACTGTAGG	TTTGCCACCA	CCTCCTGCAT	CTTGGGGCGG	CTAATATCCA	120
GGAAACTCTC	AATCAAGTCA	CCGTCNATNA	AACCTGTGGC	TGGTTCTGTC	TTCCGCTCGG	180
TGTGAAAGGA	TCTCCAGAAG	GAGTGCTCGA	TCTTCCCCAC	ACTTTTGATG	ACTTTATTGA	240
GTCGATTCTG	CATGTCCAGC	AGGAGGTTGT	ACCAGCTCTC	TGACAGTGAG	GTCAACAGCC	300
CTATCATGCC	NTTGAACGTG	CCGAAGAACA	CCGAGCCTTG	TGTGGGGGGT	GNAGTCTCAC	360
CCAGATTCTG	CATTACCAGA	NAGCCGTGGC	AAAAGANATT	GACAACTCGC	CCAGGNNGAA	420
AAAGAACACC	TCCTGGAAGT	GCTNGCCGCT	CCTCGTCCNT	TGGTGGNNGC	GCNTNCCTTT	480
T						481

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 472 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

AACATCTTCC	TGTATAATGC	TGTGTAATAT	CGATCCGATN	TTGTCTGCTG	AGAATTCATT	60
ACTTGGA AAA	GCAACTNAA	GCCTGGACAC	TGGTATTAAA	ATTCACAATA	TGCAACACTT	120
TAAACAGTGT	GTCAATCTGC	TCCCTTACTT	TGTCATCACC	AGTCTGGGAA	TAAGGGTATG	180
CCCTATTAC	ACCTGTATAA	AGGGCGCTAA	GCATTTTTGA	TTCAACATCT	TTTTTTTTGA	240
CACAAGTCCG	AAAAAAGCAA	AAGTAAACAG	TTNTTAATTT	GTTAGCCAAT	TCACCTTCTT	300
CATGGGACAG	AGCCATTTGA	TTTAAAAAGC	AAATTGCATA	ATATTGAGCT	TTGGGAGCTG	360
ATATNTGAGC	GGAAGANTAG	CCTTTCTACT	TCACCAGACA	CAACTCCTTT	CATATTGGGA	420
TGTTNACNAA	AGTTATGTCT	CTTACAGATG	GGATGCTTTT	GTGGCAATTC	TG	472

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 413 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

AGAAACCACT	ATCTCTNAAA	ACAACCTCTC	ATACCTTGCT	GACCTAATTT	TGTGTGCGTG	60
TGTGTGTGCG	CGCATATTAT	ATAGACAGGC	ACATCTTTTT	TACTTTTGTA	AAAGCTTATG	120
CCTCTTTGGT	ATCTATATCT	GTGAAAGTTT	TAATGATCTG	CCATAATGTC	TTGGGGACCT	180
TTGTCTTCTG	TGTAAATGGT	ACTAGAGAAA	ACACCTATNT	TATGAGTCAA	TCTAGTTNGT	240
TTTATTCGAC	ATGAAGGAAA	TTTCCAGATN	ACAACACTNA	CAAACCTCTC	CTTGACTAGG	300
GGGGACAAAG	AAAAGCANAA	CTGAACATNA	GAAACAATTN	CCTGGTGAGA	AATTNCATAA	360

ACAGAAATTG GGTNGTATAT TGAAANANNG CATCATTNAA ACGTTTTTTT TTT

413

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 448 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

CGCAGCGGGT CCTCTCTATC TAGCTCCAGC CTCTCGCCTG CCCCACTCCC CGCGTCCCGC	60
GTCCTAGCCN ACCATGGCCG GGCCCGTCG CGCCCCGCTG CTCCTGCTGG CCATCCTGGC	120
CGTGGCCCTG GCCGTGAGCC CCGCGGCCCG CTCCAGTCCC GGCAAGCCGC CGCGCCTGGT	180
GGGAGGCCCA TGGACCCCGC GTGGAAGAAG AAGGTGTGCG GCGTGCACTG GACTTTGCCG	240
TCGGCNANTA CAACAAACCC GCAACNACTT TTACCNAGCN CGCGCTGCAG GTTGTGCCGC	300
CCCAANCAAA TTGTTACTNG GGGTAANTAA TTCTTGGAAG TTGAACCTGG GCCAAACNNG	360
TTTACCAGAA CCNAGCCAAT TNGAACAAAT NCCCCTCCAT AACAGCCCCT TTAAAAAGG	420
GAANCANTCC TGNTCTTTTC CAAATTTT	448

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 463 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GAATTTTGTG CACTGGCCAC TGTGATGGAA CCATTGGGCC AGGATGCTTT GAGTTTATCA	60
GTAGTGATTC TGCCAAAGTT GGTGTTGTAA CATGAGTATG TAAAATGTCA AAAAATTAGC	120
AGAGGTCTAG GTCTGCATAT CAGCAGACAG TTTGTCCGTG TATTTTGTAG CCTTGAAGTT	180
CTCAGTGACA AGTTNNTTCT GATGCGAAGT TCTNATTCCA GTGTTTTAGT CCTTTGCATC	240
TTTATGTTN AGACTTGCCT CTNTNAAATT GCTTTTGTNT TCTGCAGGTA CTATCTGTGG	300
TTTAACAAAA TAGAANNACT TCTCTGCTTN GAANATTGTA ATATCTTACA TCTNAAAATN	360
AATTCTCTCC CCATANNAAC ACCCANGCCC TTGGGANAAT TGAAAAANG GNTCCTTCNN	420
AATTCNNANA ANTTCAGNTN TCATACAACA NAACNGGANC CCC	463

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 400 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

AGGGATTGAA GGTCTNTTNT ACTGTCTGGAC TGTTTCANCCA CCAACTCTAC AAGTTGCTGT	60
CTTCCACTCA CTGTCTGTAA GCNTNTTAAAC CCAGACTGTA TCTTCATAAA TAGAACAAAT	120
TCTTCACCAG TCACATCTTC TAGGACCTTT TTGGATTTCAG TTAGTATAAG CTCTTCCACT	180
TCCTTTGTGA AGACTTCATC TGGTAAAGTC TTAAGTTTTG TAGAAAGGAA TTTAATTGCT	240
CGTTCTCTAA CAATGTCCTC TCCTTGAAGT ATTTGGCTGA ACAACCCACC TNAAGTCCCT	300
TTGTGCATCC ATTTTAAATA TACTTAATAG GGCATTGGTN CACTAGGTGA AATTCTGCAA	360
GAGTCATCTG TCTGCAAAAG TTGCGTTAGT ATATCTGCCA	400

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 480 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

GAGCTCGGAT CCAATAATCT TTGTCTGAGG GCAGCACACA TATNCAGTGC CATGGNAACT	60
GGTCTACCCC ACATGGGAGC AGCATGCCGT AGNTATATAA GGTCATTCCC TGAGTCAGAC	120
ATGCCTCTTT GACTACCGTG TGCCAGTGCT GGTGATTCTC ACACACCTCC NNCCGCTCTT	180
TGTGGAAAAA CTGGCACTTG NCTGGAACATA GCAAGACATC ACTTACAAAT TCACCCACGA	240
GACACTTGAA AGGTGTAACA AAGCGACTCT TGCATTGCTT TTTGTCCCTC CGGCACCAGT	300
TGTCAATACT AACCCGCTGG TTTGCCTCCA TCACATTGTT GATCTGTAGC TCTGGATACA	360
TCTCCTGACA GTACTGAAGA ACTTCTTCTT TTGTTTCAAA AGCAACTCTT GGTGCCTGTT	420
NGATCAGGTT CCCATTTCCC AGTCCGAATG TTCACATGGC ATATNTTACT TCCCACAAAA	480

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

ATACAGCCCA NATCCACCA CGAAGATGCG CTTGTTGACT GAGAACCTGA TGCGGTCACT	60
GGTCCCCTG TAGCCCCAGC GACTCTCCAC CTGCTGGAAG CGGTTGATGC TGCACTCCTT	120
CCCACGCAGG CAGCAGCGGG GCCGGTCAAT GAACTCCACT CGTGGCTTGG GGTTGACGGT	180
TAANTGCAGG AAGAGGCTGA CCACCTCGCG GTCCACCAGG ATGCCCCACT GTGCGGGACC	240
TGCAGCGAAA CTCCTCGATG GTCATGAGCG GGAAGCGAAT GANGCCCAGG GCCTTGCCCA	300
GAACCTTCCG CCTGTTCTCT GCGTCACCT GCAGCTGCTG CCGCTNACAC TCGGCCTCGG	360
ACCAGCGGAC AAACGGCGTT GAACAGCCGC ACCTCACGGA TGCCANTGT GTCGCGCTCC	420
AGGAACGGCN CCAGCGTGTC CAGGTCAATG TCGGTGAANC CTCCGCGGGT AATGGCG	477

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 377 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

GAACGGCTGG ACCTTGCTC GCATTGTGCT GCTGGCAGGA ATACCTTGGC AAGCAGCTCC	60
AGTCCGAGCA GCCCCAGACC GGTGCCGCC GAAGCTAAGC CTGCCTCTGG CCTTCCCCTC	120
CGCCTCAATG CAGAACCANT AGTGGGAGCA CTGTGTTTAG AGTTAAGAGT GAACACTGTN	180
TGATTTTACT TGGGAATTTT CTCTGTTATA TAGCTTTTCC CAATGCTAAT TTCCAAACAA	240
CAACAACAAA ATAACATGTT TGCCTGTNA GTTGATATAA AGTANGTGAT TCTGTATNTA	300
AAGAAAATAT TACTGTTACA TATACTGCTT GCAANTTCTG TATTTATTGG TNCTCTGGAA	360
ATAAATATAT TATTA	377

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 495 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

CCCTTTGAGG GGTTAGGGTC CAGTCCCAG TGGAAGAAAC AGGCCAGGAG AANTGCGTGC	60
CGAGCTGANG CAGATTTCCC ACAGTGACCC CAGAGCCCTG GGCTATAGTC TCTGACCCCT	120
CCAAGGAAAG ACCACCTTCT GGGGACATGG GCTGGAGGGC AGGACCTAGA GGCACCAAGG	180
GAAGGCCCA TTCCGGGGCT GTTCCCGAG GAGGAAGGGA AGGGGCTCTG TGTGCCCCC	240
ACGAGGAANA GGCCCTGANT CCTGGGATCA NACACCCCTT CACGTGTATC CCCACACAAA	300

TGCAAGCTCA CCAAGGTCCC CTCTCAGTCC CTTCCCTACA CCCTGAACGG NCACTGGCCC	360
ACACCCACCC AGANCANCCA CCCGCCATGG GGAATGTNCT CAAGGAATCG CNGGGCAACG	420
TGGACTCTNG TCCCNNAAGG GGGCAGAATC TCCAATAGAN GGANNGAACC CTTGCTNANA	480
AAAAAAAAANA AAAAA	495

(2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 472 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

GGTTACTTGG TTTCATTGCC ACCACTTAGT GGATGTCATT TAGAACCATT TTGTCTGCTC	60
CCTCTGGAAG CCTTGCGCAG AGCGGACTTT GTAATTGTTG GAGAATAACT GCTGAATTTT	120
TAGCTGTTTT GAGTTGATTC GCACCACTGC ACCACAACCTC AATATGAAAA CTATTTNACT	180
TATTTATTAT CTTGTGAAAA GTATACAATG AAAATTTTGT TCATACTGTA TTTATCAAGT	240
ATGATGAAAA GCAATAGATA TATATTCTTT TATTATGTTN AATTATGATT GCCATTATTA	300
ATCGGCAAAA TGTGGAGTGT ATGTTCTTTT CACAGTAATA TATGCCTTTT GTAACCTCAC	360
TTGGTTATTT TATTGTAAAT GAATTACAAA ATTCTTAATT TAAGAAAATG GTANGTTATA	420
TTTANTTCAN TAATTTCTTT CCTTGTTTAC GTTAATTTTG AAAAGAATGC AT	472

(2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 476 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

CTGAAGCATT TCTTCAAACCT TNTCTACTTT TGTCATTGAT ACCTGTAGTA AGTTGACAAT	60
GTGGTGAAAT TTCAAAATTA TATGTAACCT CTACTAGTTT TACTTTCTCC CCCAAGTCTT	120
TTTTAACTCA TGATTTTAC ACACACAATC CAGAACTTAT TATATAGCCT CTAAGTCTTT	180
ATTCTTCACA GTAGATGATG AAAGAGTCCT CCAGTGTCTT GNGCANAATG TTCTAGNTAT	240
AGCTGGATAC ATACNGTGGG AGTTCTATAA ACTCATACCT CAGTGGGACT NAACCAAAAT	300
TGTGTTAGTC TCAATTCCTA CCACACTGAG GAGCCTCCC AAATCACTAT ATTCTTATCT	360
GCAGGTACTC CTCCAGAAAA ACNGACAGGG CAGGCTTGCA TGAAAAAGTN ACATCTGCGT	420
TACAAAGTCT ATCTTCCTCA NANGTCTGTN AAGGAACAAT TTAATCTTCT AGCTTT	476

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 479 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

ACTCTTTCTA ATGCTGATAT GATCTTGAGT ATAAGAATGC ATATGTCACT AGAATGGATA	60
AAATAATGCT GCAAACTTAA TGTTCTTATG CAAAATGGAA CGCTAATGAA ACACAGCTTA	120
CAATCGCAAA TCAAACTCA CAAGTGCTCA TCTGTTGTAG ATTTAGTGTA ATAAGACTTA	180
GATTGTGCTC CTTCGGATAT GATTGTTTCT CANATCTTGG GCAATNTTCC TTAGTCAAAT	240
CAGGCTACTA GAAATCTGTT ATTGGATATN TGAGAGCATG AAATTTTAA NAATACACTT	300
GTGATTATNA AATTAATCAC AAATTTCACT TATACCTGCT ATCAGCAGCT AGAAAAACAT	360
NTNNTTTTNA NATCAAAGTA TTTTGTGTTT GGAANTGTNN AAATGAAATC TGAATGTGGG	420
TTCNATCTTA TTTTTCCTN GACNACTANT TNCTTTTNA GGGNCTATTC TGANCCATC	479

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 461 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

AGTGACTTGT CCTCCAACAA AACCCCTTGA TCAAGTTTGT GGCCTGACA ATCAGACCTA	60
TGCTAGTTCC TGTCATCTAT TCGCTACTAA ATGCAGACTG GAGGGGACCA AAAAGGGGCA	120
TCAACTCCAG CTGGATTATT TTGGAGCCTG CAAATCTATT CCTACTTGTA CGGACTTTGA	180
AGTGATTGAG TTTCTCTAC GGATGAGAGA CTGGCTCAAG AATATCCTCA TGCAGCTTTA	240
TGAAGCCACT CTGAACACGC TGGTTATCTA GATGAGAACA GAGAAATAAA GTCAGAAAAT	300
TTACCTGGAG AAAAGAGGCT TTGGCTGGGG ACCATCCCAT TGAACCTTCT CTTAAGGACT	360
TTAAGAAAAA CTACCACATG TTGTGTATCC TGGTGCCGGC CGTTTATGAA CTGACCACCC	420
TTTGAATAA TCTTGACGCT CCTGAACCTG CTCCTCTGCG A	461

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 171 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

GTGGCCGCGC GCAGGTGTTT CCTCGTACCG CAGGGCCCCC TCCCTTCCCC AGGCGTCCCT	60
CGGCGCCTCT GCGGGCCCCG GGAGGAGCGG CTGGCGGGTG GGGGGAGTGT GACCCACCCT	120
CGGTGAGAAA AGCCTTCTCT AGCGATCTGA GAGGCGTGCC TTGGGGGTAC C	171

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 269 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TGCGGACGAA GATTCTGCCA GCAGTTGGTC	60
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC	120
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA	180
CAGCCGGAAC AGAGCCCGGT GAAGCGGGAG GCCTCGGGGA GCCCCTCGGG AAGGGCGGCC	240
CGAGAGATAC GCAGGTGCAG GTGGCCGCC	269

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TTTTTTTTTT TTTTGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA	60
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTTCC GTCAACTTCC TTTGTCGTGG	120
TTGATTGGTT TGTCTTATG GGGGCGGGT GGGGTAGGGG AAACGAAGCA AATAACATGG	180
AGTGGGTGCA CCCTCCCTGT AGAACCTGGT TACAAAGCTT GGGGCAGTTC ACCTGGTCTG	240
TGACCGTCAT TTTCTTGACA TCAATGTTAT TAGAAGTCAG GATATCTTTT AGAGAGTCCA	300
CTGTTCTGGA GGGAGATTAG GGTTCCTTGC CAAATCCAAC AAAATCCACT GAAAAAGTTG	360
GATGATCAGT ACGAATACCG AGGCATATTC TCATATCGGT GGCCA	405

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 470 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	TTTTTTTTTT	60
GGCACTTAAT	CCATTTTAT	TCAAAATGT	CTACAAATTT	AATCCCATT	TACGGTATTT	120
TCAAAATCTA	AATTATTCAA	ATTAGCCAAA	TCCTTACCAA	ATAATACCCA	AAAATCAAAA	180
ATATACTTCT	TTCAGCAAAC	TGTTACATA	AATTAAGGAA	ATATATACGG	CTGGTGTTTT	240
CAAAGTACAA	TTATCTTAAC	ACTGCAAACA	TTTTAAGGAA	CTAAAATAAA	AAAAAACACT	300
CCGCAAAGGT	TAAAGGGAAC	AACAAATTCT	TTTACAACAC	CATTATAAAA	ATCATATCTC	360
AAATCTTAGG	GGAATATATA	CTTCACACGG	GATCTTAACT	TTTACTCACT	TTGTTTATTT	420
TTTTAAACCA	TTGTTTGGGC	CCAACACAAT	GGAATCCCCC	CTGGACTAGT		470

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 581 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

TTTTTTTTTT	TTTTTTTTGA	CCCCCTCTT	ATAAAAAACA	AGTTACCATT	TTATTTTACT	60
TACACATATT	TATTTTATAA	TTGGTATTAG	ATATTCAAAA	GGCAGCTTTT	AAAATCAAAC	120
TAAATGGAAA	CTGCCTTAGA	TACATAATTC	TTAGGAATTA	GCTTAAATC	TGCCTAAAGT	180
GAAAATCTTC	TCTAGCTCTT	TTGACTGTAA	ATTTTGTGACT	CTTGTAAC	ATCCAAATTC	240
ATTTTCTTG	TCTTTAAAT	TATCTAATCT	TTCCATTTT	TCCCTATTCC	AAGTCAATTT	300
GCTTCTCTAG	CCTCATTTC	TAGCTCTTAT	CTACTATTAG	TAAGTGGCTT	TTTCTCTAAA	360
AGGGAAAACA	GGAAGAGAAA	TGGCACACAA	AACAAACATT	TTATATTCAT	ATTTCTACCT	420
ACGTTAATAA	AATAGCATTT	TGTGAAGCCA	GCTCAAAAGA	AGGCTTAGAT	CCTTTTATGT	480
CCATTTTAGT	CACTAAACGA	TATCAAAGTG	CCAGAATGCA	AAAGGTTTGT	GAACATTTAT	540
TCAAAGCTA	ATATAAGATA	TTTCACATAC	TCATCTTTCT	G		581

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 578 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

TTTTTTTTTT	TTTTTTTTTT	TTTTTCTCTT	CTTTTTTTTT	GAAATGAGGA	TCGAGTTTTT	60
CACTCTCTAG	ATAGGGCATG	AAGAAAATC	ATCTTTCCAG	CTTTAAAATA	ACAATCAAAT	120
CTCTTATGCT	ATATCATATT	TTAAGTTAAA	CTAATGAGTC	ACTGGCTTAT	CTTCTCCTGA	180
AGGAAATCTG	TTCATTCTTC	TCATTCATAT	AGTTATATCA	AGTACTACCT	TGCATATTGA	240
GAGGTTTTTTC	TTCTCTATTT	ACACATATAT	TTCCATGTGA	ATTGTATCA	AACCTTTATT	300
TTCATGCAAA	CTAGAAAATA	ATGTTTCTTT	TGCATAAGAG	AAGAGAACAA	TATAGCATT	360
CAAACTGCT	CAAATTGTTT	GTAAAGTTAT	CCATTATAAT	TAGTTGGCAG	GAGCTAATAC	420
AAATCACATT	TACGACAGCA	ATAATAAAAC	TGAAGTACCA	GTTAAATATC	CAAAATAATT	480
AAAGGAACAT	TTTAGCCTG	GGTATAATTA	GCTAATTCAC	TTTACAAGCA	TTTATTAGAA	540
TGAATTCACA	TGTTATTATT	CCTAGCCCAA	CACAATGG			578

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 538 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

TTTTTTTTTT	TTTTTCAGTA	ATAATCAGAA	CAATATTTAT	TTTATATTT	AAAATTCATA	60
GAAAAGTGCC	TTACATTTAA	TAAAAGTTTG	TTTCTCAAAG	TGATCAGAGG	AATTAGATAT	120
GTCTTGAACA	CCAATATTAA	TTTGAGGAAA	ATACACCAAA	ATACATTAAG	TAAATTATTT	180
AAGATCATAG	AGCTTGTAAG	TGAAAAGATA	AAATTTGACC	TCAGAAACTC	TGAGCATTA	240
AAATCCACTA	TTAGCAAATA	AATTACTATG	GACTTCTTGC	TTTAATTTTG	TGATGAATAT	300
GGGGTGTCAC	TGGTAAACCA	ACACATTCTG	AAGGATACAT	TACTTAGTGA	TAGATTCTTA	360
TGTACTTTGC	TAATACGTGG	ATATGAGTTG	ACAAGTTTCT	CTTTCTTCAA	TCTTTAAGG	420
GGCGAGAAAT	GAGGAAGAAA	AGAAAAGGAT	TACGCATACT	GTTCTTTCTA	TGGAAGGATT	480
AGATATGTTT	CCTTTGCCAA	TATTAATAAT	ATAATAATGT	TTACTACTAG	TGAAACCC	538

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 473 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

TTTTTTTTTT	TTTTTTAGTC	AAGTTTCTAT	TTTTATTATA	ATTAAAGTCT	TGGTCATTTC	60
ATTTATTAGC	TCTGCAACTT	ACATATTTAA	ATTAAAGAAA	CGTTTTAGAC	AACTGTACAA	120
TTTATAAATG	TAAGGTGCCA	TTATTGAGTA	ATATATTCCT	CCAAGAGTGG	ATGTGTCCCT	180
TCTCCACCA	ACTAATGAAC	AGCAACATTA	GTTTAATTTT	ATTAGTAGAT	ATACACTGCT	240
GCAAACGCTA	ATTCTCTTCT	CCATCCCCAT	GTGATATTGT	GTATATGTGT	GAGTTGGTAG	300
AATGCATCAC	AATCTACAAT	CAACAGCAAG	ATGAAGCTAG	GCTGGGCTTT	CGGTGAAAAA	360
AGACTGTGTC	TGTCTGAATC	AAATGATCTG	ACCTATCCTC	GGTGGCAAGA	ACTCTTCGAA	420
CCGCTTCCTC	AAAGGCGCTG	CCACATTTGT	GGCTCTTTGC	ACTTGTTTCA	AAA	473

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1621 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

CGCCATGGCA	CTGCAGGGCA	TCTCGGTCAT	GGAGCTGTCC	GGCCTGGCCC	CGGGCCCGTT	60
CTGTGCTATG	GTCCTGGCTG	ACTTCGGGGC	GCGTGTGGTA	CGCGTGGACC	GGCCCGGCTC	120
CCGCTACGAC	GTGAGCCGCT	TGGGCCGGGG	CAAGCGCTCG	CTAGTGCTGG	ACCTGAAGCA	180
GCCGCGGGGA	GCCGCCGTGC	TGCGGCGTCT	GTGCAAGCGG	TCGGATGTGC	TGCTGGAGCC	240
CTTCCGCCGC	GGTGTCTATG	AGAACTCCA	GCTGGGCCCA	GAGATTCTGC	AGCGGGAAAA	300
TCCAAGGCTT	ATTTATGCCA	GGCTGAGTGG	ATTTGGCCAG	TCAGGAAGCT	TCTGCCGGTT	360
AGCTGGCCAC	GATATCAACT	ATTTGGCTTT	GTCAGGTGTT	CTCTCAAAAA	TTGGCAGAAG	420
TGGTGAGAAT	CCGTATGCCC	CGCTGAATCT	CCTGGCTGAC	TTTGCTGGTG	GTGGCCTTAT	480
GTGTGCACTG	GGCATTATAA	TGGCTCTTTT	TGACCGCACA	CGCACTGACA	AGGGTCAGGT	540
CATTGATGCA	AATATGGTGG	AAGGAACAGC	ATATTTAAGT	TCTTTTCTGT	GGAAAACCTCA	600
GAAATCGAGT	CTGTGGGAAG	CACCTCGAGG	ACAGAACATG	TTGGATGGTG	GAGCACCTTT	660
CTATACGACT	TACAGGACAG	CAGATGGGGA	ATTCTATGGCT	GTTGGAGCAA	TAGAACCCCCA	720
GTTCTACGAG	CTGCTGATCA	AAGGACTTGG	ACTAAAGTCT	GATGAACTTC	CCAATCAGAT	780
GAGCATGGAT	GATTGGCCAG	AAATGAAGAA	GAAGTTTGCA	GATGTATTTG	CAAAGAAGAC	840
GAAGGCAGAG	TGGTGTCAAA	TCTTTGACGG	CACAGATGCC	TGTGTGACTC	CGGTTCTGAC	900
TTTTGAGGAG	GTTGTTTCATC	ATGATCACAA	CAAGGAACGG	GGCTCGTTTA	TCACCAGTGA	960
GGAGCAGGAC	GTGAGCCCCC	GCCCTGCACC	TCTGCTGTTA	AACACCCCAG	CCATCCCTTC	1020
TTTCAAAAGG	GATCCTTTCA	TAGGAGAACA	CAGTGAGGAG	ATACTGAAG	AATTTGGATT	1080
CAGCCGCGAA	GAGATTTATC	AGCTTAACTC	AGATAAAATC	ATTGAAAGTA	ATAAGGTAAA	1140
AGCTAGTCTC	TAACCTCCAG	GCCACGGCT	CAAGTGAATT	TGAATACTGC	ATTTACAGTG	1200
TAGAGTAACA	CATAACATTG	TATGCATGGA	AACATGGAGG	AACAGTATTA	CAGTGTCTTA	1260
CCACTCTAAT	CAAGAAAAGA	ATTACAGACT	CTGATTCTAC	AGTGATGATT	GAATTCTAAA	1320
AATGGTTATC	ATTAGGGCTT	TTGATTTATA	AACTTTGGG	TACTTATACT	AAATTATGGT	1380
AGTTATTCTG	CCTTCCAGTT	TGCTTGATAT	ATTTGTTGAT	ATTAAGATTC	TTGACTTATA	1440
TTTTGAATGG	GTTCTAGTGA	AAAAGGAATG	ATATATTCTT	GAAGACATCG	ATATACATTT	1500
ATTTACACTC	TTGATTCTAC	AATGTAGAAA	ATGAGGAAAT	GCCACAAATT	GTATGGTGAT	1560

AAAAGTCACG TGAAACAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1620
A 1621

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 382 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Met	Ala	Leu	Gln	Gly	Ile	Ser	Val	Met	Glu	Leu	Ser	Gly	Leu	Ala	Pro	1	5	10	15
Gly	Pro	Phe	Cys	Ala	Met	Val	Leu	Ala	Asp	Phe	Gly	Ala	Arg	Val	Val	20	25	30	
Arg	Val	Asp	Arg	Pro	Gly	Ser	Arg	Tyr	Asp	Val	Ser	Arg	Leu	Gly	Arg	35	40	45	
Gly	Lys	Arg	Ser	Leu	Val	Leu	Asp	Leu	Lys	Gln	Pro	Arg	Gly	Ala	Ala	50	55	60	
Val	Leu	Arg	Arg	Leu	Cys	Lys	Arg	Ser	Asp	Val	Leu	Leu	Glu	Pro	Phe	65	70	75	80
Arg	Arg	Gly	Val	Met	Glu	Lys	Leu	Gln	Leu	Gly	Pro	Glu	Ile	Leu	Gln	85	90	95	
Arg	Glu	Asn	Pro	Arg	Leu	Ile	Tyr	Ala	Arg	Leu	Ser	Gly	Phe	Gly	Gln	100	105	110	
Ser	Gly	Ser	Phe	Cys	Arg	Leu	Ala	Gly	His	Asp	Ile	Asn	Tyr	Leu	Ala	115	120	125	
Leu	Ser	Gly	Val	Leu	Ser	Lys	Ile	Gly	Arg	Ser	Gly	Glu	Asn	Pro	Tyr	130	135	140	
Ala	Pro	Leu	Asn	Leu	Leu	Ala	Asp	Phe	Ala	Gly	Gly	Gly	Leu	Met	Cys	145	150	155	160
Ala	Leu	Gly	Ile	Ile	Met	Ala	Leu	Phe	Asp	Arg	Thr	Arg	Thr	Asp	Lys	165	170	175	
Gly	Gln	Val	Ile	Asp	Ala	Asn	Met	Val	Glu	Gly	Thr	Ala	Tyr	Leu	Ser	180	185	190	
Ser	Phe	Leu	Trp	Lys	Thr	Gln	Lys	Ser	Ser	Leu	Trp	Glu	Ala	Pro	Arg	195	200	205	
Gly	Gln	Asn	Met	Leu	Asp	Gly	Gly	Ala	Pro	Phe	Tyr	Thr	Thr	Tyr	Arg	210	215	220	
Thr	Ala	Asp	Gly	Glu	Phe	Met	Ala	Val	Gly	Ala	Ile	Glu	Pro	Gln	Phe	225	230	235	240
Tyr	Glu	Leu	Leu	Ile	Lys	Gly	Leu	Gly	Leu	Lys	Ser	Asp	Glu	Leu	Pro	245	250	255	
Asn	Gln	Met	Ser	Met	Asp	Asp	Trp	Pro	Glu	Met	Lys	Lys	Lys	Phe	Ala	260	265	270	
Asp	Val	Phe	Ala	Lys	Lys	Thr	Lys	Ala	Glu	Trp	Cys	Gln	Ile	Phe	Asp	275	280	285	
Gly	Thr	Asp	Ala	Cys	Val	Thr	Pro	Val	Leu	Thr	Phe	Glu	Glu	Val	Val				

290	295	300
His His Asp His Asn Lys Glu Arg Gly Ser Phe Ile Thr Ser Glu Glu		
305	310	315
Gln Asp Val Ser Pro Arg Pro Ala Pro Leu Leu Leu Asn Thr Pro Ala		320
	325	330
Ile Pro Ser Phe Lys Arg Asp Pro Phe Ile Gly Glu His Thr Glu Glu		335
	340	345
Ile Leu Glu Glu Phe Gly Phe Ser Arg Glu Glu Ile Tyr Gln Leu Asn		350
	355	360
Ser Asp Lys Ile Ile Glu Ser Asn Lys Val Lys Ala Ser Leu		365
370	375	380

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1524 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

```

GGCACGAGGC TGC GCCAGGG CCTGAGCGGA GCGGGGGGCA GCCTCGCCAG CGGGGGCCCC      60
GGGCCTGGCC ATGCCTCACT GAGCCAGCGC CTGCGCCTCT ACCTCGCCGA CAGCTGGAAC      120
CAGTGCGACC TAGTGGCTCT CACCTGCTTC CTCCTGGGCG TGGGCTGCCG GCTGACCCCG      180
GGTTTGTACC ACCTGGGCCG CACTGTCCTC TGCATCGACT TCATGGTTTT CACGGTGCGG      240
CTGCTTCACA TCTCACGGT CAACAAACAG CTGGGGCCCA AGATCGTCAT CGTGAGCAAG      300
ATGATGAAGG ACGTGTCTT CTTCCTCTTC TTCCTCGGCG TGTGGCTGGT AGCCTATGGC      360
GTGGCCACGG AGGGGCTCCT GAGGCCACGG GACAGTGAAT TCCCAAGTAT CCTGCGCCGC      420
GTCTTCTACC GTCCCTACCT GCAGATCTTC GGGCAGATTC CCCAGGAGGA CATGGACGTG      480
GCCCTCATGG AGCACAGCAA CTGCTCGTCG GAGCCCGGCT TCTGGGCACA CCCTCCTGGG      540
GCCCAGGCGG GCACCTGCGT CTCCCAGTAT GCCAACTGGC TGGTGGTGCT GCTCCTCGTC      600
ATCTTCCTGC TCGTGGCCAA CATCCTGCTG GTCAACTTGC TCATTGCCAT GTTCAGTTAC      660
ACATTCGGCA AAGTACAGGG AACAGCGAT CTCTACTGGA AGGCGCAGCG TTACCGCCTC      720
ATCCGGGAAT TCCACTCTCG GCCCGCGCTG GCCCCGCCCT TTATCGTCAT CTCCCACTTG      780
CGCCTCCTGC TCAGGCAATT GTGCAGGCGA CCCCAGGAGC CCCAGCCGTC CTCCCCGGCC      840
CTCGAGCATT TCCGGGTTTA CTTTCTAAG GAAGCCGAGC GGAAGCTGCT AACGTGGGAA      900
TCGGTGATA AGGAGAACTT TCTGCTGGCA CGCGCTAGGG ACAAGCGGGA GAGCGACTCC      960
GAGCGTCTGA AGCGCACGTC CCAGAAGGTG GACTTGGCAC TGAACAGCT GGGACACATC     1020
CGCGAGTACG AACAGCGCCT GAAAGTGCTG GAGCGGGAGG TCCAGCAGTG TAGCCGCGTC     1080
CTGGGGTGGG TGGCCGAGGC CCTGAGCCGC TCTGCCTTGC TGCCCCCAGG TGGGCCGCCA     1140
CCCCCTGACC TGCCTGGGTC CAAAGACTGA GCCCTGCTGG CGGACTTCAA GGAGAAGCCC     1200
CCACAGGGGA TTTTGCTCCT AGAGTAAGGC TCATCTGGGC CTCGGCCCCC GCACCTGGTG     1260
GCCTTGCTCT TGAGGTGAGC CCCATGTCCA TCTGGGCCAC TGTCAGGACC ACCTTTGGGA     1320
GTGTCATCCT TACAAACCAC AGCATGCCCG GCTCTCCCA GAACCAGTCC CAGCCTGGGA     1380
GGATCAAGGC CTGGATCCCG GGCCGTTATC CATCTGGAGG CTGCAGGGTC CTTGGGGTAA     1440
CAGGGACCAC AGACCCCTCA CCACTCACAG ATTCCTCACA CTGGGGAAAT AAAGCCATTT     1500
CAGAGGAAAA AAAAAAAAAA AAAA                                     1524

```

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3410 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

GGGAACCAGC	CTGCACGCGC	TGGCTCCGGG	TGACAGCCGC	GCGCCTCGGC	CAGGATCTGA	60
GTGATGAGAC	GTGTCCCCAC	TGAGGTGCCC	CACAGCAGCA	GGTGTGAGC	ATGGGCTGAG	120
AAGCTGGACC	GGCACCAAAG	GGCTGGCAGA	AATGGGCGCC	TGGCTGATTC	CTAGGCAGTT	180
GGCGGCAGCA	AGGAGGAGAG	GCCGCAGCTT	CTGGAGCAGA	GCCGAGACGA	AGCAGTTCTG	240
GAGTGCCTGA	ACGGCCCCCT	GAGCCCTACC	CGCCTGGCCC	ACTATGGTCC	AGAGGCTGTG	300
GGTGAGCCGC	CTGCTGCGGC	ACCGGAAAGC	CCAGCTCTTG	CTGGTCAACC	TGCTAACCTT	360
TGGCCTGGAG	GTGTGTTTGG	CCGCAGGCAT	CACCTATGTG	CCGCCTCTGC	TGCTGGAAGT	420
GGGGGTAGAG	GAGAAGTTCA	TGACCATGGT	GCTGGGCATT	GGTCCAGTGC	TGGGCCTGGT	480
CTGTGTCCCG	CTCCTAGGCT	CAGCCAGTGA	CCACTGGCGT	GGACGCTATG	GCCGCCGCCG	540
GCCCTTCATC	TGGGCACTGT	CCTTGGGCAT	CCTGCTGAGC	CTCTTTCTCA	TCCCAAGGGC	600
CGGCTGGCTA	GCAGGGCTGC	TGTGCCCCGA	TCCCAGGCCC	CTGGAGCTGG	CACTGCTCAT	660
CCTGGGCGTG	GGGCTGCTGG	ACTTCTGTGG	CCAGGTGTGC	TTCACCTCAC	TGGAGGCCCT	720
GCTCTCTGAC	CTCTTCCGGG	ACCCGGACCA	CTGTGCCCAG	GCCTACTCTG	TCTATGCCTT	780
CATGATCAGT	CTTGGGGGCT	GCCTGGGCTA	CCTCCTGCCT	GCCATTGACT	GGGACACCAG	840
TGCCCTGGCC	CCCTACCTGG	GCACCCAGGA	GGAGTGCCCT	TTTGGCCTGC	TCACCCTCAT	900
CTTCCCTACC	TGCGTAGCAG	CCACACTGCT	GGTGGCTGAG	GAGGCAGCGC	TGGGCCCCAC	960
CGAGCCAGCA	GAAGGGCTGT	CGGCCCCCTC	CTTGTGCCCC	CACTGCTGTC	CATGCCGGGC	1020
CCGCTTGCT	TTCCGGAACC	TGGGCGCCCT	GCTTCCCCCG	CTGCACCAGC	TGTGCTGCCG	1080
CATGCCCCGC	ACCCTGCGCC	GGCTCTTCGT	GGCTGAGCTG	TGCAGCTGGA	TGGCACTCAT	1140
GACCTTCACG	CTGTTTTACA	CGGATTTTCGT	GGGCGAGGGG	CTGTACCAGG	GCGTGCCGAG	1200
AGCTGAGCCG	GGCACCGAGG	CCCGGAGACA	CTATGATGAA	GGCGTTCGGA	TGGGCAGCCT	1260
GGGGCTGTTC	CTGCAGTGCG	CCATCTCCCT	GGTCTTCTCT	CTGGTCATGG	ACCGGCTGGT	1320
GCAGCGATTC	GGCACTCGAG	CAGTCTATTT	GGCCAGTGTG	GCAGCTTTCC	CTGTGGCTGC	1380
CGTGCCACA	TGCCTGTCCC	ACAGTGTGGC	CGTGGTGACA	GCTTCAGCCG	CCCTCACCAG	1440
GTTACCTTC	TCAGCCCTGC	AGATCCTGCC	CTACACACTG	GCCTCCCTCT	ACCACCGGGA	1500
GAAGCAGGTG	TTCTGCCCCA	AATACCGAGG	GGACACTGGA	GGTGCTAGCA	GTGAGGACAG	1560
CCTGATGACC	AGCTTCCTGC	CAGGCCCTAA	GCCTGGAGCT	CCCTTCCCTA	ATGGACACGT	1620
GGGTGCTGGA	GGCAGTGGCC	TGCTCCACC	TCCACCCGCG	CTCTGCGGGG	CCTCTGCCTG	1680
TGATGTCTCC	GTACGTGTGG	TGGTGGGTGA	GCCCACCGAG	GCCAGGGTGG	TTCCGGGCCG	1740
GGGCATCTGC	CTGGACCTCG	CCATCCTGGA	TAGTGCCTTC	CTGCTGTCCC	AGGTGGCCCC	1800
ATCCCTGTTT	ATGGGCTCCA	TTGTCCAGCT	CAGCCAGTCT	GTCAGTGCCT	ATATGGTGTC	1860
TGCCGCAGGC	CTGGGTCTGG	TGCCCATTTA	CTTTGCTACA	CAGGTAGTAT	TTGACAAGAG	1920
CGACTTGGCC	AAATACTCAG	CGTAGAAAAC	TTCCAGCACA	TTGGGGTGGA	GGGCCTGCCT	1980
CACTGGGTCC	CAGCTCCCCG	CTCCTGTTAG	CCCCATGGGG	CTGCCGGGCT	GGCCGCCAGT	2040
TTCTGTTGCT	GCCAAAGTAA	TGTGGCTCTC	TGCTGCCACC	CTGTGCTGCT	GAGGTGCGTA	2100
GCTGCACAGC	TGGGGGCTGG	GGCGTCCCTC	TCCTCTCTCC	CCAGTCTCTA	GGGCTGCCTG	2160
ACTGGAGGCC	TTCCAAGGGG	GTTTCAGTCT	GGACTTATAC	AGGGAGGCCA	GAAGGGCTCC	2220
ATGCACTGGA	ATGCGGGGAC	TCTGCAGGTG	GATTACCCAG	GCTCAGGGTT	AACAGCTAGC	2280
CTCCTAGTTG	AGACACACCT	AGAGAAGGGT	TTTTGGGAGC	TGAATAAACT	CAGTCACCTG	2340
GTTTCCCATC	TCTAAGCCCC	TTAACCTGCA	GCTTCGTTTA	ATGTAGCTCT	TGCATGGGAG	2400
TTTCTAGGAT	GAAACACTCC	TCCATGGGAT	TTGAACATAT	GACTTATTTG	TAGGGGAAGA	2460

GTCCTGAGGG	GCAACACACA	AGAACCAGGT	CCCCTCAGCC	CACAGCACTG	TCTTTTTGCT	2520
GATCCACCCC	CCTCTTACCT	TTTATCAGGA	TGTGGCCTGT	TGGTCCTTCT	GTTGCCATCA	2580
CAGAGACACA	GGCATTAAAA	TATTTAACTT	ATTTATTTAA	CAAAGTAGAA	GGGAATCCAT	2640
TGCTAGCTTT	TCTGTGTTGG	TGTCTAATAT	TTGGGTAGGG	TGGGGGATCC	CCAACAATCA	2700
GGTCCCCCTGA	GATAGCTGGT	CATTGGGCTG	ATCATTGCCA	GAATCTTCTT	CTCCTGGGGT	2760
CTGGCCCCCCC	AAAATGCCTA	ACCCAGGACC	TTGGAAATTC	TACTCATCCC	AAATGATAAT	2820
TCCAAATGCT	GTTACCCAAG	GTTAGGGTGT	TGAAGGAAGG	TAGAGGGTGG	GGCTTCAGGT	2880
CTCAACGGCT	TCCCTAACCA	CCCCTCTTCT	CTTGGCCCAG	CCTGGTTCCC	CCCACCTCCA	2940
CTCCCCCTCTA	CTCTCTCTAG	GACTGGGCTG	ATGAAGGCAC	TGCCCAAAAT	TTCCCCCTACC	3000
CCCAACTTTC	CCCTACCCCC	AACCTTCCCC	ACCAGTCCA	CAACCCTGTT	TGGAGCTACT	3060
GCAGGACCAG	AAGCACAAAG	TGCGGTTTCC	CAAGCCTTTG	TCCATCTCAG	CCCCCAGAGT	3120
ATATCTGTGC	TTGGGGAATC	TCACACAGAA	ACTCAGGAGC	ACCCCCTGCC	TGAGCTAAGG	3180
GAGGTCTTAT	CTCTCAGGGG	GGGTTTAAGT	GCCGTTTGCA	ATAATGTCGT	CTTATTTATT	3240
TAGCGGGGTG	AATATTTTAT	ACTGTAAGTG	AGCAATCAGA	GTATAATGTT	TATGGTGACA	3300
AAATTAAAGG	CTTCTTTATA	TGTTTAAAAA	AAAAAAAAAA	AAAAAAAAAA	AAAAAAAAAA	3360
AAAAAAAAARA	AAAAAAAAAA	AAAAAAAAAA	AAAAAATAA	AAAAAAAAAA		3410

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1289 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

AGCCAGGCGT	CCCTCTGCCT	GCCCACTCAG	TGGCAACACC	CGGGAGCTGT	TTTGTCTTTT	60
GTGGAGCCTC	AGCAGTTCCC	TCTTTCAGAA	CTCACTGCCA	AGAGCCCTGA	ACAGGAGCCA	120
CCATGCAGTG	CTTCAGCTTC	ATTAAGACCA	TGATGATCCT	CTTCAATTTG	CTCATCTTTC	180
TGTGTGGTGC	AGCCCTGTTG	GCAGTGGGCA	TCTGGGTGTC	AATCGATGGG	GCATCCTTTC	240
TGAAGATCTT	CGGGCCACTG	TCGTCCAGTG	CCATGCAGTT	TGTCAACGTG	GGCTACTTCC	300
TCATCGCAGC	CGGCGTTGTG	GTCTTTGCTC	TTGGTTTCCT	GGGCTGCTAT	GGTGCTAAGA	360
CTGAGAGCAA	GTGTGCCCTC	GTGACGTTCT	TCTTCATCCT	CCTCCTCATC	TTCATTGCTG	420
AGGTTGCAGC	TGCTGTGGTC	GCCTTGGTGT	ACACCACAAT	GGCTGAGCAC	TTCCTGACGT	480
TGCTGGTAGT	GCCTGCCATC	AAGAAAGATT	ATGGTTCCCA	GGAAGACTTC	ACTCAAGTGT	540
GGAACACCAC	CATGAAAGGG	CTCAAGTGCT	GTGGCTTCAC	CAACTATACG	GATTTTGAGG	600
ACTCACCTTA	CTTCAAAGAG	AACAGTGCCT	TTCCCCCATT	CTGTTGCAAT	GACAACGTCA	660
CCAACACAGC	CAATGAAACC	TGCACCAAGC	AAAAGGCTCA	CGACCAAAAA	GTAGAGGGTT	720
GCTTCAATCA	GCTTTTGTAT	GACATCCGAA	CTAATGCAGT	CACCGTGGGT	GGTGTGGCAG	780
CTGGAATTGG	GGGCCTCGAG	CTGGCTGCCA	TGATTGTGTC	CATGTATCTG	TACTGCAATC	840
TACAATAAGT	CCACTTCTGC	CTCTGCCACT	ACTGCTGCCA	CATGGGAAGT	GTGAAGAGGC	900
ACCCTGGCAA	GCAGCAGTGA	TTGGGGGAGG	GGACAGGATC	TAACAATGTC	ACTTGGGCCA	960
GAATGGACCT	GCCCTTCTG	CTCCAGACTT	GGGGCTAGAT	AGGGACCACT	CCTTTTAGCG	1020
ATGCCTGACT	TTCCTTCCAT	TGGTGGGTGG	ATGGGTGGGG	GGCATTCCAG	AGCCTCTAAG	1080
GTAGCCAGTT	CTGTTGCCCA	TTCCCCCAGT	CTATTAAACC	CTTGATATGC	CCCCTAGGCC	1140
TAGTGGTGAT	CCCAGTGCTC	TACTGGGGGA	TGAGAGAAAG	GCATTTTATA	GCCTGGGCAT	1200
AAGTGAAATC	AGCAGAGCCT	CTGGGTGGAT	GTGTAGAAGG	CACCTCAAAA	TGCATAAACC	1260
TGTTACAATG	TTAAAAAAA	AAAAAAA				1289

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 315 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

```

Met Val Phe Thr Val Arg Leu Leu His Ile Phe Thr Val Asn Lys Gln
 1             5             10             15

Leu Gly Pro Lys Ile Val Ile Val Ser Lys Met Met Lys Asp Val Phe
      20             25             30

Phe Phe Leu Phe Phe Leu Gly Val Trp Leu Val Ala Tyr Gly Val Ala
      35             40             45

Thr Glu Gly Leu Leu Arg Pro Arg Asp Ser Asp Phe Pro Ser Ile Leu
      50             55             60

Arg Arg Val Phe Tyr Arg Pro Tyr Leu Gln Ile Phe Gly Gln Ile Pro
      65             70             75             80

Gln Glu Asp Met Asp Val Ala Leu Met Glu His Ser Asn Cys Ser Ser
      85             90             95

Glu Pro Gly Phe Trp Ala His Pro Pro Gly Ala Gln Ala Gly Thr Cys
      100            105            110

Val Ser Gln Tyr Ala Asn Trp Leu Val Val Leu Leu Leu Val Ile Phe
      115            120            125

Leu Leu Val Ala Asn Ile Leu Leu Val Asn Leu Leu Ile Ala Met Phe
      130            135            140

Ser Tyr Thr Phe Gly Lys Val Gln Gly Asn Ser Asp Leu Tyr Trp Lys
      145            150            155            160

Ala Gln Arg Tyr Arg Leu Ile Arg Glu Phe His Ser Arg Pro Ala Leu
      165            170            175

Ala Pro Pro Phe Ile Val Ile Ser His Leu Arg Leu Leu Leu Arg Gln
      180            185            190

Leu Cys Arg Arg Pro Arg Ser Pro Gln Pro Ser Ser Pro Ala Leu Glu
      195            200            205

His Phe Arg Val Tyr Leu Ser Lys Glu Ala Glu Arg Lys Leu Leu Thr

```


210	215	220
Trp Glu Ser Val His Lys Glu Asn Phe Leu Leu Ala Arg Ala Arg Asp		
225	230	235 240
Lys Arg Glu Ser Asp Ser Glu Arg Leu Lys Arg Thr Ser Gln Lys Val		
	245	250 255
Asp Leu Ala Leu Lys Gln Leu Gly His Ile Arg Glu Tyr Glu Gln Arg		
	260	265 270
Leu Lys Val Leu Glu Arg Glu Val Gln Gln Cys Ser Arg Val Leu Gly		
	275	280 285
Trp Val Ala Glu Ala Leu Ser Arg Ser Ala Leu Leu Pro Pro Gly Gly		
	290	295 300
Pro Pro Pro Pro Asp Leu Pro Gly Ser Lys Asp		
305	310	315

(2) INFORMATION FOR SEQ ID NO:113:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 553 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Met Val Gln Arg Leu Trp Val Ser Arg Leu Leu Arg His Arg Lys Ala		
1	5	10 15
Gln Leu Leu Leu Val Asn Leu Leu Thr Phe Gly Leu Glu Val Cys Leu		
	20	25 30
Ala Ala Gly Ile Thr Tyr Val Pro Pro Leu Leu Leu Glu Val Gly Val		
	35	40 45
Glu Glu Lys Phe Met Thr Met Val Leu Gly Ile Gly Pro Val Leu Gly		
	50	55 60
Leu Val Cys Val Pro Leu Leu Gly Ser Ala Ser Asp His Trp Arg Gly		
	65	70 75 80
Arg Tyr Gly Arg Arg Arg Pro Phe Ile Trp Ala Leu Ser Leu Gly Ile		
	85	90 95
Leu Leu Ser Leu Phe Leu Ile Pro Arg Ala Gly Trp Leu Ala Gly Leu		
	100	105 110

Leu Cys Pro Asp Pro Arg Pro Leu Glu Leu Ala Leu Leu Ile Leu Gly
 115 120 125
 Val Gly Leu Leu Asp Phe Cys Gly Gln Val Cys Phe Thr Pro Leu Glu
 130 135 140
 Ala Leu Leu Ser Asp Leu Phe Arg Asp Pro Asp His Cys Arg Gln Ala
 145 150 155 160
 Tyr Ser Val Tyr Ala Phe Met Ile Ser Leu Gly Gly Cys Leu Gly Tyr
 165 170 175
 Leu Leu Pro Ala Ile Asp Trp Asp Thr Ser Ala Leu Ala Pro Tyr Leu
 180 185 190
 Gly Thr Gln Glu Glu Cys Leu Phe Gly Leu Leu Thr Leu Ile Phe Leu
 195 200 205
 Thr Cys Val Ala Ala Thr Leu Leu Val Ala Glu Glu Ala Ala Leu Gly
 210 215 220
 Pro Thr Glu Pro Ala Glu Gly Leu Ser Ala Pro Ser Leu Ser Pro His
 225 230 235 240
 Cys Cys Pro Cys Arg Ala Arg Leu Ala Phe Arg Asn Leu Gly Ala Leu
 245 250 255
 Leu Pro Arg Leu His Gln Leu Cys Cys Arg Met Pro Arg Thr Leu Arg
 260 265 270
 Arg Leu Phe Val Ala Glu Leu Cys Ser Trp Met Ala Leu Met Thr Phe
 275 280 285
 Thr Leu Phe Tyr Thr Asp Phe Val Gly Glu Gly Leu Tyr Gln Gly Val
 290 295 300
 Pro Arg Ala Glu Pro Gly Thr Glu Ala Arg Arg His Tyr Asp Glu Gly
 305 310 315 320
 Val Arg Met Gly Ser Leu Gly Leu Phe Leu Gln Cys Ala Ile Ser Leu
 325 330 335
 Val Phe Ser Leu Val Met Asp Arg Leu Val Gln Arg Phe Gly Thr Arg
 340 345 350
 Ala Val Tyr Leu Ala Ser Val Ala Ala Phe Pro Val Ala Ala Gly Ala
 355 360 365
 Thr Cys Leu Ser His Ser Val Ala Val Val Thr Ala Ser Ala Ala Leu
 370 375 380
 Thr Gly Phe Thr Phe Ser Ala Leu Gln Ile Leu Pro Tyr Thr Leu Ala
 385 390 395 400

89

Ser Leu Tyr His Arg Glu Lys Gln Val Phe Leu Pro Lys Tyr Arg Gly
 405 410 415
 Asp Thr Gly Gly Ala Ser Ser Glu Asp Ser Leu Met Thr Ser Phe Leu
 420 425 430
 Pro Gly Pro Lys Pro Gly Ala Pro Phe Pro Asn Gly His Val Gly Ala
 435 440 445
 Gly Gly Ser Gly Leu Leu Pro Pro Pro Pro Ala Leu Cys Gly Ala Ser
 450 455 460
 Ala Cys Asp Val Ser Val Arg Val Val Val Gly Glu Pro Thr Glu Ala
 465 470 475 480
 Arg Val Val Pro Gly Arg Gly Ile Cys Leu Asp Leu Ala Ile Leu Asp
 485 490 495
 Ser Ala Phe Leu Leu Ser Gln Val Ala Pro Ser Leu Phe Met Gly Ser
 500 505 510
 Ile Val Gln Leu Ser Gln Ser Val Thr Ala Tyr Met Val Ser Ala Ala
 515 520 525
 Gly Leu Gly Leu Val Ala Ile Tyr Phe Ala Thr Gln Val Val Phe Asp
 530 535 540
 Lys Ser Asp Leu Ala Lys Tyr Ser Ala
 545 550

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 241 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Met Gln Cys Phe Ser Phe Ile Lys Thr Met Met Ile Leu Phe Asn Leu
 1 5 10 15
 Leu Ile Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly Ile Trp Val
 20 25 30
 Ser Ile Asp Gly Ala Ser Phe Leu Lys Ile Phe Gly Pro Leu Ser Ser
 35 40 45
 Ser Ala Met Gln Phe Val Asn Val Gly Tyr Phe Leu Ile Ala Ala Gly

90

50	55	60
Val Val Val Phe Ala Leu Gly Phe Leu Gly Cys Tyr Gly Ala Lys Thr		
65	70	75 80
Glu Ser Lys Cys Ala Leu Val Thr Phe Phe Phe Ile Leu Leu Leu Ile		
	85	90 95
Phe Ile Ala Glu Val Ala Ala Ala Val Val Ala Leu Val Tyr Thr Thr		
	100	105 110
Met Ala Glu His Phe Leu Thr Leu Leu Val Val Pro Ala Ile Lys Lys		
	115	120 125
Asp Tyr Gly Ser Gln Glu Asp Phe Thr Gln Val Trp Asn Thr Thr Met		
	130	135 140
Lys Gly Leu Lys Cys Cys Gly Phe Thr Asn Tyr Thr Asp Phe Glu Asp		
	145	150 155 160
Ser Pro Tyr Phe Lys Glu Asn Ser Ala Phe Pro Pro Phe Cys Cys Asn		
	165	170 175
Asp Asn Val Thr Asn Thr Ala Asn Glu Thr Cys Thr Lys Gln Lys Ala		
	180	185 190
His Asp Gln Lys Val Glu Gly Cys Phe Asn Gln Leu Leu Tyr Asp Ile		
	195	200 205
Arg Thr Asn Ala Val Thr Val Gly Gly Val Ala Ala Gly Ile Gly Gly		
	210	215 220
Leu Glu Leu Ala Ala Met Ile Val Ser Met Tyr Leu Tyr Cys Asn Leu		
	225	230 235 240
Gln		

(2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 366 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

GCTCTTTCTC	TCCCCTCCTC	TGAATTTAAT	TCTTTCAACT	TGCAATTTGC	AAGGATTACA	60
CATTTCACTG	TGATGTATAT	TGTGTTGCAA	AAAAAAAAAA	GTGTCTTTGT	TTAAAATTAC	120
TTGGTTTGTG	AATCCATCTT	GCTTTTTCCC	CATTGGAACT	AGTCATTAAC	CCATCTCTGA	180
ACTGGTAGAA	AAACATCTGA	AGAGCTAGTC	TATCAGCATC	TGACAGGTGA	ATTGGATGGT	240
TCTCAGAACC	ATTCACCCA	GACAGCCTGT	TTCTATCCTG	TTTAATAAAT	TAGTTTGGGT	300
TCTCTACATG	CATAACAAAC	CCTGCTCCAA	TCTGTCACAT	AAAAGTCTGT	GACTTGAAGT	360
TTAGTC						366

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 282 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

ACAAAGATGA	ACCATTTCTC	ATATTATAGC	AAAATTAAAA	TCTACCCGTA	TTCTAATATT	60
GAGAAATGAG	ATNAAACACA	ATNTTATAAA	GTCTACTTAG	AGAAGATCAA	GTGACCTCAA	120
AGACTTTACT	ATTTTCATAT	TTTAAGACAC	ATGATTTATC	CTATTTTAGT	AACCTGGTTC	180
ATACGTTAAA	CAAAGGATAA	TGTGAACAGC	AGAGAGGATT	TGTTGGCAGA	AAATCTATGT	240
TCAATCTNGA	ACTATCTANA	TCACAGACAT	TTCTATTCTT	TT		282

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 305 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

ACACATGTCG	CTTCACTGCC	TTCTTAGATG	CTTCTGGTCA	ACATANAGGA	ACAGGGACCA	60
TATTTATCCT	CCCTCCTGAA	ACAATTGCAA	AATAANACAA	AATATATGAA	ACAATTGCAA	120
AATAAGGCAA	AATATATGAA	ACAACAGGTC	TCGAGATATT	GGAAATCAGT	CAATGAAGGA	180
TACTGATCCC	TGATCACTGT	CCTAATGCAG	GATGTGGGAA	ACAGATGAGG	TCACCTCTGT	240
GACTGCCCCA	GCTTACTGCC	TGTAGAGAGT	TTCTANGCTG	CAGTTCAGAC	AGGGAGAAAT	300
TGGGT						305

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

```
ACCAAGGTGT NTGAATCTCT GACGTGGGGA TCTCTGATTC CCGCACAATC TGAGTGGAAG 60
AANTCCTGGG T 71
```

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

```
ACTCCGGTTG GTGTCAGCAG CACGTGGCAT TGAACATNGC AATGTGGAGC CCAAACCACA 60
GAAAATGGGG TGAAATTGGC CAACTTTCTA TNAACTTATG TTGGCAANTT TGCCACCAAC 120
AGTAAGCTGG CCCTTCTAAT AAAAGAAAAT TGAAAGGTTT CTCACTAANC GGAATTAANT 180
AATGGANTCA AGANACTCCC AGGCCTCAGC GT 212
```

(2) INFORMATION FOR SEQ ID NO:120:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 90 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

```
ACTCGTTGCA NATCAGGGGC CCCCCAGAGT CACCGTTGCA GGAGTCCTTC TGGTCTTGCC 60
CTCCGCCGGC GCAGAACATG CTGGGGTGTT 90
```

(2) INFORMATION FOR SEQ ID NO:121:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 218 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

```
TGTANCGTGA ANACGACAGA NAGGGTTGTC AAAAATGGAG AANCCTTGAA GTCATTTTGA      60
GAATAAGATT TGCTAAAAGA TTTGGGGCTA AAACATGGTT ATTGGGAGAC ATTTCTGAAG      120
ATATNCANGT AAATTANGGA ATGAATTCAT GGTTCCTTTG GGAATTCCTT TACGATNGCC      180
AGCATANACT TCATGTGGGG ATANCAGCTA CCCTTGTA      218
```

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 171 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

```
TAGGGGTGTA TGCAACTGTA AGGACAAAAA TTGAGACTCA ACTGGCTTAA CCAATAAAGG      60
CATTTGTTAG CTCATGGAAC AGGAAGTCGG ATGGTGGGGC ATCTTCAGTG CTGCATGAGT      120
CACCACCCCG GCGGGGTCAT CTGTGCCACA GGTCCCTGTT GACAGTGCGG T      171
```

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 76 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

```
TGTAGCGTGA AGACNACAGA ATGGTGTGTG CTGTGCTATC CAGGAACACA TTTATTATCA      60
TTATCAANTA TTGTGT      76
```

(2) INFORMATION FOR SEQ ID NO:124:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 131 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

```
ACCTTTCCCC AAGGCCAATG TCCTGTGTGC TAACTGGCCG GCTGCAGGAC AGCTGCAATT   60
CAATGTGCTG GGTCAATATG AGGGGAGGAG ACTCTAAAT AGCCAATTTT ATTCTCTTGG   120
TTAAGATTG T                                     131
```

(2) INFORMATION FOR SEQ ID NO:125:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 432 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

```
ACTTTATCTA CTGGCTATGA AATAGATGGT GGAAAATTGC GTTACCAACT ATACCACTGG   60
CTTGAAAAAG AGGTGATAGC TCTTCAGAGG ACTTGTGACT TTTGCTCAGA TGCTGAAGAA   120
CTACAGTCTG CATTTGGCAG AAATGAAGAT GAATTTGGAT TAAATGAGGA TGCTGAAGAT   180
TTGCCTCACC AAACAAAAGT GAAACAACTG AGAGAAAATT TTCAGGAAAA AAGACAGTGG   240
CTCTTGAAGT ATCAGTCACT TTTGAGAATG TTTCTTAGTT ACTGCATACT TCATGGATCC   300
CATGGTGGGG GTCTTGCATC TGTAAGAATG GAATTGATT TGCTTTTGCA AGAATCTCAG   360
CAGGAAACAT CAGAACCACT ATTTTCTAGC CCTCTGTCAG AGCAAACCTC AGTGCCTCTC   420
CTCTTTGCTT GT                                     432
```

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 112 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

ACACAACCTTG AATAGTAAAA TAGAACTGA GCTGAAATTT CTAATTCAC TTTCTAACCAT 60
 AGTAAGAATG ATATTTCCCC CCAGGGATCA CCAAATATTT ATAAAAATTT GT 112

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

ACCACGAAAC CACAAACAAG ATGGAAGCAT CAATCCACTT GCCAAGCACA GCAG 54

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 323 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

ACCTCATTAG TAATTGTTTT GTTGTTTCAT TTTTCTCTAA TGTCTCCCCT CTACCAGCTC 60
 ACCTGAGATA ACAGAAATGAA AATGGAAGGA CAGCCAGATT TCTCCTTTGC TCTCTGCTCA 120
 TTCTCTCTGA AGTCTAGGTT ACCCATTTTG GGGACCCATT ATAGGCAATA AACACAGTTC 180
 CCAAAGCATT TGGACAGTTT CTTGTTGTGT TTTAGAATGG TTTTCCTTTT TCTTAGCCTT 240
 TTCCTGCAAA AGGCTCACTC AGTCCCTTGC TTGCTCAGTG GACTGGGCTC CCCAGGGCCT 300
 AGGCTGCCTT CTTTCCATG TCC 323

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 192 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

ACATACATGT GTGTATATTT TTAAATATCA CTTTTGTATC ACTCTGACTT TTTAGCATAC	60
TGAAAACACA CTAACATAAT TTNTGTGAAC CATGATCAGA TACAACCCAA ATCATTTCATC	120
TAGCACATTC ATCTGTGATA NAAAGATAGG TGAGTTTCAT TTCCTTCACG TTGGCCAATG	180
GATAAACAAA GT	192

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 362 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

CCCTTTTSTA TGGAATGAGT AGACTGTATG TTTGAANATT TANCCACAAC CTCTTTGACA	60
TATAATGACG CAACAAAAAG GTGCTGTTTA GTCCTATGGT TCAGTTTATG CCCCTGACAA	120
GTTTCCATTG TGTTTTGCCG ATCTTCTGGC TAATCGTGGT ATCCTCCATG TTATTAGTAA	180
TTCTGTATTC CATTTTGTTA ACGCCTGGTA GATGTAACCT GCTANGAGGC TAACTTTATA	240
CTTATTTAAA AGCTCTTATT TTGTGGTCAT TAAAATGGCA ATTTATGTGC AGCACTTTAT	300
TGCAGCAGGA AGCACGTGTG GGTGGTTGT AAAGCTCTT GCTAATCTTA AAAAGTAATG	360
GG	362

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 332 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

CTTTTGAAGA GATCGTGTCC ACTCCTGTGG ACATCTTGTT TTAATGGAGT TTCCCATGCA	60
GTANGACTGG TATGGTTGCA GCTGTCCAGA TAAAAACATT TGAAGAGCTC CAAAATGAGA	120
GTTCTCCCAG GTTCGCCCTG CTGCTCCAAG TCTCAGCAGC AGCCTCTTTT AGGAGGCATC	180
TTCTGAACTA GATTAAGGCA GCTTGTAAT CTGATGTGAT TTGGTTTATT ATCCAACTAA	240
CTTCCATCTG TTATCACTGG AGAAAGCCCA GACTCCCAN GACNGGTACG GATTGTGGGC	300
ATANAAGGAT TGGGTGAAGC TGGCGTTGTG GT	332

(2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 322 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

```

ACTTTTGCCA TTTTGTATAT ATAAACAATC TTGGGACATT CTCCTGAAAA CTAGGTGTCC      60
AGTGGCTAAG AGAACTCGAT TTCAAGCAAT TCTGAAAGGA AAACCAGCAT GACACAGAAT      120
CTCAAATTCC CAAACAGGGG CTCTGTGGGA AAAATGAGGG AGGACCTTTG TATCTCGGGT      180
TTTAGCAAGT TAAATGAAN ATGACAGGAA AGGCTTATTT ATCAACAAAG AGAAGAGTTG      240
GGATGCTTCT AAAAAAACT TTGGTAGAGA AAATAGGAAT GCTNAATCCT AGGGAAGCCT      300
GTAACAATCT ACAATTGGTC CA                                         322

```

(2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 278 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

```

ACAAGCCTTC ACAAGTTTAA CTAAATTGGG ATTAATCTTT CTGTANTTAT CTGCATAATT      60
CTTGTTTTTC TTCCATCTG GCTCCTGGGT TGACAATTTG TGGAACAAC TCTATTGCTA      120
CTATTTAAAA AAAATCACAA ATCTTTCCCT TTAAGCTATG TTNAATTCAA ACTATTCCCTG      180
CTATTCCTGT TTGTCAAAG AAATTATATT TTTCAAAATA TGTNTATTG TTTGATGGGT      240
CCCACGAAAC ACTAATAAAA ACCACAGAGA CCAGCCTG                               278

```

(2) INFORMATION FOR SEQ ID NO:134:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 121 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

GTTTANAAAA	CTTGTTTAGC	TCCATAGAGG	AAAGAATGTT	AACTTTGTA	TTTTAAAACA	60
TGATTCTCTG	AGGTTAAACT	TGGTTTTCAA	ATGTTATTTT	TACTTGTATT	TTGCTTTTGG	120
T						121

(2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 350 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

ACTTANAACC	ATGCCTAGCA	CATCAGAATC	CCTCAAAGAA	CATCAGTATA	ATCCTATACC	60
ATANCAAGTG	GTGACTGGTT	AAGCGTGCGA	CAAAGGTCAG	CTGGCACATT	ACTTGTGTGC	120
AAACTTGATA	CTTTTGTTCT	AAGTAGGAAC	TAGTATACAG	TNCCTAGGAN	TGGTACTCCA	180
GGGTGCCCCC	CAACTCCTGC	AGCCGCTCCT	CTGTGCCAGN	CCCTGNAAGG	AACTTTGCT	240
CCACCTCAAT	CAAGCCCTGG	GCCATGCTAC	CTGCAATTGG	CTGAACAAAC	GTTTGCTGAG	300
TTCCCAAGGA	TGCAAAGCCT	GGTGCTCAAC	TCCTGGGGCG	TCAACTCAGT		350

(2) INFORMATION FOR SEQ ID NO:136:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 399 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

TGTACCGTGA	AGACGACAGA	AGTTGCATGG	CAGGGACAGG	GCAGGGCCGA	GGCCAGGGTT	60
GCTGTGATTG	TATCCGAATA	NTCCTCGTGA	GAAAAGATAA	TGAGATGACG	TGAGCAGCCT	120
GCAGACTTGT	GTCTGCCTTC	AANAAGCCAG	ACAGGAAGGC	CCTGCCTGCC	TTGGCTCTGA	180
CCTGGCGGCC	AGCCAGCCAG	CCACAGGTGG	GCTTCTTCCT	TTGTGGTGA	CAACNCCAAG	240
AAACTGCAG	AGGCCAGGG	TCAGGTGTNA	GTGGGTANGT	GACCATAAAA	CACCAGGTGC	300
TCCCAGGAAC	CCGGGCAAAG	GCCATCCCCA	CCTACAGCCA	GCATGCCCCAC	TGGCGTGATG	360
GGTGACAGANG	GATGAAGCAG	CCAGNTGTTC	TGCTGTGGT			399

(2) INFORMATION FOR SEQ ID NO:137:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 165 base pairs

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

ACTGGTGTGG TNGGGGGTGA TGCTGGTGGT ANAAGTTGAN GTGACTTCAN GATGGTGTGT	60
GGAGGAAGTG TGTGAACGTA GGGATGTAGA NGTTTTGGCC GTGCTAAATG AGCTTCGGGA	120
TTGGCTGGTC CCACTGGTGG TCACTGTCAT TGGTGGGGTT CCTGT	165

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 338 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

ACTCACTGGA ATGCCACATT CACAACAGAA TCAGAGGTCT GTGAAAACAT TAATGGCTCC	60
TTAACTTCTC CAGTAAGAAT CAGGGACTTG AAATGGAAAC GTTAACAGCC ACATGCCCAA	120
TGCTGGGCAG TCTCCCATGC CTTCCACAGT GAAAGGGCTT GAGAAAAATC ACATCCAATG	180
TCATGTGTTT CCAGCCACAC CAAAAGGTGC TTGGGGTGGG GGGCTGGGGG CATANANGGT	240
CANGCCTCAG GAAGCCTCAA GTTCCATTCA GCTTTGCCAC TGTACATTCC CCATNTTTAA	300
AAAAACTGAT GCCTTTTTTT TTTTTTTTGG TAAAATTC	338

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 382 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

GGGAATCTTG GTTTTTGGCA TCTGGTTTGC CTATAGCCGA GGCCACTTTG ACAGAACAAA	60
GAAAGGGACT TCGAGTAAGA AGGTGATTTA CAGCCAGCCT AGTGCCCGAA GTGAAGGAGA	120
ATTCAAACAG ACCTCGTCAT TCCTGGTGTG AGCCTGGTCG GCTCACCGCC TATCATCTGC	180

100

ATTTCCTTA CTCAGGTGCT ACCGGACTCT GGCCCCGTGAT GTCTGTAGTT TCACAGGATG	240
CCTTATTTGT CTTCTACACC CCACAGGGCC CCTACTTCT TCGGATGTGT TTTTAATAAT	300
GTCAGCTATG TGCCCCATCC TCCTTCATGC CCTCCCTCCC TTTCTACCA CTGCTGAGTG	360
GCCTGGAAGT TGTTTAAAGT GT	382

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 200 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

ACCAAANCTT CTTTCTGTTG TGTGNGATTT TACTATAGGG GTTTNGCTTN TTCTAAANAT	60
ACTTTTCATT TAACANCTTT TGTTAAGTGT CAGGCTGCAC TTTGCTCCAT ANAATTATTG	120
TTTTCACATT TCAACTTGTA TGTGTTTGTC TCTTANAGCA TTGGTGAAAT CACATATTTT	180
ATATTCAGCA TAAAGGAGAA	200

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 335 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

ACTTTATTTT CAAAACACTC ATATGTTGCA AAAACACAT AGAAAAATAA AGTTTGGTGG	60
GGGTGCTGAC TAAACTTCAA GTCACAGACT TTTATGTGAC AGATTGGAGC AGGGTTTGTT	120
ATGCATGTAG AGAACCCAAA CTAATTTATT AAACAGGATA GAAACAGGCT GTCTGGGTGA	180
AATGGTTCTG AGAACCATCC AATTCACCTG TCAGATGCTG ATANACTAGC TCTTCAGATG	240
TTTTTCTACC AGTTCAGAGA TNGGTTAATG ACTANTTCCA ATGGGGAAAA AGCAAGATGG	300
ATTCACAAAC CAAGTAATTT TAAACAAAGA CACTT	335

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 459 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

ACCAGGTAA TATTGCCACA TATATCCTTT CCAATTGCGG GCTAACAGA CGTGATTTA	60
GGGTTGTTTA AAGACAACCC AGCTTAATAT CAAGAGAAAT TGTGACCTTT CATGGAGTAT	120
CTGATGGAGA AAACACTGAG TTTTGACAAA TCTTATTTTA TTCAGATAGC AGTCTGATCA	180
CACATGGTCC AACAACTC AAATAATAAA TCAAAATATNA TCAGATGTTA AAGATTGGTC	240
TTCAAACATC ATAGCCAATG ATGCCCCGCT TGCCTATAAT CTCTCCGACA TAAAACCACA	300
TCAACACCTC AGTGGCCACC AAACCATTCA GCACAGCTTC CTTAACTGTG AGCTGTTTGA	360
AGCTACCACT CTGAGCACTA TTGACTATNT TTTTCANGCT CTGAATAGCT CTAGGGATCT	420
CAGCANGGGT GGGAGGAACC AGCTCAACCT TGGCGTANT	459

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

ACATTTCTT CCACCAAGTC AGGACTCCTG GCTTCTGTGG GAGTTCTTAT CACCTGAGGG	60
AAATCCAAAC AGTCTCTCCT AGAAAGGAAT AGTGTCACCA ACCCCACCCA TCTCCCTGAG	120
ACCATCCGAC TTCCCTGTGT	140

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 164 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

ACTTCAGTAA CAACATACAA TAACAACATT AAGTGTATAT TGCCATCTTT GTCATTTTCT	60
ATCTATACCA CTCTCCCTTC TGAAAACAAN AATCACTANC CAATCACTTA TACAAATTTG	120
AGGCAATTAA TCCATATTTG TTTTCAATAA GGAAAAAAG ATGT	164

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 303 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

ACGTAGACCA TCCAACCTTG TATTTGTAAT GGCAAACATC CAGNAGCAAT TCCTAAACAA	60
ACTGGAGGGT ATTTATACCC AATTATCCCA TTCATTAACA TGCCCTCCTC CTCAGGCTAT	120
GCAGGACAGC TATCATAAGT CGGCCAGGC ATCCAGATAC TACCATTTGT ATAAACTTCA	180
GTAGGGGAGT CCATCCAAGT GACAGGTCTA ATCAAAGGAG GAAATGGAAC ATAAGCCCAG	240
TAGTAAATN TTGCTTAGCT GAAACAGCCA CAAAAGACTT ACCGCCGTGG TGATTACCAT	300
CAA	303

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 327 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

ACTGCAGCTC AATTAGAAGT GGTCTCTGAC TTTCATCANC TTCTCCCTGG GCTCCATGAC	60
ACTGGCCTGG AGTGACTCAT TGCTCTGGTT GGTGAGAGA GTCCTTTGC CAACAGGCCT	120
CCAAGTCAGG GCTGGGATTG GTTTCCTTTC CACATCTAG CAACAATATG CTGGCCACTT	180
CCTGAACAGG GAGGGTGGGA GGAGCCAGCA TGAACAAGC TGCCACTTTC TAAAGTAGCC	240
AGACTTGCCC CTGGGCCTGT CACACCTACT GATGACCTTC TGTGCCTGCA GGATGGAATG	300
TAGGGGTGAG CTGTGTGACT CTATGGT	327

(2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 173 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

ACATTGTTTT TTTGAGATAA AGCATTGANA GAGCTCTCCT TAACGTGACA CAATGGAAGG	60
ACTGGAACAC ATACCCACAT CTTTGTCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT	120
ATATTCAAGC ACATATGTTA TATATTATTC AGTCCATGT TTATAGCCTA GTT	173

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

ACAACCACTT TATCTCATCG AATTTTAAAC CCAAACCTCAC TCACTGTGCC TTTCTATCCT	60
ATGGGATATA TTATTTGATG CTCCATTTC AATCAGATAT ATGAATAATA CACTCATACT	120
GCCCTACTAC CTGCTGCAAT AATCAGATTC CCTTCCTGTC CTGACCCTGA AGCCATTGGG	180
GTGGTCCTAG TGGCCATCAG TCCANGCCTG CACCTTGAGC CCTTGAGCTC CATTGCTCAC	240
NCCANCCAC CTCACCGACC CCATCCTCTT ACACAGCTAC CTCCTTGCTC TCTAACCCCA	300
TAGATTATNT CCAAATTCAG TCAATTAAGT TACTATTAAC ACTCTACCCG ACATGTCCAG	360
CACCACTGGT AAGCCTTCTC CAGCCAACAC ACACACACAC ACACNACAC ACACACATAT	420
CCAGGCACAG GCTACCTCAT CTTCAACAATC ACCCCTTTAA TTACCATGCT ATGGTG	477

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 207 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

ACAGTTGTAT TATAATATCA AGAAATAAAC TTGCAATGAG AGCATTTAAG AGGGAAGAAC	60
TAACGTATTT TAGAGAGCCA AGGAAGGTTT CTGTGGGGAG TGGGATGTAA GGTGGGGCCT	120
GATGATAAAT AAGAGTCAGC CAGGTAAGTG GGTGGTGTGG TATGGGCACA GTGAAGAACA	180
TTTCAGGCAG AGGGAACAGC AGTGAAA	207

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 111 base pairs

104

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

```
ACCTTGATTT CATTGCTGCT CTGATGGAAA CCCAACTATC TAATTTAGCT AAAACATGGG      60
CACTTAAATG TGGTCAGTGT TTGGACTTGT TAACTANTGG CATCTTTGGG T                111
```

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 196 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

```
AGCGCGGCAG GTCATATTGA ACATTCCAGA TACCTATCAT TACTCGATGC TGTGATAAC      60
AGCAAGATGG CTTTGAAGTC AGGGTCACCA CCAGCTATTG GACCTTACTA TGAAAACCAT      120
GGATACCAAC CGGAAAACCC CTATCCCGCA CAGCCCACTG TGGTCCCCAC TGTCTACGAG      180
GTGCATCCGG CTCAGT                196
```

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 132 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

```
ACAGCACTTT CACATGTAAG AAGGGAGAAA TTCCTAAATG TAGGAGAAAG ATAACAGAAC      60
CTTCCCCTTT TCATCTAGTG GTGGAAACCT GATGCTTTAT GTTGACAGGA ATAGAACCAG      120
GAGGGAGTTT GT                132
```

(2) INFORMATION FOR SEQ ID NO:153:

105

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 285 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

ACAANACCCA NGANAGGCCA CTGGCCGTGG TGTCATGGCC TCCAAACATG AAAGTGTCTAG	60
CTTCTGCTCT TATGTCCTCA TCTGACAACT CTTTACCATT TTTATCCTCG CTCAGCAGGA	120
GCACATCAAT AAAGTCCAAA GTCTTGGA CTGGCCTTGGC TTGGAGGAAG TCATCAACAC	180
CCTGGCTAGT GAGGGTGCGG CGCCGCTCCT GGATGACGGC ATCTGTGAAG TCGTGCACCA	240
GTCTGCAGGC CCTGTGGAAG CGCCGTCCAC ACGGAGTNAG GAATT	285

(2) INFORMATION FOR SEQ ID NO:154:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 333 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

ACCACAGTCC TGTGAGGCCA GGGCTTCATG ACCCTTTCTG TGAAAAGCCA TATTATCACC	60
ACCCCAAATT TTTCTTAAA TATCTTTAAC TGAAGGGGTC AGCCTCTTGA CTGCAAAGAC	120
CCTAAGCCGG TTACACAGCT AACTCCCACT GGCCCTGATT TGTGAAATTG CTGCTGCCTG	180
ATTGGCACAG GAGTCGAAGG TGTTCAAGTC CCCTCCTCCG TGGAACGAGA CTCTGATTG	240
AGTTTCACAA ATTCTCGGGC GACCTCGTCA TTGCTCCTCT GAAATAAAAT CCGGAGAATG	300
GTGAGGCCTG TCTCATCCAT ATGGATCTTC CGG	333

(2) INFORMATION FOR SEQ ID NO:155:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 308 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

ACTGGAAATA ATAAAACCCA CATCACAGTG TTGTGTCAAA GATCATCAGG GCATGGATGG	60
GAAAGTGCTT TGGGAACTGT AAAGTGCCTA ACACATGATC GATGATTTT GTTATAATAT	120
TTGAATCACG GTGCATACAA ACTCTCCTGC CTGCTCCTCC TGGGCCCCAG CCCCAGCCCC	180
ATCACAGCTC ACTGCTCTGT TCATCCAGGC CCAGCATGTA GTGGCTGATT CTTCTTGGCT	240
GCTTTTAGCC TCCANAAGTT TCTCTGAAGC CAACCAAACC TCTANGTGTA AGGCATGCTG	300
GCCCTGGT	308

(2) INFORMATION FOR SEQ ID NO:156:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 295 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

ACCTTGCTCG GTGCTTGGAA CATATTAGGA ACTCAAAATA TGAGATGATA ACAGTGCCTA	60
TTATTGATTA CTGAGAGAAC TGTTAGACAT TTAGTTGAAG ATTTTCTACA CAGGAACTGA	120
GAATAGGAGA TTATGTTTGG CCCTCATATT CTCTCCTATC CTCCTTGCCT CATTCTATGT	180
CTAATATATT CTCAATCAAA TAAGGTTAGC ATAATCAGGA AATCGACCAA ATACCAATAT	240
AAAACCAGAT GTCTATCCTT AAGATTTTCA AATAGAAAAC AAATTAACAG ACTAT	295

(2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 126 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

ACAAGTTTAA ATAGTGCTGT CACTGTGCAT GTGCTGAAAT GTGAAATCCA CCACATTCT	60
GAAGAGCAAA ACAAATTCTG TCATGTAATC TCTATCTTGG GTCGTGGGTA TATCTGTCCC	120
CTTAGT	126

(2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 442 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

ACCCACTGGT CTTGGAAACA CCCATCCTTA ATACGATGAT TTTTCTGTCTG TGTGAAAATG	60
AANCCAGCAG GCTGCCCCCTA GTCAGTCCTT CCTTCCAGAG AAAAAGAGAT TTGAGAAAGT	120
GCCTGGGTAA TTCACCATTA ATTTCTCTCC CCAAACCTCTC TGAGTCTTCC CTTAATATTT	180
CTGGTGGTTC TGACCAAAGC AGGTCATGGT TTGTTGAGCA TTTGGGATCC CAGTGAAGTA	240
NATGTTTGTA GCCTTGCATA CTTAGCCCTT CCCACGCACA AACGGAGTGG CAGAGTGGTG	300
CCAACCCTGT TTTCCCAAGTC CACGTAGACA GATTACAGT GCGGAATTCT GGAAGCTGGA	360
NACAGACGGG CTCTTTGCAG AGCCGGGACT CTGAGANGGA CATGAGGGCC TCTGCCTCTG	420
TGTTCAATTCT CTGATGTCCT GT	442

(2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 498 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

ACTTCCAGGT AACGTTGTTG TTTCCGTTGA GCCTGAACTG ATGGGTGACG TTGTAGGTTT	60
TCCAACAAGA ACTGAGGTTG CAGAGCGGGT AGGGAAGAGT GCTGTTCCAG TTGCACCTGG	120
GCTGCTGTGG ACTGTTGTTG ATTCCTCACT ACGGCCCAAG GTTGTGGAAC TGGCANAAAG	180
GTGTGTTGTT GGANTTGAGC TCGGGCGGCT GTGGTAGGTT GTGGGCTCTT CAACAGGGGC	240
TGCTGTGGTG CCGGGANGTG AANGTGTTGT GTCACCTGAG CTTGGCCAGC TCTGGAAAGT	300
ANTANATTCT TCCTGAAGGC CAGCGCTTGT GGAGCTGGCA NGGGTCANTG TTGTGTGTAA	360
CGAACCAGTG CTGCTGTGGG TGGGTGTANA TCCTCCACAA AGCCTGAAGT TATGGTGTCTN	420
TCAGGTAANA ATGTGGTTTC AGTGTCCTTG GGCNGCTGTG GAAGGTTGTA NATTGTCACC	480
AAGGGAATAA GCTGTGGT	498

(2) INFORMATION FOR SEQ ID NO:160:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 380 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

ACCTGCATCC AGCTTCCCTG CCAAACCTCAC AAGGAGACAT CAACCTCTAG ACAGGGGAAAC	60
AGCTTCAGGA TACTTCCAGG AGACAGAGCC ACCAGCAGCA AAACAAATAT TCCCATGCCT	120
GGAGCATGGC ATAGAGGAAG CTGANAAATG TGGGGTCTGA GGAAGCCATT TGAGTCTGGC	180
CACTAGACAT CTCATCAGCC ACTTGTGTGA AGAGATGCCC CATGACCCCA GATGCCTCTC	240
CCACCCTTAC CTCCATCTCA CACACTTGAG CTTTCCACTC TGTATAATTC TAACATCCTG	300
GAGAAAAATG GCAGTTTGAC CGAACCTGTT CACAACGGTA GAGGCTGATT TCTAACGAAA	360
CTTGTTAGAAT GAAGCCTGGA	380

(2) INFORMATION FOR SEQ ID NO:161:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 114 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

ACTCCACATC CCCTCTGAGC AGGCGGTTGT CGTTCAAGGT GTATTTGGCC TTGCCTGTCA	60
CACTGTCCAC TGGCCCCTTA TCCACTTGGT GCTTAATCCC TCGAAAGAGC ATGT	114

(2) INFORMATION FOR SEQ ID NO:162:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

ACTTTCTGAA TCGAATCAAA TGATACTTAG TGAGTTTTA ATATCCTCAT ATATATCAAA	60
GTTTACTAC TCTGATAATT TTGTAAACCA GGTAACCAGA ACATCCAGTC ATACAGCTTT	120
TGGTGATATA TAAGTTGGCA ATAACCCAGT CTGGTGATAC ATAAACTAC TCACTGT	177

(2) INFORMATION FOR SEQ ID NO:163:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 137 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

CATTTATACA GACAGGCGTG AAGACATTCA CGACAAAAAC GCGAAATTCT ATCCCGTGAC	60
CANAGAAGGC AGCTACGGCT ACTCCTACAT CCTGGCGTGG GTGGCCTTCG CCTGCACCTT	120
CATCAGCGGC ATGATGT	137

(2) INFORMATION FOR SEQ ID NO:164:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 469 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

CTTATCACAA TGAATGTTCT CCTGGGCAGC GTTGTGATCT TTGCCACCTT CGTGACTTTA	60
TGCAATGCAT CATGCTATTT CATACTAAT GAGGGAGTTC CAGGAGATTC AACCAGGAAA	120
TGCATGGATC TCAAAGGAAA CAAACACCCA ATAAACTCGG AGTGGCAGAC TGACAACTGT	180
GAGACATGCA CTTGCTACGA AACAGAAATT TCATGTTGCA CCCTTGTTTC TACACCTGTG	240
GGTTATGACA AAGACAACTG CCAAAGAATC TTCAAGAAGG AGGACTGCAA GTATATCGTG	300
GTGGAGAAGA AGGACCCAAA AAAGACCTGT TCTGTCACTG AATGGATAAT CTAATGTGCT	360
TCTAGTAGGC ACAGGGCTCC CAGGCCAGGC CTCATTCTCC TCTGGCCTCT AATAGTCAAT	420
GATTGTGTAG CCATGCCTAT CAGTAAAAAG ATNTTTGAGC AAACACTTT	469

(2) INFORMATION FOR SEQ ID NO:165:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

ACAGTTTTTT ATANATATCG ACATTGCCGG CACTTGTGTT CAGTTTCATA AAGCTGGTGG	60
ATCCGCTGTC ATCCACTATT CCTTGGCTAG AGTAAAAATT ATTCTTATAG CCCATGTCCC	120
TGCAGGCCGC CCGCCCGTAG TTCTCGTTCC AGTCGTCTTG GCACACAGGG TGCCAGGACT	180
TCCTCTGAGA TGAGT	195

(2) INFORMATION FOR SEQ ID NO:166:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 383 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

```

ACATCTTAGT AGTGTGGCAC ATCAGGGGGC CATCAGGGTC ACAGTCACTC ATAGCCTCGC      60
CGAGGTCGGA GTCCACACCA CCGGTGTAGG TGTGCTCAAT CTTGGGCTTG GCGCCACCT      120
TTGGAGAAGG GATATGCTGC ACACACATGT CCACAAAGCC TGTGAACTCG CCAAAGAATT      180
TTTGCAGACC AGCCTGAGCA AGGGGCGGAT GTTCAGCTTC AGCTCCTCCT TCGTCAGGTG      240
GATGCCAACC TCGTCTANGG TCCGTGGGAA GCTGGTGTCC ACNTCACCTA CAACCTGGGC      300
GANGATCTTA TAAAGAGGCT CCNAGATAAA CTCCACGAAA CTTCTCTGGG AGCTGCTAGT      360
NGGGGCCTTT TTGGTGAAC  TTC                                     383

```

(2) INFORMATION FOR SEQ ID NO:167:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 247 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

```

ACAGAGCCAG ACCTTGGCCA TAAATGAANC AGAGATTAAG ACTAAACCCC AAGTCGANAT      60
TGGAGCAGAA ACTGGAGCAA GAAGTGGGCC TGGGGCTGAA GTAGAGACCA AGGCCACTGC      120
TATANCCATA CACAGAGCCA ACTCTCAGGC CAAGGCNATG GTTGGGGCAG ANCCAGAGAC      180
TCAATCTGAN TCCAAAGTGG TGGCTGGAAC ACTGGTCATG ACANAGGCAG TGACTCTGAC      240
TGANGTC                                     247

```

(2) INFORMATION FOR SEQ ID NO:168:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 273 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

ACTTCTAAGT TTTCTAGAAG TGGAAGGATT GTANTCATCC TGAAAATGGG TTTACTTCAA	60
AATCCCTCAN CCTGTTCCTT CACNACTGTC TATACTGANA GTGTCATGTT TCCACAAAGG	120
GCTGACACCT GAGCCTGNAT TTTCACTCAT CCCTGAGAAG CCCTTCCAG TAGGGTGGGC	180
AATTCCCAAC TTCCTTGCCA CAAGCTTCCC AGGCTTTCTC CCCTGGAAAA CTCCAGCTTG	240
AGTCCCAGAT AACTCATGG GCTGCCCTGG GCA	273

(2) INFORMATION FOR SEQ ID NO:169:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 431 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

ACAGCCTTGG CTTCCCCAAA CTCCACAGTC TCAGTGCAGA AAGATCATCT TCCAGCAGTC	60
AGCTCAGACC AGGGTCAAAG GATGTGACAT CAACAGTTTC TGGTTTCAGA ACAGGTCTA	120
CTACTGTCAA ATGACCCCCC ATAATTCTCT AAAGGCTGTG GTAAGTTTTG CACAGGTGAG	180
GGCAGCAGAA AGGGGGTANT TACTGATGGA CACCATCTTC TCTGTATACT CCACACTGAC	240
CTTGCCATGG GCAAAGGCC CTACCACAAA AACATAGGA TCACTGCTGG GCACCAGCTC	300
ACGCACATCA CTGACAACCG GGATGGAAAA AGAANTGCCA ACTTTCATAC ATCCAACTGG	360
AAAGTGATCT GATACTGGAT TCTTAATTAC CTTCAAAAGC TTCTGGGGGC CATCAGCTGC	420
TCGAACACTG A	431

(2) INFORMATION FOR SEQ ID NO:170:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 266 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

ACCTGTGGGC TGGGCTGTTA TGCCTGTGCC GGCTGCTGAA AGGGAGTTCA GAGGTGGAGC	60
TCAAGGAGCT CTGCAGGCAT TTTGCCAANC CTCTCCANAG CANAGGGAGC AACCTACACT	120
CCCCGCTAGA AAGACACCAG ATTGGAGTCC TGGGAGGGGG AGTTGGGGTG GGCATTTGAT	180
GTATACTTGT CACCTGAATG AANGAGCCAG AGAGGAANGA GACGAANATG ANATTGGCCT	240
TCAAAGCTAG GGGTCTGGCA GGTGGA	266

(2) INFORMATION FOR SEQ ID NO:171:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1248 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

```

GGCAGCCAAA TCATAAACGG CGAGGACTGC AGCCCGCACT CGCAGCCCTG GCAGGCGGCA      60
CTGGTCATGG AAAACGAATT GTTCTGCTCG GCGCTCCTGG TGCATCCGCA GTGGGTGCTG      120
TCAGCCGCAC ACTGTTTCCA GAAGTGAGTG CAGAGCTCCT ACACCATCGG GCTGGGCCTG      180
CACAGTCTTG AGGCCGACCA AGAGCCAGGG AGCCAGATGG TGGAGGCCAG CCTCTCCGTA      240
CGGCACCCAG AGTACAACAG ACCCTTGCTC GCTAACGACC TCATGCTCAT CAAGTTGGAC      300
GAATCCGTGT CCGAGTCTGA CACCATCCGG AGCATCAGCA TTGCTTCGCA GTGCCCTACC      360
GCGGGGAACT CTTGCCTCGT TTCTGGCTGG GGTCTGCTGG CGAACGGCAG AATGCCTACC      420
GTGCTGCAGT GCGTGAACGT GTCGGTGGTG TCTGAGGAGG TCTGCAGTAA GCTCTATGAC      480
CCGCTGTACC ACCCCAGCAT GTTCTGCGCC GCGCGAGGGC AAGACCAGAA GGACTCCTGC      540
AACGGTGACT CTGGGGGGCC CCTGATCTGC AACGGGTACT TGCAGGGCCT TGTGTCTTTC      600
GGAAAAGCCC CGTGTGGCCA AGTTGGCGTG CCAGGTGTCT ACACCAACCT CTGCAAATTC      660
ACTGAGTGGA TAGAGAAAAC CGTCCAGGCC AGTTAACTCT GGGGACTGGG AACCCATGAA      720
ATTGACCCCC AAATACATCC TCGGAAGGA ATTCAGGAAT ATCTGTTCCC AGCCCCCTCT      780
CCCTCAGGCC CAGGAGTCCA GGCCCCCAGC CCCTCCTCCC TCAAACCAAG GGTACAGATC      840
CCCAGCCCCC CCTCCCTCAG ACCCAGGAGT CCAGACCCCC CAGCCCCCTCC TCCCTCAGAC      900
CCAGGAGTCC AGCCCCCTCT CCCTCAGACC CAGGAGTCCA GACCCCCCAG CCCCTCCTCC      960
CTCAGACCCA GGGGTCCAGG CCCCAACCC CTCCTCCCTC AGACTCAGAG GTCCAAGCCC     1020
CCAACCCNTC ATTCCCCAGA CCCAGAGGTC CAGGTCCCAG CCCCTCNTCC CTCAGACCCA     1080
GCGGTCCAAT GCCACCTAGA CTNTCCCTGT ACACAGTGCC CCCTTGTTGGC ACGTTGACCC     1140
AACCTTACCA GTTGGTTTTT CATTTTNGT CCCTTTCCCC TAGATCCAGA AATAAAGTTT     1200
AAGAGAAGNG CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAA     1248

```

(2) INFORMATION FOR SEQ ID NO:172:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

```

Met Val Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro
1           5           10           15

```

113

Leu Leu Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser
 20 25 30
 Glu Ser Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr
 35 40 45
 Ala Gly Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly
 50 55 60
 Arg Met Pro Thr Val Leu Gln Cys Val Asn Val Ser Val Val Ser Glu
 65 70 75 80
 Glu Val Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe
 85 90 95
 Cys Ala Gly Gly Gly Gln Xaa Gln Xaa Asp Ser Cys Asn Gly Asp Ser
 100 105 110
 Gly Gly Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe
 115 120 125
 Gly Lys Ala Pro Cys Gly Gln Val Gly Val Pro Gly Val Tyr Thr Asn
 130 135 140
 Leu Cys Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Ala Ser
 145 150 155

(2) INFORMATION FOR SEQ ID NO:173:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1265 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

GGCAGCCCGC	ACTCGCAGCC	CTGGCAGGCG	GCACTGGTCA	TGGAAAACGA	ATTGTTCTGC	60
TCGGGCGTCC	TGGTGCATCC	GCAGTGGGTG	CTGTCAGCCG	CACACTGTTT	CCAGAACTCC	120
TACACCATCG	GGCTGGGCCT	GCACAGTCTT	GAGGCCGACC	AAGAGCCAGG	GAGCCAGATG	180
GTGGAGGCCA	GCCTCTCCGT	ACGGCACCCA	GAGTACAACA	GACCCTTGCT	CGCTAACGAC	240
CTCATGCTCA	TCAAGTTGGA	CGAATCCGTG	TCCGAGTCTG	ACACCATCCG	GAGCATCAGC	300
ATTGCTTCGC	AGTGCCCTAC	CGCGGGGAAC	TCTTGCCCTG	TTTCTGGCTG	GGGTCTGCTG	360
GCGAACGGTG	AGCTCACGGG	TGTGTGTCTG	CCCTCTTCAA	GGAGGTCCTC	TGCCCAGTCG	420
CGGGGGCTGA	CCCAGAGCTC	TGCGTCCCAG	GCAGAATGCC	TACCGTGCTG	CAGTGCGTGA	480
ACGTGTCGGT	GGTGTCTGAG	GAGGTCTGCA	GTAAGCTCTA	TGACCCGCTG	TACCACCCCA	540
GCATGTTCTG	CGCCGGCGGA	GGGCAAGACC	AGAAGGACTC	CTGCAACGGT	GACTCTGGGG	600
GGCCCCGTGAT	CTGCAACGGG	TACTTGCAGG	GCCTTGTGTC	TTTCGGAAAA	GCCCCGTGTG	660
GCCAAGTTGG	CGTGCCAGGT	GTCTACACCA	ACCTCTGCAA	ATTCACTGAG	TGGATAGAGA	720

AAACCGTCCA	GGCCAGTTAA	CTCTGGGGAC	TGGGAACCCA	TGAAATTGAC	CCCCAAATAC	780
ATCCTGCGGA	AGGAATTCAG	GAATATCTGT	TCCCAGCCCC	TCCTCCCTCA	GGCCCAGGAG	840
TCCAGGCCCC	CAGCCCCTCC	TCCCTCAAAC	CAAGGGTACA	GATCCCCAGC	CCCTCCTCCC	900
TCAGACCCAG	GAGTCCAGAC	CCCCCAGCCC	CTCCTCCCTC	AGACCCAGGA	GTCCAGCCCC	960
TCCTCCNTCA	GACCCAGGAG	TCCAGACCCC	CCAGCCCCCTC	CTCCCTCAGA	CCCAGGGGTT	1020
GAGGCCCCCA	ACCCCTCCTC	CTTCAGAGTC	AGAGGTCCAA	GCCCCCAACC	CCTCGTTCCC	1080
CAGACCCAGA	GGTNNAGGTC	CCAGCCCCCTC	TTCCNTCAGA	CCCAGNGGTC	CAATGCCACC	1140
TAGATTTTCC	CTGNACACAG	TGCCCCCTTG	TGGNANGTTG	ACCCAACCTT	ACCAGTTGGT	1200
TTTTCATTTT	TNGTCCCTTT	CCCCTAGATC	CAGAAATAAA	GTTTAAGAGA	NGNGCAAAAA	1260
AAAAA						1265

(2) INFORMATION FOR SEQ ID NO:174:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1459 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

GGTCAGCCGC	ACACTGTTTC	CAGAAGTGAG	TGCAGAGCTC	CTACACCATC	GGGCTGGGCC	60
TGCACAGTCT	TGAGGCCGAC	CAAGAGCCAG	GGAGCCAGAT	GGTGGAGGCC	AGCCTCTCCG	120
TACGGCACCC	AGAGTACAAC	AGACCCTTGC	TCGTAACGA	CCTCATGCTC	ATCAAGTTGG	180
ACGAATCCGT	GTCCGAGTCT	GACACCATCC	GGAGCATCAG	CATTGCTTCG	CAGTGCCCTA	240
CCGCGGGGAA	CTCTTGCCCTC	GTTTCTGGCT	GGGTCTGCT	GGCGAACGGT	GAGCTCACGG	300
GTGTGTGTCT	GCCCTCTTCA	AGGAGGTCCT	CTGCCCAGTC	GCGGGGGCTG	ACCCAGAGCT	360
CTGCGTCCCA	GGCAGAATGC	CTACCGTGCT	GCAGTGCGTG	AACGTGTCCG	TGGTGTCTGA	420
NGAGGTCTGC	ANTAAGCTCT	ATGACCCGCT	GTACCACCCC	ANCATGTTCT	GCGCCGGCGG	480
AGGGCAAGAC	CAGAAGGACT	CCTGCAACGT	GAGAGAGGGG	AAAGGGGAGG	GCAGGCGACT	540
CAGGGAAGGG	TGGAGAAGG	GGAGACAGAG	ACACACAGGG	CCGCATGGCG	AGATGCAGAG	600
ATGGAGAGAC	ACACAGGGAG	ACAGTGACAA	CTAGAGAGAG	AAACTGAGAG	AAACAGAGAA	660
ATAAACACAG	GAATAAAGAG	AAGCAAAGGA	AGAGAGAAAC	AGAAACAGAC	ATGGGGAGGC	720
AGAAACACAC	ACACATAGAA	ATGCAGTTGA	CCTTCCAACA	GCATGGGGCC	TGAGGGCGGT	780
GACCTCCACC	CAATAGAAAA	TCCTCTTATA	ACTTTTGACT	CCCCAAAAAC	CTGACTAGAA	840
ATAGCCTACT	GTTGACGGGG	AGCCTTACCA	ATAACATAAA	TAGTCGATTT	ATGCATACGT	900
TTTATGCATT	CATGATATAC	CTTTGTTGGA	ATTTTTTGAT	ATTCTAAGC	TACACAGTTC	960
GTCTGTGAAT	TTTTTTAAAT	TGTTGCAACT	CTCCTAAAAT	TTTTCTGATG	TGTTTTATTGA	1020
AAAAATCCAA	GTATAAGTGG	ACTTGTGCAT	TCAAACCAGG	GTTGTTCAAG	GGTCAACTGT	1080
GTACCCAGAG	GGAAACAGTG	ACACAGATTC	ATAGAGGTGA	AACACGAAGA	GAAACAGGAA	1140
AAATCAAGAC	TCTACAAAGA	GGCTGGGCAG	GGTGGCTCAT	GCCTGTAATC	CCAGCACTTT	1200
GGGAGGCGAG	GCAGGCAGAT	CACCTGAGGT	AAGGAGTTCA	AGACCAGCCT	GGCCAAAATG	1260
GTGAAATCCT	GTCTGTACTA	AAAATACAAA	AGTTAGCTGG	ATATGGTGGC	AGGCGCCTGT	1320
AATCCCAGCT	ACTTGGGAGG	CTGAGGCAGG	AGAATTGCTT	GAATATGGGA	GGCAGAGGTT	1380
GAAGTGAGTT	GAGATCACAC	CACATACTC	CACTGGGGC	AACAGAGTAA	GACTCTGTCT	1440
CAAAAAAAA	AAAAAAA					1459

(2) INFORMATION FOR SEQ ID NO:175:

(i) SEQUENCE CHARACTERISTICS:

115

- (A) LENGTH: 1167 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

```

GCGCAGCCCT GGCAGGCGGC ACTGGTCATG GAAAACGAAT TGTTCCTGCTC GGGCGTCCTG      60
GTGCATCCGC AGTGGGTGCT GTCAGCCGCA CACTGTTTCC AGAACTCCTA CACCATCGGG      120
CTGGGCCTGC ACAGTCTTGA GGCCGACCAA GAGCCAGGGA GCCAGATGGT GGAGGCCAGC      180
CTCTCCGTAC GGCACCCAGA GTACAACAGA CTCTTGCTCG CTAACGACCT CATGCTCATC      240
AAGTTGGACG AATCCGTGTC CGAGTCTGAC ACCATCCGGA GCATCAGCAT TGCTTCGCAG      300
TGCCCTACCG CGGGGAATC TTGCCTCGTN TCTGGCTGGG GTCTGCTGGC GAACGGCAGA      360
ATGCCTACCG TGCTGCACTG CGTGAACGTG TCGGTGGTGT CTGAGGANGT CTGCAGTAAG      420
GACTATGACC CGCTGTACCA CCCCAGCATG TTCTGCGCCG GCGGAGGGCA AGACCAGAAG      480
GACTCCTGCA ACGGTGACTC TGGGGGGCCC CTGATCTGCA ACGGGTACTT GCAGGGCCTT      540
GTGTCTTTTC GAAAAGCCCC GTGTGGCCAA CTTGGCGTGC CAGGTGTCTA CACCAACCTC      600
TGCAAATTCA CTGAGTGGAT AGAGAAAACC GTCCAGNCCA GTTAACTCTG GGGACTGGGA      660
ACCCATGAAA TTGACCCCCA AATACATCCT GCGGAANGAA TTCAGGAATA TCTGTTCCCA      720
GCCCCTCCTC CCTCAGGCCC AGGAGTCCAG GCCCCAGCC CCTCCTCCCT CAAACCAAGG      780
GTACAGATCC CCAGCCCCTC CTCCCTCAGA CCCAGGAGTC CAGACCCCCC AGCCCCCTNT      840
CCNTCAGACC CAGGAGTCCA GCCCCTCCTC CNTCAGACGC AGGAGTCCAG ACCCCCCAGC      900
CCNTCNTCCG TCAGACCCAG GGGTGCAGGC CCCCACCCCT TCNTCCNTCA GAGTCAGAGG      960
TCCAAGCCCC CAACCCCTCG TTCCCAGAC CCAGAGGTNC AGGTCCCAGC CCCTCCTCCC     1020
TCAGACCCAG CGGTCCAATG CCACCTAGAN TNTCCCTGTA CACAGTGCCC CCTTGTGGCA     1080
NGTTGACCCA ACCTTACCAG TTGGTTTTTC ATTTTTTGTC CCTTTCCCCT AGATCCAGAA     1140
ATAAAGTNTA AGAGAAGCGC AAAAAAA      1167

```

(2) INFORMATION FOR SEQ ID NO:176:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1           5           10           15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20           25           30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val

```

116

35	40	45
Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Leu Leu Leu		
50	55	60
Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser		
65	70	75
Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly		
85	90	95
Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Gly Arg Met		
100	105	110
Pro Thr Val Leu His Cys Val Asn Val Ser Val Val Ser Glu Xaa Val		
115	120	125
Cys Ser Lys Leu Tyr Asp Pro Leu Tyr His Pro Ser Met Phe Cys Ala		
130	135	140
Gly Gly Gly Gln Asp Gln Lys Asp Ser Cys Asn Gly Asp Ser Gly Gly		
145	150	155
Pro Leu Ile Cys Asn Gly Tyr Leu Gln Gly Leu Val Ser Phe Gly Lys		
165	170	175
Ala Pro Cys Gly Gln Leu Gly Val Pro Gly Val Tyr Thr Asn Leu Cys		
180	185	190
Lys Phe Thr Glu Trp Ile Glu Lys Thr Val Gln Xaa Ser		
195	200	205

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1119 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

GCGCACTCGC AGCCCTGGCA GGCGGCACTG GTCATGGAAA ACGAATTGTT CTGCTCGGGC	60
GTCCTGGTGC ATCCGCAGTG GGTGCTGTCA GCCGCACACT GTTCCAGAA CTCCTACACC	120
ATCGGGCTGG GCCTGCACAG TCTTGAGGCC GAACAAGAGC CAGGGAGCCA GATGGTGGAG	180
GCCAGCCTCT CCGTACGGCA CCCAGAGTAC AACAGACCCT TGCTCGCTAA CGACCTCATG	240
CTCATCAAGT TGGACGAATC CGTGTCGGAG TCTGACACCA TCCGGAGCAT CAGCATTGCT	300
TCGCAGTGCC CTACCGCGGG GAACTCTTGC CTCGTTTCTG GCTGGGGTCT GCTGGCGAAC	360
GATGCTGTGA TTGCCATCCA GTCCAGACT GTGGGAGGCT GGGAGTGTGA GAAGCTTTCC	420
CAACCCTGGC AGGGTTGTAC CATTCGGCA ACTTCCAGTG CAAGGACGTC CTGCTGCATC	480

117

```

CTCACTGGGT GCTCACTACT GCTCACTGCA TCACCCGGAA CACTGTGATC AACTAGCCAG      540
CACCATAGTT CTCCGAAGTC AGACTATCAT GATTACTGTG TTGACTGTGC TGTCTATTGT      600
ACTAACCATG CCGATGTTTA GGTGAAATTA GCGTCACTTG GCCTCAACCA TCTTGGTATC      660
CAGTTATCCT CACTGAATTG AGATTTCCTG CTTCAAGGAT AGCCATTCCC ACATAATTTT      720
TGACCTACAG AGGTGAGGGA TCATATAGCT CTTCAAGGAT GCTGGTACTC CCCTCACAAA      780
TTCATTTCCT CTGTTGTAGT GAAAGGTGCG CCCTCTGGAG CCTCCCAGGG TGGGTGTGCA      840
GGTCACAATG ATGAATGTAT GATCGTGTTT CCATTACCCA AAGCCTTTAA ATCCCTCATG      900
CTCAGTACAC CAGGGCAGGT CTAGCATTTT TTCATTTAGT GTATGCTGTC CATTTCATGCA      960
ACCACCTCAG GACTCCTGGA TTCTCTGCCT AGTTGAGCTC CTGCATGCTG CCTCCTTGGG     1020
GAGGTGAGGG AGAGGGCCCA TGGTTCAATG GGATCTGTGC AGTTGTAACA CATTAGGTGC     1080
TTAATAAACA GAAGCTGTGA TGTAAAAAAA AAAAAAAA      1119

```

(2) INFORMATION FOR SEQ ID NO:178:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 164 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

```

Met Glu Asn Glu Leu Phe Cys Ser Gly Val Leu Val His Pro Gln Trp
1              5              10              15

Val Leu Ser Ala Ala His Cys Phe Gln Asn Ser Tyr Thr Ile Gly Leu
20            25            30

Gly Leu His Ser Leu Glu Ala Asp Gln Glu Pro Gly Ser Gln Met Val
35            40            45

Glu Ala Ser Leu Ser Val Arg His Pro Glu Tyr Asn Arg Pro Leu Leu
50            55            60

Ala Asn Asp Leu Met Leu Ile Lys Leu Asp Glu Ser Val Ser Glu Ser
65            70            75            80

Asp Thr Ile Arg Ser Ile Ser Ile Ala Ser Gln Cys Pro Thr Ala Gly
85            90            95

Asn Ser Cys Leu Val Ser Gly Trp Gly Leu Leu Ala Asn Asp Ala Val
100           105           110

Ile Ala Ile Gln Ser Xaa Thr Val Gly Gly Trp Glu Cys Glu Lys Leu
115           120           125

Ser Gln Pro Trp Gln Gly Cys Thr Ile Ser Ala Thr Ser Ser Ala Arg
130           135           140

Thr Ser Cys Cys Ile Leu Thr Gly Cys Ser Leu Leu Leu Thr Ala Ser

```

145

150

155

160

Pro Gly Thr Leu

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 250 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

CTGGAGTGCC TTGGTGTTC AAGCCCCTGC AGGAAGCAGA ATGCACCTTC TGAGGCACCT	60
CCAGCTGCCC CCGCCCGGGG GATGCGAGGC TCGGAGCACC CTGCCCCGGC TGTGATTGCT	120
GCCAGGCACT GTTCATCTCA GCTTTTCTGT CCCTTTGCTC CCGGCAAGCG CTTCTGCTGA	180
AAGTTCATAT CTGGAGCCTG ATGTCTTAAC GAATAAAGGT CCCATGCTCC ACCCGAAAAA	240
AAAAAAAAAA	250

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 202 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

ACTAGTCCAG TGTGGTGGAA TTCCATTGTG TTGGGCCCAA CACAATGGCT ACCTTTAACA	60
TCACCCAGAC CCCGCCCTG CCCGTGCCCC ACGCTGCTGC TAACGACAGT ATGATGCTTA	120
CTCTGCTACT CGGAAACTAT TTTATGTAA TTAATGTATG CTTTCTTGT TATAAATGCC	180
TGATTTAAAA AAAAAAAAAA AA	202

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 558 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

TCCYTTTGT NAGGTTTKG AGACAMCCCK AGACCTWAAN CTGTGTCACA GACTTCYNGG	60
AATGTTTAGG CAGTGCTAGT AATTCYTCG TAAATGATTCT GTTATTACTT TCCTNATTCT	120
TTATTCCTCT TTCTTCTGAA GATTAATGAA GTTGAAAATT GAGGTGGATA AATACAAAAA	180
GGTAGTGTGA TAGTATAAGT ATCTAAGTGC AGATGAAAGT GTGTTATATA TATCCATTCA	240
AAATTATGCA AGTTAGTAAT TACTCAGGGT TAACTAAATT ACTTTAATAT GCTGTTGAAC	300
CTACTCTGTT CCTTGGCTAG AAAAAATTAT AAACAGGACT TTGTTAGTTT GGGAAGCCAA	360
ATTGATAATA TTCTATGTT TAAAAGTTGG GCTATACATA AATTATTAAG AAATATGGAW	420

TTTTATTCCC AGGAATATGG KGTTCAATTTT ATGAATATTA CSCRGGATAG AWGTWTGAGT	480
AAAAYCAGTT TTGGTWAATA YGTWAATATG TCMTAAATAA ACAAKGCTTT GACTTATTTT	540
CAAAAAAAAA AAAAAAAAA	558

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 479 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

ACAGGGWTTK GRGGATGCTA AGSCCCCRGA RWTYGTTTGA TCCAACCCTG GCTTWTTTTTC	60
AGAGGGGAAA ATGGGGCCTA GAAGTTACAG MSCATYTAGY TGGTGCGMTG GCACCCCTGG	120
CSTCACACAG ASTCCCGAGT AGCTGGGACT ACAGGCACAC AGTCACTGAA GCAGGCCCTG	180
TTWGCAATTC ACGTTGCCAC CTCCAACCTA AACATTCTTC ATATGTGATG TCCTTAGTCA	240
CTAAGGTTAA ACTTTCCAC CCAGAAAAGG CAACTTAGAT AAAATCTTAG AGTACTTTCA	300
TACTMTTCTA AGTCCTCTTC CAGCCTCACT KKGAGTCCTM CYTGGGGGTT GATAGGAANT	360
NTCTCTTGGC TTTCTCAATA AARTCTCTAT YCATCTCATG TTTAATTGG TACGCATARA	420
AWTGSTGARA AAATTAAAT GTTCTGGTTY MACTTTAAAA ARAAAAAAAAA AAAAAAAAA	479

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

AGGCGGGAGC AGAAGCTAAA GCCAAAGCCC AAGAAGAGTG GCAGTGCCAG CACTGGTGCC	60
AGTACCAGTA CCAATAACAG TGCCAGTGCC AGTGCCAGCA CCAGTGGTGG CTTCAGTGCT	120
GGTGCCAGCC TGACCGCCAC TCTCACATTT GGGCTCTTCG CTGGCCTTGG TGGAGCTGGT	180
GCCAGCACCA GTGGCAGCTC TGGTGCTGT GGTTCCTCCT ACAAGTGAGA TTTTAGATAT	240
TGTTAATCCT GCCAGTCTTT CTCTCAAGC CAGGGTGCAT CCTCAGAAAC TACTCAACA	300
CAGCACTCTA GGCAGCCACT ATCAATCAAT TGAAGTTGAC ACTCTGCATT ARATCTATTT	360
GCCATTTCAA AAAAAAAAAA AAAA	384

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 496 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

ACCGAATTGG GACCGCTGGC TTATAAGCGA TCATGTYNT CCRGTATKAC CTCAACGAGC	60
--	----

120

AGGGAGATCG	AGTCTATACG	CTGAAGAAAT	TTGACCCGAT	GGGACAACAG	ACCTGCTCAG	120
CCCATCCTGC	TCGGTTCTCC	CCAGATGACA	AATACTCTSG	ACACCGAATC	ACCATCAAGA	180
AACGCTTCAA	GGTGCTCATG	ACCCAGCAAC	CGCGCCCTGT	CCTCTGAGGG	TCCCTTAAAC	240
TGATGTCTTT	TCTGCCACCT	GTTACCCCTC	GGAGACTCCG	TAACCAAAC	CTTCGGACTG	300
TGAGCCCTGA	TGCCTTTTGT	CCAGCCATAC	TCTTTGGCAT	CCAGTCTCTC	GTGGCGATTG	360
ATTATGCTTG	TGTGAGGCAA	TCATGGTGGC	ATCACCCATA	AAGGGAACAC	ATTTGACTTT	420
TTTTTCTCAT	ATTTTAAATT	ACTACMAGAW	TATTWMAGAW	WAAATGAWTT	GAAAAACTST	480
TAAAAA	AAAAAA					496

(2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

GCTGGTAGCC	TATGGCGKGG	CCCACGGAGG	GGCTCCTGAG	GCCACGGRAC	AGTGACTTCC	60
CAAGTATCYT	GCGCSGCGTC	TTCTACCGTC	CCTACCTGCA	GATCTTCGGG	CAGATTCCCC	120
AGGAGGACAT	GGACGTGGCC	CTCATGGAGC	ACAGCAACTG	YTCGTCCGAG	CCCGGCTTCT	180
GGGCACACCC	TCCTGGGGCC	CAGGCGGGCA	CCTGCGTCTC	CCAGTATGCC	AACTGGCTGG	240
TGGTGCTGCT	CCTCGTCATC	TTCTGCTCG	TGGCAACAT	CCTGTGGTTC	AACTTGCTCA	300
TTGCCATGTT	CAGTTACACA	TTGGGCAAAG	TACAGGGCAA	CAGCGATCTC	TACTGGGAAG	360
GCGCAGCGTT	ACCGCCTCAT	CCGG				384

(2) INFORMATION FOR SEQ ID NO:186:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 577 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

GAGTTAGCTC	CTCCACAACC	TTGATGAGGT	CGTCTGCAGT	GGCCTCTCGC	TTCATACCGC	60
TNCCATCGTC	ATACTGTAGG	TTTGCCACCA	CYTCTGGCA	TCTTGGGGCG	GCNTAATATT	120
CCAGGAAACT	CTCAATCAAG	TCACCGTCGA	TGAAACCTGT	GGGCTGGTTC	TGTCTCCGC	180
TCGGTGTGAA	AGGATCTCCC	AGAAGGAGTG	CTCGATCTTC	CCCACACTTT	TGATGACTTT	240
ATTGAGTCGA	TTCTGCATGT	CCAGCAGGAG	GTTGTACCAG	CTCTCTGACA	GTGAGGTCAC	300
CAGCCCTATC	ATGCCGTTGA	MCGTGCCGAA	GARCACCGAG	CCTTGTGTGG	GGGKKGAAGT	360
CTCACCCAGA	TTCTGCATTA	CCAGAGAGCC	GTGGCAAAAG	ACATTGACAA	ACTCGCCCGAG	420
GTGGAAAAAG	AMCAMCTCCT	GGARGTGCTN	GCCGCTCCTC	GTCMGTGGT	GGCAGCGCTW	480
TCCTTTTGAC	ACACAAACAA	GTTAAAGGCA	TTTTCAGCCC	CCAGAAANTT	GTCATCATCC	540
AAGATNTCGC	ACAGCACTNA	TCCAGTTGGG	ATTAAAT			577

(2) INFORMATION FOR SEQ ID NO:187:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 534 base pairs
- (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

AACATCTTCC	TGTATAATGC	TGTGTAATAT	CGATCCGATN	TTGTCTGSTG	AGAATYCATW	60
ACTKGGAAAA	GMAACATTAA	AGCCTGGACA	CTGGTATTAA	AATTCACAAT	ATGCAACACT	120
TTAAACAGTG	TGTCAATCTG	CTCCCYYNAC	TTTGTCATCA	CCAGTCTGGG	AAKAAGGGTA	180
TGCCCTATTC	ACACCTGTTA	AAAGGGCGCT	AAGCATTTTT	GATTCAACAT	CTTTTTTTTT	240
GACACAAGTC	CGAAAAAAGC	AAAAGTAAAC	AGTTATYAAT	TTGTTAGCCA	ATTCACCTTC	300
TTCATGGGAC	AGAGCCATYT	GATTTAAAAA	GCAAATTGCA	TAATATTGAG	CTTYGGGAGC	360
TGATATTTGA	GCGGAAGAGT	AGCCTTTCTA	CTTCACCAGA	CACAACTCCC	TTTCATATTG	420
GGATGTTNAC	NAAAGTWATG	TCTCTWACAG	ATGGGATGCT	TTTGTGGCAA	TTCTGTTCTG	480
AGGATCTCCC	AGTTTATTTA	CCACTTGCAC	AAGAAGGCGT	TTTCTTCCTC	AGGC	534

(2) INFORMATION FOR SEQ ID NO:188:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 761 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

AGAAACCACT	ATCTCTNAAA	ACAACCTCTC	ATACCTTGTC	GACCTAATTT	TGTGTGCGTG	60
TGTGTGTGCG	CGCATATTAT	ATAGACAGGC	ACATCTTTTT	TACTTTTGTA	AAAGCTTATG	120
CCTCTTTGGT	ATCTATATCT	GTGAAAGTTT	TAATGATCTG	CCATAATGTC	TTGGGGACCT	180
TTGTCTTCTG	TGTAAATGGT	ACTAGAGAAA	ACACCTATNT	TATGAGTCAA	TCTAGTTNGT	240
TTTATTCGAC	ATGAAGGAAA	TTTCCAGATN	ACAACACTNA	CAAACCTCTC	CTKGACKARG	300
GGGGACAAAG	AAAAGCAAAA	CTGAMCATAA	RAAACAATWA	CCTGGTGAGA	ARTTGCAATA	360
ACAGAAATWR	GGTAGTATAT	TGAARNACAG	CATCATTAAT	RMGTTWTKTT	WTTCTCCCTT	420
GCAAAAAACA	TGTACNGACT	TCCCGTTGAG	TAATGCCAAG	TTGTTTTTTT	TATNATAAAA	480
CTTGCCCTTC	ATTACATGTT	TNAAAGTGGT	GTGGTGCGGC	AAAATATTGA	AATGATGGAA	540
CTGACTGATA	AAGCTGTACA	AATAAGCAGT	GTGCCTAACA	AGCAACACAG	TAATGTTGAC	600
ATGCTTAATT	CACAAATGCT	AATTTCAATTA	TAAATGTTTG	CTAAAATACA	CTTTGAACTA	660
TTTTTCTGTN	TTCCAGAGC	TGAGATNTTA	GATTTTATGT	AGTATNAAAGT	GAAAAANTAC	720
GAAATAATA	ACATTGAAGA	AAAANANAAA	AAANAAAAAA	A		761

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 482 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

TTTTTTTTTT	TTTGCCGATN	CTACTATTTT	ATTGCAGGAN	GTGGGGGTGT	ATGCACCGCA	60
CACCGGGGCT	ATNAGAAGCA	AGAAGGAAGG	AGGGAGGGCA	CAGCCCCTTG	CTGAGCAACA	120
AAGCCGCCTG	CTGCCTTCTC	TGTCTGTCTC	CTGGTGCAGG	CACATGGGGA	GACCTTCCCC	180

122

AAGGCAGGGG	CCACCAGTCC	AGGGGTGGGA	ATACAGGGGG	TGGGANGTGT	GCATAAGAAG	240
TGATAGGCAC	AGGCCACCCG	GTACAGACCC	CTCGGCTCCT	GACAGGTNGA	TTTCGACCAG	300
GTCATTGTGC	CCTGCCCAGG	CACAGCGTAN	ATCTGGAAAA	GACAGAATGC	TTTCCTTTTC	360
AAATTTGGCT	NGTCATNGAA	NGGGCANTTT	TCCAANTTNG	GCTNGGTCTT	GGTACNCTTG	420
GTTCTGGCCCA	GCTCCNCGTC	CAAAAANTAT	TCACCCNNCT	CCNAATTGCT	TGCNNGNCCC	480
CC						482

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

TTTTTTTTTT	TTTAAAACA	GTTTTTCACA	ACAAAATTTA	TTAGAAGAAT	AGTGGTTTTG	60
AAAACCTCTG	CATCCAGTGA	GAACCTACCAT	ACACCACATT	ACAGCTNGGA	ATGTNCTCCA	120
AATGTCTGGT	CAAATGATAC	AATGGAACCA	TTCAATCTTA	CACATGCACG	AAAGAACAAG	180
CGCTTTTGAC	ATACAATGCA	CAAAAAAAAA	AGGGGGGGGG	GACCACATGG	ATTTAAATTT	240
TAAGTACTCA	TCACATACAT	TAAGACACAG	TTCTAGTCCA	GTCNAAAATC	AGAAGTGCNT	300
TGAAAAATTT	CATGTATGCA	ATCCAACCAA	AGAACTTNAT	TGGTGATCAT	GANTNCTCTA	360
CTACATCNAC	CTTGATCATT	GCCAGGAACN	AAAAGTTNAA	ANCACNCNGT	ACAAAAANAA	420
TCTGTAATTN	ANTTCAACCT	CCGTACNGAA	AAATNTTNNT	TATACACTCC	C	471

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 402 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

GAGGGATTGA	AGGTCTGTTC	TASTGTCGGM	CTGTTTCAGCC	ACCAACTCTA	ACAAGTTGCT	60
GTCTTCCACT	CACTGTCTGT	AAGCTTTTTA	ACCCAGACWG	TATCTTCATA	AATAGAACAA	120
ATTCTTCACC	AGTCACATCT	TCTAGGACCT	TTTTGGATTC	AGTTAGTATA	AGCTCTTCCA	180
CTTCCTTTGT	TAAGACTTCA	TCTGGTAAAG	TCTTAAGTTT	TGTAGAAAGG	AATTYAATTG	240
CTCGTTCTCT	AACAATGTCC	TCTCCTTGAA	GTATTTGGCT	GAACAACCCA	CCTAAAGTCC	300
CTTTGTGCAT	CCATTTTAAA	TATACTTAAT	AGGGCATTGK	TNCACTAGGT	TAAATTCTGC	360
AAGAGTCATC	TGTCTGCAAA	AGTTGCGTTA	GTATATCTGC	CA		402

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 601 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

GAGCTCGGAT	CCAATAATCT	TTGTCTGAGG	GCAGCACACA	TATNCAGTGC	CATGGNAACT	60
GGTCTACCCC	ACATGGGAGC	AGCATGCCGT	AGNTATATAA	GGTCATTCCC	TGAGTCAGAC	120
ATGCYTYTTT	GAYTACCGTG	TGCCAAGTGC	TGGTGATTCT	YAACACACYT	CCATCCCGYT	180
CTTTTGTGGA	AAAAGTGGCA	CTTKTCTGGA	ACTAGCARGA	CATCACTTAC	AAATTCACCC	240
ACGAGACACT	TGAAAGGTGT	AACAAAGCGA	YTCTTGCACT	GCTTTTGTG	CCTCCGGCAC	300
CAGTTGTCAA	TACTAACCCG	CTGGTTTGCC	TCCATCACAT	TTGTGATCTG	TAGCTCTGGA	360
TACATCTCCT	GACAGTACTG	AAGAACTTCT	TCTTTTGTTC	CAAAAGCARG	TCTTGGTGCC	420
TGTTGGATCA	GGTTCCCAT	TCCCAGTCYG	AATGTTTACA	TGGCATATTT	WACTTCCAC	480
AAAACATTGC	GATTTGAGGC	TCAGCAACAG	CAAATCCTGT	TCCGGCATTG	GCTGCAAGAG	540
CCTCGATGTA	GCCGGCCAGC	GCCAAGGCAG	GCGCCGTGAG	CCCCACCAGC	AGCAGAAGCA	600
G						601

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 608 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

ATACAGCCCA	NATCCCACCA	CGAAGATGCG	CTTGTTGACT	GAGAACCTGA	TGCGGTCACT	60
GGTCCCGCTG	TAGCCCCAGC	GACTCTCCAC	CTGCTGGAAG	CGGTTGATGC	TGCACTCYTT	120
CCCAACGCAG	GCAGMAGCGG	GSCCGGTCAA	TGAACTCCAY	TCGTGGCTTG	GGGTKGACGG	180
TKAAGTGCAG	GAAGAGGCTG	ACCACCTCGC	GGTCCACCAG	GATGCCCCGAC	TGTGCGGGAC	240
CTGCAGCGAA	ACTCCTCGAT	GGTCATGAGC	GGGAAGCGAA	TGAGGCCCAG	GGCCTTGCCC	300
AGAACCTTCC	GCCTGTCTC	TGGCGTCACC	TGCAGCTGCT	GCCGCTGACA	CTCGGCCTCG	360
GACCAGCGGA	CAAACGGCRT	TGAACAGCCG	CACCTCACGG	ATGCCCAGTG	TGTCGCGCTC	420
CAGGAMMGSC	ACCAGCGTGT	CCAGGTCAAT	GTCGGTGAAG	CCCTCCGCGG	GTRATGGCGT	480
CTGCAGTGTT	TTTGTCGATG	TTCTCCAGGC	ACAGGCTGGC	CAGCTGCGGT	TCATCGAAGA	540
GTCGCGCCTG	CGTGAGCAGC	ATGAAGGCGT	TGTCGGCTCG	CAGTTCTTCT	TCAGGAACTC	600
CACGCAAT						608

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 392 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

GAACGGCTGG	ACCTTGCCTC	GCATTGTGCT	TGCTGGCAGG	GAATACCTTG	GCAAGCAGYT	60
CCAGTCCGAG	CAGCCCCAGA	CCGCTGCCGC	CCGAAGCTAA	GCCTGCCTCT	GGCCTTCCCC	120
TCCGCCTCAA	TGCAGAACCA	GTAGTGGGAG	CACTGTGTTT	AGAGTTAAGA	GTGAACACTG	180
TTTGATTTTA	CTTGGAATT	TCCTCTGTTA	TATAGCTTTT	CCCAATGCTA	ATTTCAAAC	240
AACAACAACA	AAATAACATG	TTTGCCTGTT	AAGTTGTATA	AAAGTAGGTG	ATTCTGTATT	300
TAAAGAAAAT	ATTACTGTTA	CATATACTGC	TTGCAATTTT	TGTATTTATT	GKTNCTSTGG	360
AAATAAATAT	AGTTATTAAA	GGTTGTCANT	CC			392

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 502 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

CCSTTKGAGG	GGTKAGGKYC	CAGTTYCCGA	GTGGAAGAAA	CAGGCCAGGA	GAAGTGCCTG	60
CCGAGCTGAG	GCAGATGTTT	CCACAGTGAC	CCCCAGAGCC	STGGGSTAT	GTYTCTGACC	120
CCTCNCAAGG	AAAGACCACS	TTCTGGGGAC	ATGGGCTGGA	GGGCAGGACC	TAGAGGCACC	180
AAGGGAAGGC	CCCATTCCGG	GGSTGTTCCC	CGAGGAGGAA	GGGAAGGGGC	TCTGTGTGCC	240
CCCCASGAGG	AAGAGGCCCT	GAGTCCTGGG	ATCAGACACC	CCTTCACGTG	TATCCCCACA	300
CAAATGCAAG	CTCACCAAGG	TCCCCTCTCA	GTCCCCCTTC	STACACCCTG	AMCGGCCACT	360
GSCSCACACC	CACCCAGAGC	ACGCCACCCG	CCATGGGGAR	TGTGCTCAAG	GARTCGCNGG	420
GCARCGTGGA	CATCTNGTCC	CAGAAGGGGG	CAGAATCTCC	AATAGANGGA	CTGARCMSTT	480
GCTNANAAAA	AAAAANAAAA	AA				502

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 665 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

GGTTACTTGG	TTTCATTGCC	ACCACTTAGT	GGATGTCATT	TAGAACCATT	TTGTCTGCTC	60
CCTCTGGAAG	CCTTGCGCAG	AGCGGACTTT	GTAATTGTTG	GAGAATAACT	GCTGAATTTT	120
WAGCTGTTTK	GAGTTGATTS	GCACCACTGC	ACCCACAAC	TCAATATGAA	AACYAWTTGA	180
ACTWATTTAT	TATCTTGTTA	AAAGTATAAC	AATGAAAATT	TTGTTCATAC	TGTATTKATC	240
AAGTATGATG	AAAAGCAAWA	GATATATATT	CTTTTATTAT	GTTAAATTAT	GATTGCCATT	300
ATTAATCGGC	AAAATGTGGA	GTGTATGTTT	TTTTCACAGT	AATATATGCC	TTTGTAACT	360
TCACTTGTTT	ATTTTATTGT	AAATGARTTA	CAAAATTCTT	AATTTAAGAR	AATGGTATGT	420
WATATTTAT	TCATTAATTT	CTTCCTKGT	TTACGTWAAT	TTTGAAAAGA	WTGCATGATT	480
TCTTGACAGA	AATCGATCTT	GATGCTGTGG	AAGTAGTTTG	ACCCACATCC	CTATGAGTTT	540
TTCTTAGAAT	GTATAAAGGT	TGTAGCCCAT	CNAACTTCAA	AGAAAAAAT	GACCACATAC	600
TTTGCAATCA	GGCTGAAATG	TGGCATGCTN	TTCTAATTCC	AACTTTATAA	ACTAGCAAAN	660
AAGTG						665

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 492 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

TTTNTTTTTT	TTTTTTTTTGC	AGGAAGGATT	CCATTTATTG	TGGATGCATT	TTCACAATAT	60
ATGTTTATTG	GAGCGATCCA	TTATCAGTGA	AAAGTATCAA	GTGTTTATAA	NATTTTTTAGG	120
AAGGCAGATT	CACAGAACAT	GCTNGTCNGC	TTGCAGTTTT	ACCTCGTANA	GATNACAGAG	180
AATTATAGTC	NAACCAGTAA	ACNAGGAATT	TACTTTTCAA	AAGATTAAAT	CCAAACTGAA	240
CAAAATTCTA	CCCTGAAACT	TACTCCATCC	AAATATTGGA	ATAANAGTCA	GCAGTGATAC	300
ATTCTCTTCT	GAACTTTAGA	TTTTCTAGAA	AAATATGTAA	TAGTGATCAG	GAAGAGCTCT	360
TGTTCAAAAG	TACAACNAAG	CAATGTTCCC	TTACCATAGG	CCTTAATTCA	AACTTTGATC	420
CATTTCACTC	CCATCACGGG	AGTCAATGCT	ACCTGGGACA	CTTGTATTTT	GTTTCATNCTG	480
ANCNTGGCTT	AA					492

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 478 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

TTTNTTTTGN	ATTTCANTCT	GTANNAANTA	TTTTCATTAT	GTTTATTANA	AAAATATNAA	60
TGNTTCCACN	ACAAATCATN	TTACNTNAGT	AAGAGGCCAN	CTACATTGTA	CAACATACAC	120
TGAGTATATT	TTGAAAAGGA	CAAGTTTAAA	GTANACNCAT	ATTGCCGANC	ATANCACATT	180
TATACATGGC	TTGATTGATA	TTTAGCACAG	CANAAACTGA	GTGAGTTACC	AGAAAANAAT	240
NATATATGTC	AATCNGATTT	AAGATACAAA	ACAGATCCTA	TGGTACATAN	CATCNTGTAG	300
GAGTTGTGGC	TTTATGTTTA	CTGAAAGTCA	ATGCAGTTCC	TGTACAAAGA	GATGGCCGTA	360
AGCATTCTAG	TACCTCTACT	CCATGGTTAA	GAATCGTACA	CTTATGTTTA	CATATGTNCA	420
GGGTAAGAAT	TGTGTTAAGT	NAANTTATGG	AGAGGTCCAN	GAGAAAAATT	TGATNCAA	478

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 482 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

AGTGACTTGT	CCTCCAACAA	AACCCCTTGA	TCAAGTTTGT	GGCACTGACA	ATCAGACCTA	60
TGCTAGTTCC	TGTCATCTAT	TCGCTACTAA	ATGCAGACTG	GAGGGGACCA	AAAAGGGGCA	120
TCAACTCCAG	CTGGATTATT	TTGGAGCCTG	CAAATCTATT	CCTACTTGTA	CGGACTTTGA	180
AGTGATTGAG	TTTCCTCTAC	GGATGAGAGA	CTGGCTCAAG	AATATCCTCA	TGCAGCTTTA	240
TGAAGCCNAC	TCTGAACACG	CTGGTTATCT	NAGATGAGAA	NCAGAGAAAT	AAAGTCNAGA	300
AAATTTACCT	GGANGAAAAG	AGGCTTTNGG	CTGGGGACCA	TCCCATTGAA	CCTTCTCTTA	360
ANGGACTTTA	AGAANAAACT	ACCACATGTN	TGTNGTATCC	TGGTGCCNGG	CCGTTTANTG	420
AACNTNGACN	NCACCCTTNT	GGAATANANT	CTTGACNGCN	TCCTGAACTT	GCTCCTCTGC	480
GA						482

(2) INFORMATION FOR SEQ ID NO:200:

126

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 270 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TCGGACGAA GATTCTGCCA GCAGTTGGTC	60
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC	120
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA	180
CAGCCGGAAC AGAGCCCGGT GAANGCGGA GGCCTCGGG AGCCCTCGG GAAGGGCGGC	240
CCGAGAGATA CGCAGGTGCA GGTGGCCGCC	270

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 419 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

TTTTTTTTTT TTTTGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA	60
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTTAC GTCAACTTCC TTTGTCGTGG	120
TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAANCGAAGC ANAANTAACA	180
TGGAGTGGGT GCACCCTCCC TGTAGAACCT GTTACNAAA GCTTGGGGCA GTTCACCTGG	240
TCTGTGACCG TCATTTTCTT GACATCAATG TTATTAGAAG TCAGGATATC TTTTAGAGAG	300
TCCACTGTNT CTGGAGGGAG ATTAGGGTTT CTTGCCAANA TCCAANCAAA ATCCACNTGA	360
AAAAGTTGGA TGATNCANGT ACNGAATACC GANGGCATAN TTCTCATANT CGGTGGCCA	419

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 509 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

TTTNTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT	60
TGGCACTTAA TCCATTTTTA TTTCAAAATG TCTACAAANT TTNAATNCNC CATTATACNG	120
GTNATTTTNC AAAATCTAAA NNTTATTCAA ATNTNAGCCA AANTCCTTAC NCAAAATNNAA	180
TACNCNCAAA AATCAAAAAT ATACNTNTCT TTCAGCAAAC TTNGTTACAT AAATTAAGAA	240
AATATATACG GCTGGTGTTT TCAAAGTACA ATTATCTTAA CACTGCAAAC ATNTTTNNAA	300
GGAACATAAA TAAAAAATAA CACTNCCGCA AAGGTAAAG GGAACAACAA ATTCNTTTTA	360
CAACANCNNC NATTATAAAA ATCATATCTC AAATCTTAGG GGAATATATA CTTACACNG	420
GGATCTTAAC TTTTACTNCA CTTTGTATT TTTTTTANAA CCATTGTNTT GGGCCCAACA	480
CAATGGNAAT NCCNCCNCNC TGGACTAGT	509

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

TTTTNTTTTT	TTTTTTTTTGC	AGGAAGGATT	CCATTTATTG	TGGATGCATT	TTCACAATAT	60
ATGTTTATTG	GAGCGATCCA	TTATCAGTGA	AAAGTATCAA	GTGTTTATAA	NATTTTTAGG	120
AAGGCAGATT	CACAGAACAT	GCTNGTCNGC	TTGCAGTTTT	ACCTCGTANA	GATNACAGAG	180
AATTATAGTC	NAACCAGTAA	ACNAGGAATT	TACTTTTCAA	AAGATTAAAT	CCAAACTGAA	240
CAAAATTCTA	CCCTGAAACT	TACTCCATCC	AAATATTGGA	ATAANAGTCA	GCAGTGATAC	300
ATTCTCTTCT	GAACTTTAGA	TTTTCTAGAA	AAATATGTAA	TAGTGATCAG	GAAGAGCTCT	360
TGTTCAAAAG	TACAACNAAG	CAATGTTCCC	TTACCATAGG	CCTTAATTCA	AACTTTGATC	420
CATTTCACTC	CCATCACGGG	AGTCAATGCT	ACCTGGGACA	CTTGTATTTT	GTTTCATNCTG	480
ANCNTGGCTT	AA					492

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 478 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

TTTNTTTTGN	ATTTCACTCT	GTANNAANTA	TTTTCATTAT	GTTTATTANA	AAAATATNAA	60
TGTNTCCACN	ACAAATCATN	TTACNTNAGT	AAGAGGCCAN	CTACATTGTA	CAACATACAC	120
TGAGTATATT	TTGAAAAGGA	CAAGTTTAAA	GTANACNCAT	ATTGCCGANC	ATANCACATT	180
TATACATGGC	TTGATTGATA	TTTAGCACAG	CANAACTGA	GTGAGTTACC	AGAAANAAAT	240
NATATATGTC	AATCNGATTT	AAGATACAAA	ACAGATCCTA	TGGTACATAN	CATCNTGTAG	300
GAGTTGTGGC	TTTATGTTTA	CTGAAAGTCA	ATGCAGTTCC	TGTACAAAGA	GATGGCCGTA	360
AGCATTCTAG	TACCTCTACT	CCATGGTTAA	GAATCGTACA	CTTATGTTTA	CATATGTNCA	420
GGGTAAGAAT	TGTGTAAAGT	NAANTTATGG	AGAGGTCCAN	GAGAAAAATT	TGATNCAA	478

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 482 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

AGTGACTTGT	CCTCCAACAA	AACCCCTTGA	TCAAGTTTGT	GGCACTGACA	ATCAGACCTA	60
TGCTAGTTCC	TGTCATCTAT	TCGCTACTAA	ATGCAGACTG	GAGGGGACCA	AAAAGGGGCA	120
TCAACTCCAG	CTGGATTATT	TTGGAGCCTG	CAAATCTATT	CCTACTTGTA	CGGACTTTGA	180
AGTGATTCAG	TTTCCTCTAC	GGATGAGAGA	CTGGCTCAAG	AATATCCTCA	TGCAGCTTTA	240
TGAAGCCNAC	TCTGAACACG	CTGGTTATCT	NAGATGAGAA	NCAGAGAAAT	AAAGTCNAGA	300
AAATTTACCT	GGANGAAAAG	AGGCTTTNGG	CTGGGGACCA	TCCCATTTGAA	CCTTCTCTTA	360
ANGGACTTTA	AGAANAAACT	ACCACATGTN	TGTNGTATCC	TGGTGCCNGG	CCGTTTANTG	420
AACNTNGACN	NCACCCTTNT	GGAATANANT	CTTGACNGCN	TCCTGAACTT	GCTCCTCTGC	480
GA						482

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 270 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

CGGCCGCAAG TGCAACTCCA GCTGGGGCCG TCGGACGAA GATTCTGCCA GCAGTTGGTC	60
CGACTGCGAC GACGGCGGCG GCGACAGTCG CAGGTGCAGC GCGGGCGCCT GGGGTCTTGC	120
AAGGCTGAGC TGACGCCGCA GAGGTCGTGT CACGTCCCAC GACCTTGACG CCGTCGGGGA	180
CAGCCGGAAC AGAGCCCGGT GAANGCGGGA GGCCTCGGGG AGCCCTCGG GAAGGGCGGC	240
CCGAGAGATA CGCAGGTGCA GGTGGCCGCC	270

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 419 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

TTTTTTTTTT TTTTGAATC TACTGCGAGC ACAGCAGGTC AGCAACAAGT TTATTTTGCA	60
GCTAGCAAGG TAACAGGGTA GGGCATGGTT ACATGTTTCC GTCAACTTCC TTTGTCGTGG	120
TTGATTGGTT TGTCTTTATG GGGGCGGGGT GGGGTAGGGG AAANCGAAGC ANAANTAACA	180
TGGAGTGGGT GCACCCTCCC TGTAAGAACT GGTACNAAA GCTTGGGGCA GTTCACCTGG	240
TCTGTGACCG TCATTTTCTT GACATCAATG TTATTAGAAG TCAGGATATC TTTTAGAGAG	300
TCCACTGTNT CTGGAGGGAG ATTAGGGTTT CTTGCCAANA TCCAANCAAA ATCCACNTGA	360
AAAAGTTGGA TGATNCANGT ACNGAATACC GANGGCATAN TTCTCATANT CCGTGGCCA	419

(2) INFORMATION FOR SEQ ID NO:202:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 509 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

TTTNTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT	60
TGGCACTTAA TCCATTTTAA TTTCAAAATG TCTACAAANT TTNAATNCNC CATTATACNG	120
GTNATTTTNC AAAATCTAAA NNTTATTCAA ATNTNAGCCA AANTCCTTAC NCAAAATNAA	180
TACNCNCAAA AATCAAAAAT ATACNTNTCT TTCAGCAAAC TINGTTACAT AAATTAAGAA	240
AATATATACG GCTGGTGTTT TCAAAGTACA ATTATCTTAA CACTGCAAAC ATNTTTNNAA	300
GGAACATAAA TAAAAAATAA CACTNCCGCA AAGGTAAAG GGAACAACAA ATTCNTTTTA	360
CAACANCNNC NATTATAAAA ATCATATCTC AAATCTTAGG GGAATATATA CTTCACACNG	420
GGATCTTAAC TTTTACTNCA CTTTGTATAT TTTTTTANAA CCATTGTNTT GGGCCCAACA	480
CAATGGNAAT NCCNCCNCNC TGGACTAGT	509

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 583 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

```

TTTTTTTTTT TTTTTTTTGA CCCCCCTCTT ATAAAAAACA AGTTACCATT TTATTTTACT      60
TACACATATT TATTTTATAA TTGGTATTAG ATATTCAAAA GGCAGCTTTT AAAATCAAAC      120
TAAATGGAAA CTGCCTTAGA TACATAATTC TTAGGAATTA GCTTAAAATC TGCCTAAAGT      180
GAAAATCTTC TCTAGCTCTT TTGACTGTAA ATTTTGTACT CTTGTAAAAC ATCCAAATTC      240
ATTTTCTCTG TCTTTAAAAT TATCTAATCT TTCCATTTTT TCCCTATTCC AAGTCAATTT      300
GCTTCTCTAG CCTCATTTC TAGCTCTTAT CTACTATTAG TAAGTGGCTT TTTTCCTAAA      360
AGGGAAAACA GGAAGAGANA ATGGCACACA AAACAAACAT TTTATATTCA TATTTCTACC      420
TACGTTAATA AAATAGCATT TTGTGAAGCC AGCTCAAAAG AAGGCTTAGA TCCTTTTATG      480
TCCATTTTAG TCACTAAACG ATATCNAAAG TGCCAGAATG CAAAAGGTTT GTGAACATTT      540
ATTCAAAAGC TAATATAAGA TATTTACAT ACTCATCTTT CTG                               583

```

(2) INFORMATION FOR SEQ ID NO:204:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 589 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

```

TTTTTTTTNT TTTTTTTTTT TTTTTNCTC TTCTTTTTTT TTGANAATGA GGATCGAGTT      60
TTTCACTCTC TAGATAGGGC ATGAAGAAAA CTCATCTTTC CAGCTTTAAA ATAACAATCA      120
AATCTCTTAT GCTATATCAT ATTTTAAGTT AAATAATGA GTCCTGGCT TATCTTCTCC      180
TGAAGGAAAT CTGTTTCATT TTCTCATTCA TATAGTTATA TCAAGTACTA CCTTGCATAT      240
TGAGAGGTTT TTCTTCTCTA TTTACACATA TATTTCCATG TGAATTTGTA TCAAACCTTT      300
ATTTTCATGC AAATAAGAAA ATAATGTNTT CTTTTCGATA AGAGAAGAGA ACAATATNAG      360
CATTACAAAA CTGCTCAAAT TGTTGTGTTA GNTTATCCAT TATAATTAGT TNGGCAGGAG      420
CTAATACAAA TCACATTTAC NGACNAGCAA TAATAAAACT GAAGTACCAG TTAAATATCC      480
AAAATAATTA AAGGAACATT TTAGCCTGG GTATAATTAG CTAATTCAT TTACAAGCAT      540
TTATTNAGAA TGAATTCACA TGTTATTATT CCNTAGCCCA ACACAATGG                               589

```

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 545 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

128

TTTTTNTTTT	TTTTTTCAGT	AATAATCAGA	ACAATATTTA	TTTTTATATT	TAAAATTCAT	60
AGAAAAGTGC	CTTACATTTA	ATAAAAGTTT	GTTTCTCAAA	GTGATCAGAG	GAATTAGATA	120
TNGTCTTGAA	CACCAATATT	AATTGAGGA	AAATACACCA	AAATACATTA	AGTAAATTAT	180
TTAAGATCAT	AGAGCTTGTA	AGTGAAAAGA	TAAAATTTGA	CCTCAGAAAC	TCTGAGCATT	240
AAAAATCCAC	TATTAGCAAA	TAAATTACTA	TGGACTTCTT	GCTTTAATTT	TGTGATGAAT	300
ATGGGGTGTC	ACTGGTAAAC	CAACACATTC	TGAAGGATAC	ATTACTTAGT	GATAGATTCT	360
TATGTACTTT	GCTANATNAC	GTGGATATGA	GTTGACAAGT	TTCTCTTTCT	TCAATCTTTT	420
AAGGGGCNGA	NGAAATGAGG	AAGAAAAGAA	AAGGATTACG	CATACTGTTC	TTTCTATNGG	480
AAGGATTAGA	TATGTTTCCT	TTGCCAATAT	TAAAAAATA	ATAATGTTTA	CTACTAGTGA	540
AACCC						545

(2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 487 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

TTTTTTTTTT	TTTTTTAGTC	AAGTTTCTNA	TTTTTATTAT	AATTAAAGTC	TTGGTCATT	60
CATTTATTAG	CTCTGCAACT	TACATATTTA	AATTAAAGAA	ACGTTNTTAG	ACAACTGTNA	120
CAATTATATA	ATGTAAGGTG	CCATTATTGA	GTANATATAT	TCCTCCAAGA	GTGGATGTGT	180
CCCTTCTCCC	ACCAACTAAT	GAANCAGCAA	CATTAGTTTA	ATTTTATTAG	TAGATNATAC	240
ACTGCTGCAA	ACGCTAATTC	TCTTCTCCAT	CCCCATGTNG	ATATTGTGTA	TATGTGTGAG	300
TTGGTNAGAA	TGCATCANCA	ATCTNACAAT	CAACAGCAAG	ATGAAGCTAG	GCNTGGGCTT	360
TCGGTGAAAA	TAGACTGTGT	CTGTCTGAAT	CAAATGATCT	GACCTATCCT	CGGTGGCAAG	420
AACTCTTCGA	ACCGCTTCCT	CAAAGGCNGC	TGCCACATTT	GTGCNTCTN	TTGCACTTGT	480
TTCAAAA						487

(2) INFORMATION FOR SEQ ID NO:207:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 332 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

TGAATTGGCT	AAAAGACTGC	ATTTTANAA	CTAGCAACTC	TTATTTCTTT	CCTTTAAAAA	60
TACATAGCAT	TAAATCCCAA	ATCCTATTTA	AAGACCTGAC	AGCTTGAGAA	GGTCACTACT	120
GCATTTATAG	GACCTTCTGG	TGGTCTGCT	GTTACNTTTG	AANTCTGACA	ATCCTTGANA	180
ATCTTTGCAT	GCAGAGGAGG	TAAAAGGTAT	TGGATTTTCA	CAGAGGAANA	ACACAGCGCA	240
GAAATGAAGG	GGCCAGGCTT	ACTGAGCTTG	TCCACTGGAG	GGCTCATGGG	TGGGACATGG	300
AAAAGAAGGC	AGCCTAGGCC	CTGGGGAGCC	CA			332

(2) INFORMATION FOR SEQ ID NO:208:

(i) SEQUENCE CHARACTERISTICS:

129

- (A) LENGTH: 524 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

```

AGGGCGTGGT GCGGAGGGCG TTACTGTTTT GTCTCAGTAA CAATAAATAC AAAAAGACTG      60
GTTGTGTTCC GGCCCCATCC AACCACGAAG TTGATTTCTC TTGTGTGCAG AGTGACTGAT      120
TTTAAAGGAC ATGGAGCTTG TCACAATGTC ACAATGTCAC AGTGTGAAGG GCACACTCAC      180
TCCCGCGTGA TTCACATTTA GCAACCAACA ATAGCTCATG AGTCCATACT TGTAATAACT      240
TTTGGCAGAA TACTTNTTGA AACTTGCAGA TGATAACTAA GATCCAAGAT ATTTCCCAAA      300
GTAAATAGAA GTGGGTCATA ATATTAATTA CCTGTTCACA TCAGCTTCCA TTTACAAGTC      360
ATGAGCCCAG AACTGACAT CAAACTAAGC CCACTTAGAC TCCTCACCAC CAGTCTGTCC      420
TGTCA TCAGA CAGGAGGCTG TCACCTTGAC CAAATTCTCA CCAGTCAATC ATCTATCCAA      480
AAACCATTAC CTGATCCACT TCCGGTAATG CACCACCTTG GTGA                        524

```

(2) INFORMATION FOR SEQ ID NO:209:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 159 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

```

GGGTGAGGAA ATCCAGAGTT GCCATGGAGA AAATTCCAGT GTCAGCATTG TTGCTCCTTG      60
TGGCCCTCTC CTACACTCTG GCCAGAGATA CCACAGTCAA ACCTGGAGCC AAAAAGGACA      120
CAAAGGACTC TCGACCCAAA CTGCCCCAGA CCCTCTCCA                        159

```

(2) INFORMATION FOR SEQ ID NO:210:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 256 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

```

ACTCCCTGGC AGACAAAGGC AGAGGAGAGA GCTCTGTTAG TTCTGTGTTG TTGAACTGCC      60
ACTGAATTTT TTTCCACTTG GACTATTACA TGCCANTTGA GGGACTAATG GAAAAACGTA      120
TGGGGAGATT TTANCCAATT TANGTNTGTA AATGGGGAGA CTGGGGCAGG CGGGAGAGAT      180
TTGCAGGGTG NAAATGGGAN GGCTGGTTTG TTANATGAAC AGGGACATAG GAGGTAGGCA      240
CCAGGATGCT AAATCA                        256

```

(2) INFORMATION FOR SEQ ID NO:211:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 264 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

```

ACATTGTTTT TTTGAGATAA AGCATTGAGA GAGCTCTCCT TAACGTGACA CAATGGAAGG      60
ACTGGAACAC ATACCCACAT CTTGTTCCTG AGGGATAATT TTCTGATAAA GTCTTGCTGT      120
ATATTCAAGC ACATATGTTA TATATTATTC AGTTCCATGT TTATAGCCTA GTTAAGGAGA      180
GGGGAGATAC ATTCNGAAAG AGGACTGAAA GAAATACTCA AGTNGGAAAA CAGAAAAAGA      240
AAAAAAGGAG CAAATGAGAA GCCT                                     264

```

(2) INFORMATION FOR SEQ ID NO:212:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 328 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

```

ACCCAAAAAT CCAATGCTGA ATATTTGGCT TCATTATTCC CANATTCTTT GATTGTCAAA      60
GGATTTAATG TTGTCTCAGC TTGGGCACTT CAGTTAGGAC CTAAGGATGC CAGCCGGCAG      120
GTTTATATAT GCAGCAACAA TATTCAAGCG CGACAACAGG TTATTGAACT TGCCCCCCAG      180
TTNAATTTCA TTCCCATGTA CTTGGGATCC TTATCATCAG CCAGAGAGAT TGAAAATTTA      240
CCCCTACNAC TCTTTACTCT CTGGANAGGG CCAGTGGTGG TAGCTATAAG CTTGGCCACA      300
TTTTTTTTTC CTTTATTCCT TTGTCAGA                                     328

```

(2) INFORMATION FOR SEQ ID NO:213:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 250 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

```

ACTTATGAGC AGAGCGACAT ATCCNAGTGT AGACTGAATA AACTGAATT CTCTCCAGTT      60
TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT      120
CATTATGCCA AAGGANATAT ACATTTCAAT TCTCCAAACT TCTTCTCAT TCCAAGAGTT      180
TTCAATATTT GCATGAACCT GCTGATAANC CATGTTAANA AACAAATATC TCTCTNACCT      240
TCTCATCGGT                                     250

```

(2) INFORMATION FOR SEQ ID NO:214:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 444 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

ACCCAGAATC	CAATGCTGAA	TATTTGGCTT	CATTATTCCC	AGATTCTTTG	ATTGTCAAAG	60
GATTTAATGT	TGTCTCAGCT	TGGGCACTTC	AGTTAGGACC	TAAGGATGCC	AGCCGGCAGG	120
TTTATATATG	CAGCAACAAT	ATTCAAGCGC	GACAACAGGT	TATTGAACCT	GCCCGCCAGT	180
TGAATTTTAT	TCCCATTGAC	TTGGGATCCT	TATCATCAGC	CANAGAGATT	GAAAAATTAC	240
CCCTACGACT	CTTTACTCTC	TGGAGAGGGC	CAGTGGTGGT	AGCTATAAGC	TTGGCCACAT	300
TTTTTTTTTC	TTTATTCCTT	TGTCAGAGAT	GCGATTTCATC	CATATGCTAN	AAACCAACAG	360
AGTGACTTTT	ACAAAATTCC	TATAGANATT	GTGAATAAAA	CCTTACCTAT	AGTTGCCATT	420
ACTTTGCTCT	CCCTAATATA	CCTC				444

(2) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 366 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

ACTTATGAGC	AGAGCGACAT	ATCCAAGTGT	ANACTGAATA	AAACTGAATT	CTCTCCAGTT	60
TAAAGCATTG	CTCACTGAAG	GGATAGAAGT	GACTGCCAGG	AGGGAAAGTA	AGCCAAGGCT	120
CATTATGCCA	AAGGANATAT	ACATTTCAAT	TCTCCAAACT	TCTTCCTCAT	TCCAAGAGTT	180
TTCAATATTT	GCATGAACCT	GCTGATAAGC	CATGTTGAGA	AACAAATATC	TCTCTGACCT	240
TCTCATCGGT	AAGCAGAGGC	TGTAGGCAAC	ATGGACCATA	GCGAANAAAA	AACTTAGTAA	300
TCCAAGCTGT	TTTCTACACT	GTAACCAGGT	TTCCAACCAA	GGTGGAATC	TCCTATACTT	360
GGTGCC						366

(2) INFORMATION FOR SEQ ID NO:216:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 260 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

CTGTATAAAC	AGAACTCCAC	TGCANGAGGG	AGGGCCGGGC	CAGGAGAATC	TCCGCTTGTC	60
CAAGACAGGG	GCCTAAGGAG	GGTCTCCACA	CTGCTNNTAA	GGGCTNTNC	ATTTTTTTAT	120
TAATAAAAAG	TNNAAGG	CTCTTCTCAA	CTTTTTTCCC	TNNGGCTGGA	AAATTTAAAA	180
ATCAAAAATT	TCCTNAAGTT	NTCAAGCTAT	CATATATACT	NTATCCTGAA	AAAGCAACAT	240

AATTCTTCCT TCCCTCCTTT

260

(2) INFORMATION FOR SEQ ID NO:217:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 262 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

ACCTACGTGG	GTAAGTTTAN	AAATGTTATA	ATTTTCAGGAA	NAGGAACGCA	TATAATTGTA	60
TCTTGCCTAT	AATTTTCTAT	TTTAATAAGG	AAATAGCAAA	TTGGGGTGGG	GGGAATGTAG	120
GGCATTCTAC	AGTTTGAGCA	AAATGCAATT	AAATGTGGAA	GGACAGCACT	GAAAAATTTT	180
ATGAATAATC	TGTATGATTA	TATGTCTCTA	GAGTAGATTT	ATAATTAGCC	ACTTACCCTA	240
ATATCCTTCA	TGCTTGTAAG	GT				262

(2) INFORMATION FOR SEQ ID NO:218:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

ACCAAGGTGG	TGCATTACCG	GAANTGGATC	AANGACACCA	TCGTGGCCAA	CCCCTGAGCA	60
CCCCTATCAA	CTCCCTTTTG	TAGTAAACTT	GGAACCTTGG	AAATGACCAG	GCCAAGACTC	120
AGGCCTCCCC	AGTTCTACTG	ACCTTTGTCC	TTANGTNTNA	NGTCCAGGGT	TGCTAGGAAA	180
ANAAATCAGC	AGACACAGGT	GTAAA				205

(2) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 114 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

TACTGTTTTG	TCTCAGTAAC	AATAAATACA	AAAAGACTGG	TTGTGTTCCG	GCCCCATCCA	60
ACCACGAAGT	TGATTTCTCT	TGTGTGCAGA	GTGACTGATT	TTAAAGGACA	TGGA	114

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:

133

- (A) LENGTH: 93 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

ACTAGCCAGC ACAAAGGCA GGGTAGCCTG AATTGCTTTC TGCTCTTTAC ATTTCTTTTA	60
AAATAAGCAT TTAGTGCTCA GTCCCTACTG AGT	93

(2) INFORMATION FOR SEQ ID NO:221:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 167 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

ACTANGTGCA GGTGCGCACA AATATTGTC GATATTCCCT TCATCTTGGA TTCCATGAGG	60
TCTTTTGCCC AGCCTGTGGC TCTACTGTAG TAAGTTTCTG CTGATGAGGA GCCAGNATGC	120
CCCCCACTAC CTTCCCTGAC GCTCCCCANA AATCACCCAA CCTCTGT	167

(2) INFORMATION FOR SEQ ID NO:222:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 351 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

AGGGCGTGGT GCGGAGGGCG GTACTGACCT CATTAGTAGG AGGATGCATT CTGGCACCCC	60
GTTCTTCACC TGTCCCCCAA TCCTTAAAAG GCCATACTGC ATAAAGTCAA CAACAGATAA	120
ATGTTTGCTG AATTAAAGGA TGGATGAAAA AAATTAATAA TGAATTTTGT CATAATCCAA	180
TTTTCTCTTT TATATTTCTA GAAGAAGTTT CTTTGAGCCT ATTAGATCCC GGGAATCTTT	240
TAGGTGAGCA TGATTAGAGA GCTTGTAGGT TGCTTTTACA TATATCTGGC ATATTTGAGT	300
CTCGTATCAA AACAATAGAT TGGTAAAGGT GGTATTATTG TATTGATAAG T	351

(2) INFORMATION FOR SEQ ID NO:223

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 383 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

AAAACAAACA AACAAAAAAA ACAATTCTTC ATTCAGAAAA ATTATCTTAG GGA	60
TTGTAATTAT GGTCAATTTA ATWRTRTTKT GGGGCATTTT CTTACATTGT CTTGACAAGA	120
TTAAAATGTC TGTGCCAAAA TTTTGTATTT TATTTGGAGA CTTCTTATCA AAAGTAATGC	180
TGCCAAAGGA AGTCTAAGGA ATTAGTAGTG TTCCCMTCAC TTGTTTGGAG TGTGCTATTC	240
TAAAAGATTT TGATTTCCTG GAATGACAAT TATATTTTAA CTTTGGTGGG GGAAANAGTT	300
ATAGGACCAC AGTCTTCACT TCTGATACTT GTAAATTAAT CTTTATTGCG ACTTGT	360
TTTGTGTTG ACCATTAAGC TATATGTTTA AAA	383

(2) INFORMATION FOR SEQ ID NO:224

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 320 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224

CCCCTGAAGG CTTCTTGTTA GAAAATAGTA CAGTTACAAC CAATAGGAAC AACAAAAAGA	60
AAAAGTTTGT GACATTGTAG TAGGGAGTGT GTACCCCTTA CTCCCATCA AAAAAAAT	120
GGATACATGG TTAAAGGATA RAAGGGCAAT ATTTTATCAT ATGTTCTAAA AGAGAAGGAA	180
GAGAAAATAC TACTTTCTCR AAATGGAAGC CCTTAAAGGT GCTTTGATAC TGAAGGACAC	240
AAATGTGGCC GTCCATCCTC CTTTARAGTT GCATGACTTG GACACGGTAA CTGTTGCAGT	300
TTTARACTCM GCATTGTGAC	320

CLAIMS

1. A method for detecting prostate cancer in a patient, comprising:
 - (a) contacting a biological sample obtained from the patient with a binding agent which is capable of binding to a polypeptide, the polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences and variants of said nucleotide sequences; and
 - (b) detecting in the sample a protein or polypeptide that binds to the binding agent, thereby detecting prostate cancer in the patient.
2. The method of claim 1 wherein the binding agent is a monoclonal antibody.
3. The method of claim 2 wherein the binding agent is a polyclonal antibody.
4. A method for monitoring the progression of prostate cancer in a patient, comprising:
 - (a) contacting a biological sample obtained from the patient with a binding agent that is capable of binding to a polypeptide, said polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences and variants of said nucleotide sequences;
 - (b) determining in the sample an amount of a protein or polypeptide that binds to the binding agent;
 - (c) repeating steps (a) and (b); and

(d) comparing the amount of polypeptide detected in steps (b) and (c) to monitor the progression of prostate cancer in the patient.

5. A monoclonal antibody that binds to a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, wherein said protein comprises an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 8-29, 41-45, 47-52, 54-65, 70, 73, 74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 109-111, 115-160, 171, 173-175, 177, 181, 188, 191, 193, 194, 198, 203, 204, 207, 209-211, 220, 222-224, the complements of said nucleotide sequences variants of said nucleotide sequences.

6. A method for inhibiting the development of prostate cancer in a patient, comprising administering to the patient a therapeutically effective amount of a monoclonal antibody according to claim 5.

7. The method of claim 6 wherein the monoclonal antibody is conjugated to a therapeutic agent.

8. A method for detecting prostate cancer in a patient comprising:

- (a) obtaining a biological sample from the patient;
- (b) contacting the sample with at least two oligonucleotide primers in a polymerase chain reaction, wherein at least one of the oligonucleotides is specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or of a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences variants of said nucleotide sequences; and
- (c) detecting in the sample a DNA sequence that amplifies in the presence of the oligonucleotide primers, thereby detecting prostate cancer.

9. The method of claim 8, wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a DNA molecule having a sequence selected from SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.

10. A diagnostic kit comprising:

- (a) one or more monoclonal antibodies of claim 5; and
- (b) a detection reagent.

11. A diagnostic kit comprising:

- (a) one or more monoclonal antibodies that bind to a polypeptide encoded by a DNA molecule having a nucleotide sequence selected from the group consisting of SEQ ID Nos: 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106, 161-170, 179, 180, 182-187, 189, 190, 192, 195-197, 199-202, 205, 206, 208, 212-219, 221, the complements of said sequences and variants of said nucleotide sequences; and
- (b) a detection reagent.

12. The kit of claims 10 or 11 wherein the monoclonal antibodies are immobilized on a solid support.

13. The kit of claim 12 wherein the solid support comprises nitrocellulose, latex or a plastic material.

14. The kit of claims 10 or 11 wherein the detection reagent comprises a reporter group conjugated to a binding agent.

15. The kit of claim 14 wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.

16. The kit of claim 14 wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

17. A diagnostic kit comprising at least two oligonucleotide primers, at least one of the oligonucleotide primers being specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences and variants of said nucleotide sequences.

18. A diagnostic kit of claim 17 wherein at least one of the oligonucleotide primers comprises at least about 10 contiguous nucleotides of a DNA molecule having a sequence selected from SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.

19. A method for detecting prostate cancer in a patient, comprising:

- (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with an oligonucleotide probe specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences and variants of said nucleotide sequences; and
- (c) detecting in the sample a DNA sequence that hybridizes to the oligonucleotide probe, thereby detecting prostate cancer in the patient.

20. The method of claim 19 wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule having a sequence selected from the group consisting of SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.

21. A diagnostic kit comprising an oligonucleotide probe specific for a DNA molecule encoding a polypeptide comprising an immunogenic portion of a prostate

protein or a variant thereof, said protein comprising an amino acid sequence encoded by a DNA molecule having a sequence selected from the group consisting of nucleotide sequences recited in SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224, the complements of said nucleotide sequences variants of said nucleotide sequences.

22. The diagnostic kit of claim 21, wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule having a sequence selected from the group consisting of SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/574, 33/577, C07K 16/30, A61K 39/395, 47/48, C12Q 1/68, G01N 33/543		A2	(11) International Publication Number: WO 98/37418							
			(43) International Publication Date: 27 August 1998 (27.08.98)							
(21) International Application Number: PCT/US98/03690		(81) Designated States: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).								
(22) International Filing Date: 25 February 1998 (25.02.98)		<p>Published</p> <p><i>Without international search report and to be republished upon receipt of that report.</i></p>								
(30) Priority Data:										
<table border="0"> <tr> <td>08/806,596</td> <td>25 February 1997 (25.02.97)</td> <td>US</td> </tr> <tr> <td>08/904,809</td> <td>1 August 1997 (01.08.97)</td> <td>US</td> </tr> <tr> <td>09/020,747</td> <td>9 February 1998 (09.02.98)</td> <td>US</td> </tr> </table>				08/806,596	25 February 1997 (25.02.97)	US	08/904,809	1 August 1997 (01.08.97)	US	09/020,747
08/806,596	25 February 1997 (25.02.97)	US								
08/904,809	1 August 1997 (01.08.97)	US								
09/020,747	9 February 1998 (09.02.98)	US								
(71) Applicant: CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).										
(72) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US).										
(74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).										
(54) Title: COMPOUNDS FOR IMMUNODIAGNOSIS OF PROSTATE CANCER AND METHODS FOR THEIR USE										
(57) Abstract										
<p>Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.</p>										

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/574, 33/577, C07K 16/30, A61K 39/395, 47/48, C12Q 1/68, G01N 33/543		A3	(11) International Publication Number: WO 98/37418
			(43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/03690		(81) Designated States: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 25 February 1998 (25.02.98)			
(30) Priority Data: 08/806,596 25 February 1997 (25.02.97) US 08/904,809 1 August 1997 (01.08.97) US 09/020,747 9 February 1998 (09.02.98) US			
(71) Applicant: CORIXA CORPORATION [US/US]; Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US).			
(72) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US).			
(74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).			
		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
		(88) Date of publication of the international search report: 25 February 1999 (25.02.99)	

(54) Title: COMPOUNDS FOR IMMUNODIAGNOSIS OF PROSTATE CANCER AND METHODS FOR THEIR USE

(57) Abstract

Compounds and methods for diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. The inventive polypeptides may be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BK	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

PC., US 98/03690

IPC 6 G01N33/574 G01N33/577 G01N33/543 C07K16/30 C12Q1/68
A61K39/395 A61K47/48

B. FIELDS SEARCHED

IPC 6 C120 C07K

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 21671 A (UNIV COLUMBIA ; FISHER PAUL B (US); SHEN RUOQUAN (US)) 18 July 1996 see the whole document ---	1-10, 12-22
A	EL-SHIRBINY A M: "PROSTATIC SPECIFIC ANTIGEN" ADVANCES IN CLINICAL CHEMISTRY, vol. 31, 1994, pages 99-133, XP000617158 see the whole document ---	1-10, 12-22
A	WO 93 14775 A (WRIGHT GEORGE L JR) 5 August 1993 see the whole document ---	1-10, 12-22
	--- -/--	

☒ Patent family members are listed in annex.

- *A*** document defining the general state of the art which is not considered to be of particular relevance
- *E*** earlier document but published on or after the international filing date
- *L*** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O*** document referring to an oral disclosure, use, exhibition or other means
- *P*** document published prior to the international filing date but later than the priority date claimed

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of mailing of the international search report

30 DEC 1998

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

International Application No

PC1, JS 98/03690

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 09820 A (SLOAN KETTERING INST CANCER ;ISRAELI RON S (US); HESTON WARREN D W) 11 May 1994 see the whole document ---	1-10, 12-22
A	WO 95 04548 A (JENNER TECHNOLOGIES) 16 February 1995 see the whole document ---	1-10, 12-22
A	ROBSON C N ET AL: "IDENTIFICATION OF PROSTATIC ANDROGEN REGULATED GENES USING THE DIFFERENTIAL DISPLAY TECHNIQUE" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, TORONTO, MAR. 18 - 22, 1995, no. MEETING 86, 18 March 1995, AMERICAN ASSOCIATION FOR CANCER RESEARCH, page 266 XP002019344 see the whole document ---	1-10, 12-22
A	BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR" PROSTATE, vol. 26, no. 4, April 1995, pages 213-224, XP000611577 see the whole document ---	1-10, 12-22
A	ALEXEYEV ET AL.: "IMPROVED ANTIBIOTIC-RESISTANCE GENE CASSETTES AND OMEGA ELEMENTS FOR E.COLI VECTOR CONSTRUCTION AND IN VITRO DELETION/INSESION MUTAGENESIS" GENE, vol. 160, 1995, pages 63-67, XP002076033 & DATABASE EMBL AC: U35129, 1995 "pBSL141" see abstract ---	1-10, 12-22
P,A	DATABASE EMBL AC: AA453562, 11 June 1997 HILLIER ET AL.: "HOMO SAPIENS cDNA CLONE 788180" XP002075910 see abstract -----	1-10, 12-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/03690

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 6 and 7 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see FURTHER INFORMATION sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-10, 12-22 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-10,12-22 (all partially)

Invention 1:

Methods and diagnostic kits for detecting and monitoring prostate cancer comprising either a binding agent capable of binding to a polypeptide encoded by a DNA molecule with Seq.ID 2 or oligonucleotide primers specific for a DNA molecule with Seq. ID 2 as well as an monoclonal antibody binding to a prostate protein encoded by a DNA molecule with Seq. ID 2 used in a method for inhibiting development of prostate cancer.

2. Claims: 1-10,12-22 (all partially)

Inventions 2-130:

Methods and diagnostic kits for detecting and monitoring prostate cancer comprising either a binding agent capable of binding to a polypeptide encoded by a DNA molecule with Seq.ID 3 or oligonucleotide primers specific for a DNA molecule with Seq. ID 3 as well as an monoclonal antibody binding to a prostate protein encoded by a DNA molecule with Seq. ID 3 used in a method for inhibiting development of prostate cancer.

...ibidem for Seq. ID 8-29,
41-45, 47-52, 54-65, 70, 73, 74, 79, 81, 87, 90, 92, 93, 97, 103, 104, 107, 115-160, 171, 181, 188, 191, 193, 194, 198, 203, 204, 207, 209-211, 220, 222-224.

3. Claims: 1-4, 8, 9, 11-22 (all partially)

Inventions 131-215:

Methods and diagnostic kits for detecting and monitoring prostate cancer comprising either a binding agent capable of binding to a polypeptide encoded by a DNA molecule with Seq.ID 5 or oligonucleotide primers specific for a DNA molecule with Seq. ID 5 as well as an monoclonal antibody binding to a prostate protein encoded by a DNA molecule with Seq. ID 5 used in a method for inhibiting development of prostate cancer.

...ibidem for each of Seq. ID
6, 7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106, 161-170, 179, 180, 182-187, 189, 190, 192, 195-197, 198-202, 205, 206, 208, 212-219.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1, JS 98/03690

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9621671 A	18-07-1996	AU 4751196 A CA 2209941 A EP 0804458 A	31-07-1996 18-07-1996 05-11-1997
WO 9314775 A	05-08-1993	CA 2106487 A	01-08-1993
WO 9409820 A	11-05-1994	CA 2147499 A EP 0668777 A JP 8506005 T US 5538866 A	11-05-1994 30-08-1995 02-07-1996 23-07-1996
WO 9504548 A	16-02-1995	AU 686660 B AU 7631294 A CA 2168952 A EP 0721345 A JP 9504000 T	12-02-1998 28-02-1995 16-02-1995 17-07-1996 22-04-1997

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)